



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/12, C07K 14/705, C12N 1/19, 1/21, 5/10, 15/62, C07K 19/00, C12N 15/11, G01N 33/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/53058</b> <b>(43) International Publication Date:</b> 21 October 1999 (21.10.99)
<b>(21) International Application Number:</b> PCT/US99/07417 <b>(22) International Filing Date:</b> 2 April 1999 (02.04.99) <b>(30) Priority Data:</b> 09/060,939 15 April 1998 (15.04.98) US <b>(71) Applicant:</b> GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US). <b>(72) Inventors:</b> DE SAUVAGE, Frederic, J.; 187 Shooting Star Isle, Foster City, CA 94404 (US). CARPENTER, David, A.; 1582 22nd Avenue, San Francisco, CA 94122 (US). <b>(74) Agents:</b> SVOBODA, Craig, G. et al.; Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080-4990 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> VERTEBRATE PATCHED-2 PROTEIN <b>(57) Abstract</b>  The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antibodies, vectors and host cells expressing, immunoadhesins, agonists and antagonists to <i>patched-2</i> .		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## VERTEBRATE PATCHED-2 PROTEIN

### FIELD OF THE INVENTION

5 The present invention relates generally to signaling molecules, specifically to signaling and mediator molecules in the hedgehog (*hh*) cascade which are involved in cell proliferation and differentiation.

### BACKGROUND OF THE INVENTION

Development of multicellular organisms depends, at least in part, on mechanisms which specify, direct or maintain positional information to pattern cells, tissues, or organs. Various secreted signaling  
10 molecules, such as members of the transforming growth factor-beta (TGF- $\beta$ ), Wnt, fibroblast growth factors and hedgehog families have been associated with patterning activity of different cells and structures in *Drosophila* as well as in vertebrates. Perrimon, *Cell* 80: 517-520 (1995).

Segment polarity genes were first discovered in *Drosophila*, which when mutated caused a change in the pattern of structures of the body segments. These changes affected the pattern along the head to tail  
15 axis. Hedgehog (*Hh*) was first identified as a segment-polarity gene by a genetic screen in *Drosophila melanogaster*, Nusslein-Volhard *et al.*, *Roux. Arch. Dev. Biol.* 193: 267-282 (1984), that plays a wide variety of developmental functions. Perrimon, *supra*. Although only one *Drosophila Hh* gene has been identified, three mammalian *Hh* homologues have been isolated: Sonic *Hh* (*Shh*), Desert *Hh* (*Dhh*) and Indian *Hh* (*Ihh*), Echelard *et al.*, *Cell* 75: 1417-30 (1993); Riddle *et al.*, *Cell* 75: 1401-16 (1993). *Shh* is expressed at high  
20 level in the notochord and floor plate of developing vertebrate embryos, and acts to establish cell fate in the developing limb, somites and neural tube. *In vitro* explant assays as well as ectopic expression of *Shh* in transgenic animals show that *SHh* plays a key role in neural tube patterning, Echelard *et al.* (1993), *supra*.; Ericson *et al.*, *Cell* 81: 747-56 (1995); Marti *et al.*, *Nature* 375: 322-5 (1995); Roelink *et al.* (1995), *supra*; Hynes *et al.*, *Neuron* 19: 15-26 (1997). *Hh* also plays a role in the development of limbs (Krauss *et al.*, *Cell*  
25 75: 1431-44 (1993); Laufer *et al.*, *Cell* 79, 993-1003 (1994)), somites (Fan and Tessier-Lavigne, *Cell* 79, 1175-86 (1994); Johnson *et al.*, *Cell* 79: 1165-73 (1994)), lungs (Bellusci *et al.*, *Develop.* 124: 53-63 (1997) and skin (Oro *et al.*, *Science* 276: 817-21 (1997). Likewise, *Ihh* and *Dhh* are involved in bone, gut and germinal cell development, Apelqvist *et al.*, *Curr. Biol.* 7: 801-4 (1997); Bellusci *et al.*, *Development* 124:  
30 53-63 (1997); Bitgood *et al.*, *Curr. Biol.* 6: 298-304 (1996); Roberts *et al.*, *Development* 121: 3163-74 (1995). Specifically, *Ihh* has been implicated in chondrocyte development [Vortkamp, A. *et al.*, *Science* 273: 613-22 (1996)] while *Dhh* plays a key role in testis development. Bitgood *et al.*, *supra*. With the exception of the gut, in which both *Ihh* and *Shh* are expressed, the expression patterns of the hedgehog family members do not overlap. Bitgood *et al.*, *supra*.

At the cell surface, *Hh* function appears to be mediated by a multicomponent receptor complex  
35 involving patched (*ptch*) and smoothened (*smo*), two multi-transmembrane proteins initially identified as segment polarity genes in *Drosophila* and later characterized in vertebrates. Nakano *et al.*, *Nature* 341: 508-513 (1989); Goodrich *et al.*, *Genes Dev.* 10: 301-312 (1996); Marigo *et al.*, *Develop.* 122: 1225-1233 (1996); van den Heuvel, M. & Ingham, P.W., *Nature* 382: 547-551 (1996); Alcedo, J. *et al.*, *Cell* 86: 221-232 (1996); Stone, D.M. *et al.*, *Nature* 384: 129-34 (1996). Upon binding of *Hh* to *Ptch*, the normal inhibitory  
40 effect of *Ptch* on *Smo* is relieved, allowing *Smo* to transduce the *Hh* signal across the plasma membrane. It

remains to be established if the *Ptch/Smo* receptor complex mediates the action of all 3 mammalian hedgehogs or if specific components exist. Interestingly, a second murine *Ptch* gene, *Ptch-2* was recently isolated [Motoyama, J. *et al.*, *Nature Genetics* **18**: 104-106 (1998)], but its function as a *Hh* receptor has not been established. In order to characterize *Ptch-2* and compare it to *Ptch* with respect to the biological function of the various *Hh* family members, Applicants have isolated the human *Ptch-2* gene. Biochemical analysis of *Ptch* and *Ptch-2* show that both bind to all members of the *Hh* family with similar affinity and that both molecules can form a complex with *Smo*. However, the expression patterns of *Ptch-2* and *Ptch* do not overlap. While *Ptch* is expressed throughout the mouse embryo, *Ptch-2* is found mainly in spermatocytes which require Desert Hedgehog (*Dhh*) for proper development suggesting that *Ptch-2* mediates *Dhh*'s activity in the testis. Chromosomal localization of *Ptch-2* places it on chromosome 1p33-34, a region deleted in some germ cell tumors, raising the possibility that *Ptch-2* may be a tumor suppressor in *Dhh* target cells.

#### SUMMARY OF THE INVENTION

In one embodiment, the invention provides an isolated nucleic acid molecule having at least about 80% sequence identity to (a) a DNA molecule encoding a patched-2 polypeptide comprising the sequence of amino acids 1 to 1203 of Fig. 1, or (b) the complement of the DNA molecule of (a); and encoding a polypeptide having *patched-2* biological activity. The sequence identity preferably is > 91%, more preferably about 92%, most preferably about 95%. In one aspect, the isolated nucleic acid has at least > 91%, preferably at least about 92%, and even more preferably at least about 95% sequence identity with a polypeptide having amino acid residues 1 to about 1203 of Fig. 1. In a further aspect, the isolated nucleic acid molecule comprises DNA encoding a human *patched-2* polypeptide having amino acid residues 1 to about 1203 of Fig. 1. In yet another aspect, the invention provides for an isolated nucleic acid comprising DNA having at least a 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the cDNA in ATCC Deposit No. 209778 (designation: pRK7.hptc2.Flag-1405), alternatively the coding sequence of clone pRK7.hptc2.Flag-1405, deposited under accession number ATCC 209778. In a still further aspect, the invention provides for a nucleic acid comprising human *patched-2* encoding sequence of the cDNA in ATCC deposit No. 209778 (designation: pRK7.hptc2.Flag-1405) or a sequence which hybridizes thereto under stringent conditions.

In another embodiment, the invention provides a vector comprising DNA encoding a human *patched-2* polypeptide. A host cell comprising such a vector is also provided. By way of example, the host cells may be mammalian cells, (e.g. CHO cells), prokaryotic cells (e.g., *E. coli*) or yeast cells (e.g., *Saccharomyces cerevisiae*). A process for producing *patched-2* polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of *patched-2* and recovering the same from the cell culture.

In yet another embodiment, the invention provides an isolated *patched-2* polypeptide. In particular, the invention provides isolated native sequence *patched-2* polypeptide, which in one embodiment is a human *patched-2* including an amino acid sequence comprising residues 1 to about 1203 of Figure 1. Human *patched-2* polypeptides with or without the initiating methionine are specifically included. Alternatively, the invention provides a human *patched-2* polypeptide encoded by the nucleic acid deposited under accession

number ATCC Deposit No. 209778.

In yet another embodiment, the invention provides chimeric molecules comprising a *patched-2* polypeptide patched-2 to a heterologous polypeptide or amino acid sequence. An example of such a chimeric molecule comprises a *patched-2* polypeptide patched-2 to an epitope tag sequence or a constant region of an immunoglobulin.

In yet another embodiment, the invention provides expressed sequence tag (EST) comprising the nucleotide sequences identified in Fig. 2A (905531) (SEQ ID NO:3) and Fig. 2B (1326258) (SEQ ID NO:5).

In yet another embodiment, the invention provides for alternatively spliced variants of human *patched-2* having *patched-2* biological activity.

In yet another embodiment, the invention provides for method of using *patched-2* for the treatment of disorders which are mediated at least in part by Hedgehog (Hh), especially Desert hedgehog (*Dhh*). In particular, testicular cancer. In yet another embodiment, the invention provides a method of using antagonists or agonists of *patched-2* for treating disorders or creating a desirable physiological condition effected by blocking *Hh* signaling, especially *Dhh* signaling. (E.g., contraception).

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the nucleotide (SEQ ID NO:1) and derived amino acid (SEQ ID NO:2) sequence of a native sequence of human *Ptch-2*.

Figure 2A shows EST 905531 (SEQ ID NO:3) and Fig. 2B shows EST 1326258 (SEQ ID NO:5) in alignment with human *Ptch* (SEQ ID NO:18). These ESTs were used in the cloning of human full-length *Ptch-2* (SEQ ID NO:1).

Figure 3 shows a comparison between human *Ptch* (SEQ ID NO:4) and *Ptch-2* (SEQ ID NO:2). Gaps introduced for optimal alignment are indicated by dashes. Identical amino acids are boxed. The 12 transmembrane domains are indicated by the gray boxes, all of which are conserved between the two sequences. Alignment results between the two sequences indicate 53% identity. The most significant difference is a shorter C-terminal intracellular domain in human *Ptch-2* (SEQ ID NO:2) in comparison with human *Ptch* (SEQ ID NO:4).

Figure 4 shows a northern blot of *Ptch-2* (SEQ ID NO:2) which indicates expression is limited to the testis. Multiple human fetal and adult tissue northern blots were probed with fragments corresponding to the 3'-untranslated region of murine *Ptch-2*.

Figure 5 shows a chromosomal localization of two BAC clones which were isolated by PCR screening with human *patched-2* derived probes. Both probes were mapped by FISH to human chromosome 1p33-34.

Figure 6 is an *in situ* hybridization comparing *Ptch* (SEQ ID NO:4), *Ptch-2* (SEQ ID NO:2) and *Fused* (FuRK) (SEQ ID NO:10) expression. High magnification of mouse testis showing expression of (a) *Ptch*, *Ptch-2* (SEQ ID NO:2) (b) and FuRK (SEQ ID NO:10) (c). Low magnification of testis section hybridized with *Ptch-2* sense (SEQ ID NO:11) (d) and anti-sense probe (SEQ ID NO:12) (e) respectively. Fig. 6(f) shows low magnification of testis section hybridized with FuRK (SEQ ID NO:10 encoding nucleic acid). Scale bar: a, b, c: 0.05 mm; d, e, f: 0.33 mm.

Figure 7A is logarithmic plot comparing the binding *Ptch-2* (SEQ ID NO:2) to *Dhh* (SEQ ID

NO:13) and *Shh* (SEQ ID NO:14). Competitive binding of recombinant murine  $^{125}$ I-*Shh* to 293 cells overexpressing *Ptch* (SEQ ID NO:4) or *Ptch-2* (SEQ ID NO:2). There was no detectable binding to mock transfected cells (data not shown). Figure 7B is a western blot illustrating co-immunoprecipitation of epitope tagged *Ptch* (SEQ ID NO:4) or *Ptch-2* (SEQ ID NO:2) with epitope tagged *Smo* (SEQ ID NO:15). Immunoprecipitation was performed with antibodies to the Flag tagged *Ptch* (SEQ ID NO:4) and analyzed on a 6% acrylamide gel with antibodies to the Myc tagged *Smo* (SEQ ID NO:15). Protein complexes can be detected for both *Ptch* (SEQ ID NO:4) and *Ptch-2* (SEQ ID NO:2) with *Smo* (SEQ ID NO:15). *Ptch* (SEQ ID NO:4) and *Ptch-2* (SEQ ID NO:2) express at similar levels as shown by immunoprecipitation using antibodies to the Flag-tag and western blot using the same anti-Flag antibody.

Figure 8 is a sequence comparison between human *Ptch-2* (SEQ ID NO:2) and murine *Ptch-2* (SEQ ID NO:7), which indicates that there is about 91% identity between the two sequences.

Figure 9 is an *in situ* hybridization which demonstrates the accumulation of *Ptch* (SEQ ID NO:4) and *Ptch-2* (SEQ ID NO:2) mRNA detected by *in situ* hybridization in basal cells of E18 transgenic mice overexpressing *SMO-M2* (SEQ ID NO:16) (Xie *et al.*, *Nature* 391: 90-92 (1998).

Figure 10 is a partial sequence representing clone 3A (SEQ ID NO:8), a partial *patched-2* fragment which was initially isolated from a fetal brain library.

Figure 11 is a partial sequence representing clone 16.1 (SEQ ID NO:9), a partial *patched-2* fragment which isolated from a testis library.

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

### I. Definitions

The terms "*patched-2*" and "*patched-2* polypeptide" when used herein encompass native sequence *patched-2* and *patched-2* variants (which are further defined herein) having *patched-2* biological activity. *Patched-2* may be isolated from a variety of sources, such as from testes tissue types or from another source, or prepared by recombinant or synthetic methods.

A "native sequence *patched-2*" comprises a polypeptide having the same amino acid sequence as a human *patched-2* derived from nature. Such native sequence *patched-2* can be isolated from nature or can be produced by recombinant and/or synthetic means. The term "native sequence vertebrate *patched-2*" specifically encompasses naturally occurring truncated forms of human *patched-2*, naturally occurring variant forms (*e.g.*, alternatively spliced forms) and naturally-occurring allelic variants of human *patched-2*. Thus, one embodiment of the invention, the native sequence *patched-2* is a mature or full-length native *Ptch-2* comprising amino acids 1 to 1203 of Fig. 1 (SEQ ID NO:2) with or without the initiating methionine at position 1.

"*Patched-2* variant" means an active human *patched-2* as defined below having at least > 91% amino acid sequence identity to (a) a DNA molecule encoding a *patched-2* polypeptide, or (b) the complement of the DNA molecule of (a). In a particular embodiment, the *patched-2* variant has at least > 91% amino acid sequence homology with the human *Ptch-2* (SEQ ID NO:2) having the deduced amino acid sequence shown in Fig. 1 for a full-length native sequence human *patched-2*. Such *patched-2* variants

include, without limitation, *patched-2* polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the sequence of Fig. 1 (SEQ ID NO:2). Preferably, the nucleic acid or amino acid sequence identity is at least about 92%, more preferably at least about 93%, and even more preferably at least about 95%.

5 "Percent (%) amino acid sequence identity" with respect to the *patched-2* sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the *patched-2* sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid  
10 sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST-2 software that are set to their default parameters. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

"Percent (%) nucleic acid sequence identity" with respect to the *patched-2* sequences identified  
15 herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the *patched-2* sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST-2 software that are set to their default parameters.  
20 Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

The term "epitope tagged" when used herein refers to a chimeric polypeptide comprising *patched-2* polypeptide, or a portion thereof, *patched-2* to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not  
25 interfere with activity of the *patched-2* polypeptide. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 to about 50 amino acid residues (preferably, between about 10 to about 20 residues).

As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the  
30 binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesin comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous"), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a  
35 ligand. The immunoglobulin constant domain sequence in the immunoadhesins may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3 or IgG-4 subtypes, IgA (including IgA-1 and IgA-2, IgE, IgD or IgM. Immunoadhesion reported in the literature include fusions of the T cell receptor [Gascoigne *et al.*, *Proc. Natl. Acad. Sci. USA* **84**: 2936-2940 (1987)]; CD4 [Capron *et al.*, *Nature* **337**: 525-531 (1989); Traunecker *et al.*, *Nature* **339**: 68-70 (1989); Zettmeissl *et al.*, *DNA Cell Biol. USA* **9**: 347-353 (1990); Byrn

*et al.*, *Nature* 344, 667-670 (1990)]; L-selectin (homing receptor) [Watson *et al.*, *J. Cell. Biol.* 110, 2221-2229 (1990); Watson *et al.*, *Nature* 349, 164-167 (1991)]; CD44\* [Aruffo *et al.*, *Cell* 61, 1303-1313 (1990)]; CD28\* and B7\* [Linsley *et al.*, *J. Exp. Med.* 173, 721-730 (1991)]; CTLA-4\* [Lisley *et al.*, *J. Exp. Med.* 174, 561-569 (1991)]; CD22\* [Stamenkovic *et al.*, *Cell* 66, 1133-1144 (1991)]; TNF receptor [Ashkenazi *et al.*, *Proc. Natl. Acad. Sci. USA* 88, 10535-10539 (1991); Lesslauer *et al.*, *Eur. J. Immunol.* 27, 2883-2886 (1991); Poppel *et al.*, *J. Exp. Med.* 174, 1483-1489 (1991)]; NP receptors [Bennett *et al.*, *J. Biol. Chem.* 266, 23060-23067 (1991)]; IgE receptor  $\alpha$ -chain\* [Ridgway and Gorman, *J. Cell. Biol.* 115, abstr. 1448 (1991)]; HGF receptor [Mark, M.R. *et al.*, *J. Biol. Chem.*, 267(36): 26166-26171 (1992)], where the asterisk (\*) indicates that the receptor is a member of the immunoglobulin superfamily.

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends upon the ability of denatured DNA to reanneal when complementary strands are present in an environment near but below their  $T_m$  (melting temperature). The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. Moreover, stringency is also inversely proportional to salt concentrations. For additional details and explanation of stringency of hybridization reactions, see Ausubel *et al.*, *Current Protocols in Molecular Biology* (1995).

"Stringent conditions," as defined herein may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50  $\mu$ g/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the vertebrate *patched-2* natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

An "isolated" *patched-2* nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the *patched-2* nucleic acid. An isolated *patched-2* nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated *patched-2* nucleic acid molecules therefore are distinguished from the corresponding native *patched-2* nucleic acid molecule as it exists in natural cells.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

The term "antibody" is used in the broadest sense and specifically covers single monoclonal antibodies (including agonist and antagonist antibodies), antibody compositions with polyeptopic specificity, as well as antibody fragments (e.g., Fab, F(ab')<sub>2</sub> and Fv), so long as they exhibit the desired biological activity.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler & Milstein, *Nature* 256:495 (1975), or may be made by recombinant DNA methods [see, e.g. U.S. Patent No. 4,816,567 (Cabilly *et al.*)].

The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while

the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity [U.S. Patent No. 4,816,567; Cabilly *et al.*; Morrison *et al.*, Proc. Natl. Acad. Sci. USA **81**, 6851-6855 (1984)].

5 "Humanized" forms of non-human (e.g. murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a  
10 non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, corresponding non-human residues replace Fv framework residues of the human immunoglobulin. Furthermore, humanized antibody may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance. In general, the humanized antibody will comprise  
15 substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details see: Jones *et al.*, Nature **321**, 522-525 (1986); Riechmann *et al.*, Nature  
20 **332**, 323-327 (1988); Presta, Curr. Op. Struct. Biol. **2** 593-596 (1992) and U.S. Patent No. 5,225,539 (Winter) issued July 6, 1993.

"Active" or "activity" for the purposes herein refers to form(s) of *patched-2* which retain the biologic and/or immunologic activities of native or naturally occurring *patched-2*. A preferred activity is the ability to bind to and affect, e.g., block or otherwise modulate, *hedgehog* (*Hh*), especially *desert hedgehog* (*Dhh*) signaling. For example, the regulation of the pathogenesis of testicular cancer, male spermatocyte  
25 formation and basal cell carcinoma.

The term "antagonist" is used herein in the broadest sense to include any molecule which blocks, prevents, inhibits, neutralizes the normal functioning of *patched-2* in the *hedgehog* (*Hh*) signaling pathway. One particular form of antagonist includes a molecule that interferes with the interaction between *Dhh* and  
30 *patched-2*. Alternatively, an antagonist could also be a molecule which increases the levels of *patched-2*. In a similar manner, the term "agonist" is used herein to include any molecule which promotes, enhances or stimulates the binding of a *Hh* to *patched-2* in the *Hh* signaling pathway or otherwise upregulates it (e.g., blocking binding of *Ptch-2* (SEQ ID NO:2) to *Smo* (SEQ ID NO:17). Suitable molecules that affect the protein-protein interaction of *Hh* and *patched-2* and its binding proteins include fragments of the latter or  
35 small bioorganic molecules, e.g., peptidomimetics, which will prevent or enhance, as the case may be, the binding of *Hh* to *patched-2*. Non-limiting examples include proteins, peptides, glycoproteins, glycopeptides, glycolipids, polysaccharides, oligosaccharides, nucleic acids, bioorganic molecules, peptidomimetics, pharmacological agents and their metabolites, transcriptional and translation control sequences, and the like.

Another preferred form of antagonist includes antisense oligonucleotides that inhibit proper transcription of wild type *patched-2*.

The term "modulation" or "modulating" means upregulation or downregulation of a signaling pathway. Cellular processes under the control of signal transduction may include, but are not limited to, transcription of specific genes; normal cellular functions, such as metabolism, proliferation, differentiation, adhesion, apoptosis and survival, as well as abnormal processes, such as transformation, blocking of differentiation and metastasis.

The techniques of "polymerase chain reaction," or "PCR", as used herein generally refers to a procedure wherein minute amounts of a specific piece of nucleic acid, RNA and/or DNA are amplified as described in U.S. Pat. No. 4,683,195 issued 28 July 1987. Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified. The 5' terminal nucleotides of the two primers may coincide with the ends of the amplified material. PCR sequences form total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage, or plasmid sequences, etc. See generally Mullis *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* 51: 263 (1987); Erlich, Ed., PCR Technology, (Stockton Press, NY, 1989). As used herein, PCR is considered to be one, but not the only, example of a nucleic acid test sample comprising the use of a known nucleic acid as a primer and a nucleic acid polymerase to amplify or generate a specific piece of nucleic acid.

## II. Compositions and Methods of the Invention

### A. Full-length *patched-2*

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as *patched-2*. In particular, Applicants have identified and isolated cDNA encoding a human *patched-2* polypeptide, as disclosed in further detail in the Examples below. Using BLAST, BLAST-2 and FastA sequence alignment computer programs (set to the default parameters), Applicants found that a full-length native sequence human *patched-2* (i.e., *Ptch-2* in Figure 3, SEQ ID NO:2) has 53% amino acid sequence identity with a human *patched* (i.e., *Ptch*, SEQ ID NO:4). Moreover a human full-length *patched-2* (i.e., *Ptch-2*, SEQ ID NO:2) has about a 91% sequence identity with murine *Ptch-2* (SEQ ID NO:7) (Fig. 8). Accordingly, it is presently believed that the human *patched-2* (i.e., *Ptch-2*, SEQ ID NO:2) disclosed in the present application is a newly identified member of the mammalian hedgehog signaling cascade, specifically *Desert hedgehog*.

The full-length native sequence of human *patched-2* gene, or portions thereof, may be used as hybridization probes for a cDNA library to isolate the full-length gene or to isolate still other vertebrate homolog genes (for instance, those encoding naturally-occurring variants of *patched-2* or *patched-2* from other species) which have a desired sequence identity to the human *patched-2* sequence disclosed in Fig.1 (SEQ ID NO:2). Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from the nucleotide sequence of Fig. 1 (SEQ ID NO:1) or from genomic sequences including promoters, enhancer elements and introns of native sequence vertebrate *patched-2*. By way of example, a screening method will comprise isolating the coding region of the vertebrate *patched-2* gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may

be labeled by a variety of labels, including radionucleotides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the vertebrate *patched-2* gene of the present invention can be used to screen libraries of human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes to.

B. Patched-2 Variants

In addition to the full-length native sequence *patched-2* described herein, it is contemplated that *patched-2* variants can be prepared. *Patched-2* variants can be prepared by introducing appropriate nucleotide changes into a known *patched-2* DNA, or by synthesis of the desired *patched-2* polypeptides.

Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of *patched-2*.

Variations in the native full-length sequence *patched-2* or in various domains of the *patched-2* described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more codons encoding the *patched-2* that results in a change in the amino acid sequence of *patched-2* as compared with the native sequence *patched-2*. Optionally, the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of *patched-2*. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the *patched-2* with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity in the *in vitro* assay described in the Examples below.

The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res., 10: 6487 (1987)], cassette mutagenesis [Wells et al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the vertebrate *patched-2* variant DNA.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The

Proteins, (W.H. Freeman & Co., N.Y.); Chothia, *J. Mol. Biol.*, 150:1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

In the comparison between human *patched* and *patched-2* sequences depicted in Figure 3 (e.g., *Ptch*, SEQ ID NO:4 and *Ptch-2*, SEQ ID NO:2), the 12 transmembrane domains are identified in gray, while identical residues are boxed. Gaps are indicated by dashes (-) and are inserted to maximize the total identity score between the two sequences.

### C. Modifications of *patched-2*

Covalent modifications of *patched-2* are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of *patched-2* with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues of the *patched-2*. Derivatization with bifunctional agents is useful, for instance, for crosslinking *patched-2* to a water-insoluble support matrix or surface for use in the method for purifying anti-*patched-2* antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazo-acetyl)-2-phenylethane, glutaraldehyde, N-hydroxy-succinimide esters, for example, esters with 4-azido-salicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis-(succinimidyl-propionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)-dithio]propionimide.

Other modifications include deamidation of glutamyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of *patched-2* comprises linking the *patched-2* polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. Such modifications would be expected to increase the half-life of the molecules in circulation in a mammalian system; Extended half-life of *patched-2* molecules might be useful under certain circumstances, such as where the *patched-2* variant is administered as a therapeutic agent.

The *patched-2* of the present invention may also be modified in a way to form a chimeric molecule comprising *patched-2* bonded to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of *patched-2* with a tag polypeptide, which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl- terminus of the *patched-2*. The presence of such epitope-tagged forms of the *patched-2* can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the *patched-2* to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of the *patched-2* with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

Ordinarily, the C-terminus of a contiguous amino acid sequence of a patched-2 receptor is fused to the N-terminus of a contiguous amino acid sequence of an immunoglobulin constant region, in place of the variable region(s). However, N-terminal fusions are also possible.

Typically, such fusions retain at least functionally active hinge, CH2 and CH3 domains of the constant region of an immunoglobulin heavy chain. Fusions are also made to the C-terminus of the Fc portion of a constant domain, or immediately N-terminal to the CH1 of the heavy chain or the corresponding region of the light chain. This ordinarily is accomplished by constructing the appropriate DNA sequence and expressing it in recombinant cell culture. Alternatively, immunoadhesins may be synthesized according to known methods.

The precise site at which the fusion is made is not critical; particular sites are well known and may be selected in order to optimize the biological activity, secretion or binding characteristics of the immunoadhesins.

In a preferred embodiment, the C-terminus of a contiguous amino acid sequence which comprises the binding site(s) of *patched-2*, at the N-terminal end, to the C-terminal portion of an antibody (in particular the Fc domain), containing the effector functions of an immunoglobulin, e.g. immunoglobulin G<sub>1</sub> (IgG-1). As herein above mentioned, it is possible to fuse the entire heavy chain constant region to the sequence containing the binding site(s). However, more preferably, a sequence beginning in the hinge region just upstream of the papain cleavage site (which defines IgG Fc chemically; residue 216, taking the first residue of heavy chain constant region to be 114 [Kobayashi *et al.*, *supra*], or analogous sites of other immunoglobulins) is used in the fusion. Although it was earlier thought that in immunoadhesins the immunoglobulin light chain would be required for efficient secretion of the heterologous protein-heavy chain fusion proteins, it has been found that even the immunoadhesins containing the whole IgG1 heavy chain are efficiently secreted in the absence of light chain. Since the light chain is unnecessary, the immunoglobulin heavy chain constant domain sequence used in the construction of the immunoadhesins of the present invention may be devoid of a light chain binding site. This can be achieved by removing or sufficiently altering immunoglobulin heavy chain sequence elements to which the light chain is ordinarily linked so that such binding is no longer possible. Thus, the CH1 domain can be entirely removed in certain embodiments of the *patched-2*/immunoglobulin chimeras.

In a particularly preferred embodiment, the amino acid sequence containing the extracellular domain(s) of *patched-2* is fused to the hinge region and CH2, CH3; or CH1, hinge, CH2 and CH3 domains of an IgG-1, IgG-2, IgG-3, or IgG-4 heavy chain.

In some embodiments, the *patched-2*/immunoglobulin molecules (immunoadhesins) are assembled as monomers, dimers or multimers, and particularly as dimers or tetramers. Generally, these assembled immunoadhesins will have known unit structures similar to those of the corresponding immunoglobulins. A basic four chain structural unit (a dimer of two immunoglobulin heavy chain-light chain pairs) is the form in which IgG, IgA and IgE exist. A four chain unit is repeated in the high molecular weight immunoglobulins; IgM generally exists as a pentamer of basic four-chain units held together by disulfide bonds. IgA globulin, and occasionally IgG globulin, may also exist in a multimeric form in serum. In the case of multimers, each four chain unit may be the same or different.

It is not necessary that the entire immunoglobulin portion of the *patched-2*/immunoglobulin chimeras be from the same immunoglobulin. Various portions of different immunoglobulins may be combined, and

variants and derivatives of native immunoglobulins can be made as herein above described with respect to *patched-2*, in order to optimize the properties of the immunoadhesin molecules. For example, immunoadhesin constructs in which the hinge of IgG-1 was replaced with that of IgG-3 were found to be functional and showed pharmacokinetics comparable to those of immunoadhesins comprising the entire IgG-1 heavy chain.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8: 2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; an  $\alpha$ -tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)]. A preferred tag is the influenza HA tag.

#### D. Preparation of *patched-2*

The description below relates primarily to production of a particular *patched-2* by culturing cells transformed or transfected with a vector containing *patched-2* nucleic acid. It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare *patched-2*. For instance, the *patched-2* sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the vertebrate *patched-2* may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length *patched-2*.

##### 1. Isolation of DNA encoding vertebrate *patched-2*

DNA encoding *patched-2* may be obtained from a cDNA library prepared from tissue believed to possess the *patched-2* mRNA and to express it at a detectable level. Accordingly, human *patched-2* DNA can be conveniently obtained from a cDNA library prepared from human tissue, such as described in the Examples. The vertebrate *patched-2*-encoding gene may also be obtained from a genomic library or by oligonucleotide synthesis.

Libraries can be screened with probes (such as antibodies to the *patched-2* or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding vertebrate *patched-2* is to use PCR methodology [Sambrook et al., supra; Dieffenbach et al., PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)].

The Examples below describe techniques for screening a cDNA library. The oligonucleotide

sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like  $^{32}\text{P}$ -labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook *et al.*, *supra*.

Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined through sequence alignment using computer software programs such as BLAST, BLAST-2, ALIGN, DNASTar, and INHERIT which employ various algorithms to measure homology.

Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook *et al.*, *supra*, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

## 2. Selection and Transformation of Host Cells

Host cells are transfected or transformed with expression or cloning vectors described herein for *patched-2* production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in *Mammalian Cell Biotechnology: A Practical Approach*, M. Butler, ed. (IRL Press, 1991) and Sambrook *et al.*, *supra*.

Methods of transfection are known to the ordinarily skilled artisan, for example,  $\text{CaPO}_4$  and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook *et al.*, *supra*, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw *et al.*, *Gene*, 23:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, *Virology* 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transformations have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen *et al.*, *J. Bact.*, 130:946 (1977) and Hsiao *et al.*, *Proc. Natl. Acad. Sci. (USA)*, 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, *e.g.*, polybrene, polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown *et al.*, *Methods in Enzymology*, 185:527-537 (1990) and Mansour *et al.*, *Nature*, 336:348-352 (1988).

Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote,

yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriae such as *E. coli*. Various *E. coli* strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31.446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635).

5 In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for vertebrate *patched-2*-encoding vectors. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism.

Suitable host cells for the expression of vertebrate *patched-2* are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham *et al.*, *J. Gen Virol.*, 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, *Proc. Natl. Acad. Sci. USA*, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, *Biol. Reprod.* 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.

### 3. Selection and Use of a Replicable Vector

The nucleic acid (e.g., cDNA or genomic DNA) encoding *patched-2* may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques, which are known to the skilled artisan.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 $\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. A preferred replicable expression vector is the plasmid is pRK5. Holmes *et al.*, *Science*, 253:1278-1280 (1991).

Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the *patched-2* nucleic acid, such as DHFR or thymidine kinase.

An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub *et al.*, *Proc. Natl. Acad. Sci. USA*, 77:4216 (1980). A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 [Stinchcomb *et al.*, *Nature*, 282:39 (1979); Kingsman *et al.*, *Gene*, 7:141 (1979); Tschemper *et al.*, *Gene*, 10:157 (1980)]. The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, *Genetics*, 85:12 (1977)].

Expression and cloning vectors usually contain a promoter operably linked to the *patched-2* nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the  $\beta$ -lactamase and lactose promoter systems [Chang *et al.*, *Nature*, 275:615 (1978); Goeddel *et al.*, *Nature*, 281:544 (1979)], alkaline phosphatase, a tryptophan (*trp*) promoter system [Goeddel, *Nucleic Acids Res.*, 8:4057 (1980); EP 36,776], and hybrid promoters such as the *tac* promoter [deBoer *et al.*, *Proc. Natl. Acad. Sci. USA*, 80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding *patched-2*.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman *et al.*, *J. Biol. Chem.*, 255:2073 (1980)] or other glycolytic enzymes [Hess *et al.*, *J. Adv. Enzyme Reg.*, 7:149 (1968); Holland, *Biochemistry*, 17:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phospho-fructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.

*Patched-2* transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, *e.g.*, the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.

Inserting an enhancer sequence into the vector may increase transcription of a DNA encoding the *patched-2* by higher eukaryotes. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at

a position 5' or 3' to the *patched-2* coding sequence, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding *patched-2*.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of *patched-2* in recombinant vertebrate cell culture are described in Gething *et al.*, *Nature*, 293:620-625 (1981); Mantei *et al.*, *Nature*, 281:40-46 (1979); EP 117,060; and EP 117,058.

#### 4. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, *Proc. Natl. Acad. Sci. USA*, 77:5201-5205 (1980)], dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence *patched-2* polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence to *patched-2* DNA and encoding a specific antibody epitope.

#### 5. Purification of Polypeptide

Forms of *patched-2* may be recovered from host cell lysates. Since *patched-2* is membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in expression of *patched-2* can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

It may be desired to purify *patched-2* from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the *patched-2*. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, *Methods*

in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York (1982). The purification step(s) selected will depend, for example, on the nature of the production process used and the particular *patched-2* produced.

E. Uses for *patched-2*

(1) *Patched-2 is a specific receptor for desert hedgehog (Dhh)*

The *hedgehog (Hh)* signaling pathway has been implicated in the formation of embryonic structures in mammals and invertebrates. The multi-pass transmembrane receptor *patched*, is a negative regulator of the *Hh* pathway, repressing the serpentine signaling molecule *smoothed (Smo)*. Data have shown that loss of *Patched* leads to deregulation of the *Hh* pathway leading to formation of aberrant structures in the embryos and carcinoma in the adult.

Applicants' newly identified second human *patched* gene, termed *patched-2* (e.g., *Pich-2*, SEQ ID NO:2), has a similar 12 transmembrane domain topology as does *patched*, and can bind to all the members of the *Hh* family and can complex with *Smo* (e.g., SEQ ID NO:17). However, the expression patterns of *patched-2* and *patched* do not overlap. *Patched-2* is expressed mainly in the developing spermatocytes, which are supported directly by the *Desert hedgehog* producing Sertoli cells, which suggests that *patched-2* is a receptor for *Desert hedgehog*.

In the adult tubule, Sertoli cells, which are unusually large secretory cells, traverse the seminiferous tubule from the basal lamina to the luminal aspect, sending out cytoplasmic protrusions that engulf the germ cells. These contacts are particularly close during spermiogenesis, in which the haploid round spermatids undergo differentiation to produce the highly specialized, motile sperm. Tight junctions between adjacent Sertoli cells compartmentalize the tubule into a basal region, which contains mitotic spermatogonia and early spermatocytes, and an adluminal compartment, which contains meiotic spermatocytes and maturing spermatids. In fact, a Sertoli-derived cell line supports the meiotic progression of germ cells in culture, consistent with the view that factors derived from Sertoli cells contribute to germ cell maturation. Rassoulzadegan, M., et al., *Cell* 1993, 75: 997-1006. Loss of *Dhh* activity results in a recessive, sex-specific phenotype. Female mice homozygous for the mutation were fully viable and fertile, whereas male mice were viable but infertile. A gross examination indicated that, as early as 18.5 dpc, the testes of mutant males were noticeably smaller than those of heterozygous littermates. Bitgood et al., *Curr. Biol.*, 1996 6(3): 298-304. Thus, Sertoli cells likely independently regulate mitotic and meiotic stages of germ cell development during postnatal development. Therefore, since *patched-2* appears to be the receptor for *Dhh* (SEQ ID NO:13), molecules which modulate the binding of *Dhh* (SEQ ID NO:13) to *patched-2* would affect the activation of *Dhh* (SEQ ID NO:13) signaling, and thereby would have utility in the treatment of conditions which are modulated by *Dhh* (SEQ ID NO:13). (For example, testicular cancer). Alternatively, it is also provided that antagonists or agonists of *patched-2* may be used for treating disorders or creating a desirable physiological condition effected by blocking *Dhh* signaling. (E.g., contraception, infertility treatment).

(2) *General uses for *patched-2**

Nucleotide sequences (or their complement) encoding *patched-2* have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA and DNA. *Patched-2* nucleic acid will also be useful for the preparation of

*patched-2* polypeptides by the recombinant techniques described herein.

The full-length native sequence *patched-2* gene, or portions thereof, may be used as hybridization probes for a cDNA library to isolate the full-length gene or to isolate still other genes (for instance, those encoding naturally-occurring variants of *patched-2*) which have a desired sequence identity to the *patched-2* sequence disclosed in Fig. 1 (SEQ ID NO:1). Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from the nucleotide sequence of Fig. 1 (SEQ ID NO:1) or from genomic sequences including promoters, enhancer elements and introns of native sequence *patched-2*. By way of example, a screening method will comprise isolating the coding region of the *patched-2* gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as <sup>32</sup>P or <sup>35</sup>S, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the *patched-2* gene of the present invention can be used to screen libraries of human cDNA, genomic DNA or mRNA to determine to which members of such libraries the probe hybridizes. Hybridization techniques are described in further detail in the Examples below.

The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related *patched-2* sequences.

Nucleotide sequences encoding *patched-2* can also be used to construct hybridization probes for mapping the gene, which encodes *patched-2* and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as *in situ* hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries.

*Patched-2* polypeptides can be used in assays to identify the other proteins or molecules involved in complexing with *patched-2* which ultimately results in the modulation of *hedgehog* signaling. Alternatively, these molecules can modulate the binding of *patched-2* to *Dhh* (SEQ ID NO:13). By such methods, inhibitors of the binding interaction can be identified. Proteins involved in such binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Also, the substrate of *patched-2* can be used to isolate correlative complexing proteins. Screening assays can be designed to find lead compounds that mimic the biological activity of a native *patched-2* or to find those that act as a substrate for *patched-2*. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Such small molecule inhibitors could block the enzymatic action of *patched-2*, and thereby inhibit *hedgehog* signaling. Small molecules contemplated include synthetic organic or inorganic compounds. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art.

Nucleic acids which encode *patched-2* or its modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA sequence that is integrated into the genome of a cell from which a

transgenic animal develops. In one embodiment, cDNA encoding *patched-2* can be used to clone genomic DNA encoding *patched-2* in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA encoding *patched-2*. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009. Typically, particular cells would be targeted for *patched-2* transgene incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding *patched-2* introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding *patched-2*. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression.

Non-human homologues of vertebrate *patched-2* can be used to construct a *patched-2* "knock out" animal which has a defective or altered gene encoding *patched-2* as a result of homologous recombination between the endogenous gene encoding *patched-2* and altered genomic DNA encoding *patched-2* introduced into an embryonic cell of the animal. For example, cDNA encoding *patched-2* can be used to clone genomic DNA encoding *patched-2* in accordance with established techniques. A portion of the genomic DNA encoding *patched-2* can be deleted or replaced with another gene, such as a gene encoding a selectable marker that can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, *Cell*, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see e.g., Li *et al.*, *Cell*, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley, in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the *patched-2* polypeptide.

Suppression or inhibition (antagonism) of *Dhh* signaling is also an objective of therapeutic strategies. Since *patched-2* can combine with all members of the hedgehog family (i.e., *Shh*, *Dhh*, *Ihh*), antagonist molecules which prevent the binding of hedgehog molecules to *Ptch-2* (SEQ ID NO:2) have therapeutic utility. For example, *SHh* signaling is known to be activated in Basal Cell Carcinoma; *Dhh* (SEQ ID NO:13) is known to be involved in the regulation of spermatogenesis. Inhibitor or antagonist of *Hh* signaling would be effective therapeutics in the treatment of Basal Cell Carcinoma or male contraception, respectively.

The stimulation of *Dhh* signaling (agonism) is also an objective of therapeutic strategies. Since *Ptch-2* (SEQ ID NO:2) also binds to the other members of the *Hh* family, *Ihh* and *Shh*, activating *Dhh* signaling would be useful in disease states or disorders characterized by inactive or insufficient *Hh* signaling.

For example, degenerative disorders of the nervous system, *e.g.*, Parkinson's disease, memory deficits, Alzheimer's disease, Lou Gehrig's disease, Huntington's disease, schizophrenia, stroke and drug addiction. Additionally, *patched-2* agonists could be used to treat gut diseases, bone diseases, skin diseases, diseases of the testis (including infertility), ulcers, lung diseases, diseases of the pancreas, diabetes, osteoporosis.

5           F.       Anti-*patched-2* Antibodies

The present invention further provides anti- vertebrate *patched-2* antibodies. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

          1.       Polyclonal Antibodies

10           The anti-*patched-2* antibodies may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the *patched-2* polypeptide or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the  
15           mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants that may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

20           2.       Monoclonal Antibodies

The anti-*patched-2* antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, *Nature*, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of  
25           producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

The immunizing agent will typically include the *patched-2* polypeptide or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes  
30           are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that  
35           inhibit the growth or survival of the unfused immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression

of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Rockville, Maryland. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63].

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against *patched-2*. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980).

After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods [Goding, *supra*]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison *et al.*, *supra*] or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another

amin acid residue or are deleted so as to prevent crosslinking.

*In vitro* methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.

### 3. Humanized Antibodies

The anti-patched-2 antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeven et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole *et al.* and Boerner *et al.* are also available for the preparation of human monoclonal antibodies (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)].

### 4. Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the vertebrate *patched-2*, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

5 Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities [Milstein and Cuello, *Nature*, 305:537-539 (1983)]. Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one  
10 has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, *EMBO J.*, 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an  
15 immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for  
20 example, Suresh *et al.*, *Methods in Enzymology*, 121:210 (1986).

#### 5. Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and  
25 for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that the antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

#### 30 G. Uses for anti-*patched-2* Antibodies

The anti-*patched-2* antibodies of the invention have various utilities. For example, anti-*patched-2* antibodies may be used in diagnostic assays for *patched-2*, *e.g.*, detecting its expression in specific cells, tissues, or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either  
35 heterogeneous or homogeneous phases [Zola, *Monoclonal Antibodies: A Manual of Techniques*, CRC Press, Inc. (1987) pp. 147-158]. The antibodies used in the diagnostic assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , or  $^{125}\text{I}$ , a

fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., *Nature*, 144: 945 (1962); David et al., *Biochemistry*, 13:1014 (1974); Pain et al., *J. Immunol. Meth.*, 40:219 (1981); and Nygren, *J. Histochem. and Cytochem.*, 30:407 (1982).

Anti-*patched-2* antibodies also are useful for the affinity purification of *patched-2* from recombinant cell culture or natural sources. In this process, the antibodies against *patched-2* are immobilized on a suitable support, such a Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody then is contacted with a sample containing the *patched-2* to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the *patched-2*, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the *patched-2* from the antibody.

Basal cell carcinoma (BCC) is the most common human cancer. The *Hh* signaling pathway was found to be activated in all BCCs. Loss of *patched* function is thought to lead to unregulated *Smo* activity and is responsible for about half of all BCCs. *Patched* being a target of the *Hh* pathway itself, increases in *patched* mRNA levels have been detected in BCC [Gailani, et al., *Nature Genet.* 14: 78-81 (1996)] as well as in animal models of BCC. Oro et al., *Science* 276: 817-821 (1997); Xie et al., *Nature* 391: 90-92 (1998). Abnormal activation of *Sh* signaling, such as that which occurs in BCC, was examined to confirm whether *patched-2* expression was increased. As shown in Fig. 9, an *in situ* hybridization for *Ptch* (SEQ ID NO:4) and *Ptch-2* (SEQ ID NO:2) in *Smo*-M2 (SEQ ID NO:16) transgenic mice (Xie et al., *supra*), while lower than *Ptch*, was still high in tumor cells. This suggests that therapeutic antibodies directed toward *Ptch-2* (SEQ ID NO:2) may be useful for the treatment of BCC.

Anti-*patched-2* antibodies also have utilities similar to those articulated for under the previous section "E. Uses of Patched-2". Depending on whether anti-*patched-2* antibodies will bind *patched-2* receptors so as to either inhibit *Hh* signaling (antagonist) or inhibit *patched-2* complexing with *Smo* (SEQ ID NO:17) and thereby remove the normal inhibitory effect of *Smo* (SEQ ID NO:17) on *Hh* signaling (agonist) the antibody will have utilities corresponding to those articulated previously for *patched-2*.

#### H. *Patched-2* Antagonists

Several approaches may be suitably employed to create the *patched-2* antagonist and agonist compounds of the present invention. Any approach where the antagonist molecule can be targeted to the interior of the cell, which interferes or prevents wild type *patched-2* from normal operation is suitable. For example, competitive inhibitors, including mutant *patched-2* receptors which prevent wild type *patched-2* from properly binding with other proteins necessary for *Dhh* and *Hh* signaling. Additional properties of such antagonist or agonist molecules are readily determinable by one of ordinary skill, such as size, charge and hydrophobicity suitable for transmembrane transport.

Where mimics or other mammalian homologues of *patched-2* are to be identified or evaluated, the cells are exposed to the test compound and compared to positive controls which are exposed only to human *patched-2*, and to negative controls which were not exposed to either the compound or the natural ligand. Where antagonists or agonists of *patched-2* signal modulation are to be identified or evaluated, the cells are

exposed to the compound of the invention in the presence of the natural ligand and compared to controls which are not exposed to the test compound.

Detection assays may be employed as a primary screen to evaluate the *Hh* signaling inhibition/enhancing activity of the antagonist/agonist compounds of the invention. The assays may also be used to assess the relative potency of a compound by testing a range of concentrations, in a range from 100 mM to 1 pM, for example, and computing the concentration at which the amount of phosphorylation or signal transduction is reduced or increased by 50% (IC<sub>50</sub>) compared to controls.

Assays can be performed to identify compounds that affect *Hh* signaling of *patched-2* substrates. Specifically, assays can be performed to identify compounds that increase the phosphorylation activity of *patched-2* or assays can be performed to identify compounds that decrease the *Hh* signaling of *patched-2* substrates. These assays can be performed either on whole cells themselves or on cell extracts. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, cell based assays, etc. Such assay formats are well known in the art.

The screening assays of the present invention are amenable to high-throughput screening of chemical libraries, and are particularly suitable for identifying small molecule drug candidates.

(1) *Antagonist and agonist molecules*

To screen for antagonists and/or agonists of *patched-2* signaling, the assay mixture is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, *patched-2* induces hedgehog signaling with a reference activity. The mixture components can be added in any order that provides for the requisite hedgehog activity. Incubation may be performed at any temperature that facilitates optimal binding, typically between about 4° and 40°C, more commonly between about 15° and 40°C. Incubation periods are likewise selected for optimal binding but also minimized to facilitate rapid, high-throughput screening, and are typically between about 0.1 and 10 hours, preferably less than 5 hours, more preferably less than 2 hours. After incubation, the effect of the candidate pharmacological agent on the *patched-2* signaling is determined in any convenient way. For cell-free binding-type assays, a separation step is often used to separate bound and unbound components. Separation may, for example, be effected by precipitation (e.g. TCA precipitation, immunoprecipitation, etc.), immobilization (e.g. on a solid substrate), followed by washing. The bound protein is conveniently detected by taking advantage of a detectable label attached to it, e.g. by measuring radioactive emission, optical or electron density, or by indirect detection using, e.g. antibody conjugates.

For example, a method of screening for suitable *patched-2* antagonists and/or agonists could involve the application of *Dhh* and other hedgehog ligands. Such a screening assay could compare *in situ* hybridization in the presence and absence of the candidate antagonist and/or agonist in a *patched-2* expressing tissue as well as confirmation or absence of *patched-2* modulated cellular development.

Typically these methods involve exposing an immobilized *patched-2* to a molecule suspected of binding thereto and determining the level of ligand binding downstream activation of reporter constructs and/or evaluating whether or not the molecule activates (or blocks activation of) *patched-2*. In order to identify such *patched-2* binding ligands, *patched-2* can be expressed on the surface of a cell and used to screen

libraries of synthetic candidate compounds or naturally-occurring compounds (e.g., from endogenous sources such as serum or cells).

Suitable molecules that affect the protein-protein interaction of *patched-2* and its binding proteins include fragments of the latter or small molecules, e.g., peptidomimetics, which will inhibit ligand-receptor interaction. Such small molecules, which are usually less than 10 K molecular weight, are preferable as therapeutics since they are more likely to be permeable to cells, are less susceptible to degradation by various cellular mechanisms, and are not as apt to elicit an immune response as proteins. Small molecules include but are not limited to synthetic organic or inorganic compounds. Many pharmaceutical companies have extensive libraries of such molecules, which can be conveniently screened by using the assays of the present invention. Non-limiting examples include proteins, peptides, glycoproteins, glycopeptides, glycolipids, polysaccharides, oligosaccharides, nucleic acids, bioorganic molecules, peptidomimetics, pharmacological agents and their metabolites, transcriptional and translation control sequences, and the like.

A preferred technique for identifying molecules which bind to *patched-2* utilizes a chimeric substrate (e.g., epitope-tagged *patched-2* or *patched-2* immunoadhesin) attached to a solid phase, such as the well of an assay plate. The binding of the candidate molecules, which are optionally labeled (e.g., radiolabeled), to the immobilized receptor can be measured. Alternatively, competition for various *Hh* pathways, especially *Dhh* (SEQ ID NO:13) can be measured. In screening for antagonists and/or agonists, *patched-2* can be exposed to a *patched-2* substrate followed by the putative antagonist and/or agonist, or the *patched-2* binding protein and antagonist and/or agonist can be added simultaneously, and the ability of the antagonist and/or agonist to block *patched-2* activation can be evaluated.

#### (2) Detection assays

The *patched-2* polypeptides are useful in assays for identifying lead compounds for therapeutically active agents that modulate *patched-2* receptor/ligand hedgehog signaling. Specifically, lead compounds that either prevent the formation of *patched-2* signaling complexes or prevent or attenuate *patched-2* modulated hedgehog signaling (e.g., binding to *patched-2*) can be conveniently identified.

Various procedures known in the art may be used for identifying, evaluating or assaying the inhibition of activity of the *patched-2* proteins of the invention. As *patched-2* is believed to be a receptor for *Dhh* (SEQ ID NO:13), but also binds *Shh* (SEQ ID NO:14) and *Ihh* (SEQ ID NO:29), techniques known for use with identifying ligand/receptor modulators may also be employed with the present invention. In general, such assays involve exposing target cells in culture to the compounds and a) biochemically analyzing cell lysates to assess the level and/or identity of binding; or (b) scoring phenotypic or functional changes in treated cells as compared to control cells that were not exposed to the test substance. Such screening assays are described in U.S.P. 5,602,171, U.S.P. 5,710,173, WO 96/35124 and WO 96/40276.

#### (a) Biochemical detection techniques

Biochemical analysis can be evaluated by a variety of techniques. One typical assay mixture which can be used with the present invention contains *patched-2* and a ligand protein with which *patched-2* is normally associated (e.g., *Dhh* (SEQ ID NO:13)) usually in an isolated, partially pure or pure form. One or both of these components may be *patched-2* to another peptide or polypeptide, which may, for example, provide or enhance protein-protein binding, improve stability under assay conditions, etc.

In addition, one of the components usually comprises or is coupled to a detectable label. The label may provide for direct detection by measuring radioactivity, luminescence, optical or electron density, etc., or indirect detection such as an epitope tag, an enzyme, etc. The assay mixture can additionally comprise a candidate pharmacological agent, and optionally a variety of other components, such as salts, buffers, carrier proteins, e.g. albumin, detergents, protease inhibitors, nuclease inhibitors, antimicrobial agents, etc., which facilitate binding, increase stability, reduce non-specific or background interactions, or otherwise improve the efficiency or sensitivity of the assay.

The following detection methods may also be used in a cell-free system wherein cell lysate containing the signal transducing substrate molecule and *patched-2* is mixed with a compound of the invention. To assess the activity of the compound, the reaction mixture may be analyzed by the SDS-PAGE technique or it may be added to substrate-specific anchoring antibody bound to a solid support, and a detection procedure as described above is performed on the separated or captured substrate to assess the presence or absence of a *patched-2* binding ligand. The results are compared to those obtained with reaction mixtures to which the compound is not added. The cell-free system does not require the natural ligand or knowledge of its identity. For example, Posner *et al.* (U.S.P. 5,155,031 describes the use of insulin receptor as a substrate and rat adipocytes as target cells to demonstrate the ability of pervanadate to inhibit PTP activity. Another example, Burke *et al.*, *Biochem. Biophys. Res. Comm.* 204: 129-134 (1994) describes the use of autophosphorylated insulin receptor and recombinant PTP1B in assessing the inhibitory activity of a phosphotyrosyl mimetic.

(i) *Whole cell detection*

A common technique involves incubating cells with *patched-2* and radiolabeled ligand, lysing the cells, separating cellular protein components of the lysate using an SDS-polyacrylamide gel (SDS-PAGE) technique, in either one or two dimensions, and detecting the presence of labeled proteins by exposing X-ray film. Detection can also be effected without using radioactive labeling. In such a technique, the protein components (e.g., separated by SDS-PAGE) are transferred to a nitrocellulose membrane where the presence of *patched*-ligand complexes is detected using an anti-ligand antibody.

Alternatively, the anti-*patched-2* ligand antibody can be conjugated with an enzyme, such as horseradish peroxidase, and detected by subsequent addition of a colorimetric substrate for the enzyme. A further alternative involves detecting the anti-*patched-2* ligand by reacting with a second antibody that recognizes anti-*patched-2* ligand, this second antibody being labeled with either a radioactive moiety or an enzyme as previously described. Examples of these and similar techniques are described in Hansen *et al.*, *Electrophoresis* 14: 112-126 (1993); Campbell *et al.*, *J. Biol. Chem.* 268: 7427-7434 (1993); Donato *et al.*, *Cell Growth Diff.* 3: 258-268 (1992); Katagiri *et al.*, *J. Immunol.* 150: 585-593 (1993). Additionally, the anti-*patched-2* ligand can be detected by labeling it with a radioactive substance, followed by scanning the labeled nitrocellulose to detect radioactivity or exposure of X-ray film.

Further detection methods may be developed which are preferred to those described above. Especially for use in connection with high-throughput screening, it is expected that such methods would

exhibit good sensitivity and specificity, extended linear range, low background signal, minimal fluctuation, compatibility with other reagents, and compatibility with automated handling systems.

The *in vivo* efficacy of the treatment of the present invention can be studied against chemically induced tumors in various rodent models. Tumor cell lines propagated in *in vitro* cell cultures can be introduced in experimental rodents, e.g. mice by injection, for example by the subcutaneous route. Techniques for chemical inducement of tumors in experimental animals are well known in the art.

(ii) Kinase assays

Because *patched-2* is a negative regulator of *Hh* signaling, which when activated by *Hh* releases the normal inhibitory effect on *Smo*, the inhibition of *patched-2* binding to *Smo* can be measured by activation of various kinase substrate associated with *Hh* signaling. When the screening methods of the present invention for *patched-2* antagonists/agonists are carried out as an *ex vivo* assay, the target kinase (e.g. *fused*) can be a substantially purified polypeptide. The kinase substrate (e.g., MBP, *Gli*) is a substantially purified substrate, which in the assay is phosphorylated in a reaction with a substantially purified phosphate source that is catalyzed by the kinase. The extent of phosphorylation is determined by measuring the amount of substrate phosphorylated in the reaction. A variety of possible substrates may be used, including the kinase itself in which instance the phosphorylation reaction measured in the assay is autophosphorylation. Exogenous substrates may also be used, including standard protein substrates such as myelin basic protein (MBP); yeast protein substrates; synthetic peptide substrates, and polymer substrates. Of these, MBP and other standard protein substrates may be regarded as preferred. Other substrates may be identified, however, which are superior by way of affinity for the kinase, minimal perturbation of reaction kinetics, possession of single or homogenous reaction sites, ease of handling and post-reaction recover, potential for strong signal generation, and resistance or inertness to test compounds.

Measurement of the amount of substrate phosphorylated in the *ex vivo* assay of the invention may be carried out by means of immunoassay, radioassay or other well-known methods. In an immunoassay measurement, an antibody (such as a goat or mouse anti-phosphoserine/threonine antibody) may be used which is specific for phosphorylated moieties formed during the reaction. Using well-known ELISA techniques, the phosphoserine/threonine antibody complex would itself be detected by a further antibody linked to a label capable of developing a measurable signal (as for example a fluorescent or radioactive label). Additionally, ELISA-type assays in microtitre plates may be used to test purified substrates. Peraldi *et al.*, *J. Biochem.* 285: 71-78 (1992); Schraag *et al.*, *Anal. Biochem.* 211: 233-239 (1993); Cleavland, *Anal. Biochem.* 190: 249-253 (1990); Farley, *Anal. Biochem.* 203: 151-157 (1992) and Lozano, *Anal. Biochem.* 192: 257-261 (1991).

For example, detection schemes can measure substrate depletion during the kinase reaction. Initially, the phosphate source may be radiolabeled with an isotope such as  $^{32}\text{P}$  or  $^{33}\text{P}$ , and the amount of substrate phosphorylation may be measured by determining the amount of radiolabel incorporated into the substrate during the reaction. Detection may be accomplished by: (a) commercially available scintillant-containing plates and beads using a beta-counter, after adsorption to a filter or a microtitre well surface, or (b) photometric means after binding to a scintillation proximity assay bead or scintillant plate. Weernink and

Kijken. *J. Biochem. Biophys. Methods* **31**: 49, 1996; Braunwalder *et al.*, *Anal. Biochem.* **234**: 23 (1996); Kentrup *et al.*, *J. Biol. Chem.* **271**: 3488 (1996) and Rusken *et al.*, *Meth. Enzymol.* **200**: 98 (1991).

Preferably, the substrate is attached to a solid support surface by means of non-specific or, preferably, specific binding. Such attachment permits separation of the phosphorylated substrate from unincorporated, labeled phosphate source (such as adenosine triphosphate prior to signal detection. In one embodiment, the substrate may be physically immobilized prior to reaction, as through the use of Nunc<sup>TM</sup> high protein binding plate (Hanke *et al.*, *J. Biol. Chem.* **271**: 695 (1996)) or Wallac ScintiStrip<sup>TM</sup> plates (Braunwalder *et al.*, *Anal. Biochem.* **234**: 23 (1996)). Substrate may also be immobilized after reaction by capture on, for example, P81 phosphocellulose (for basic peptides), PEI/acidic molybdate resin or DEAE, or TCA precipitation onto Whatman<sup>TM</sup> 3MM paper, Tiganis *et al.*, *Arch. Biochem. Biophys.* **325**: 289 (1996); Morawetz *et al.*, *Mol. Gen. Genet.* **250**: 17 (1996); Budde *et al.*, *Int J. Pharmacognosy* **33**: 27 (1995) and Casnellie, *Meth. Enz.* **200**: 115 (1991). Yet another possibility is the attachment of the substrate to the support surface, as by conjugation with binding partners such as glutathione and streptavidin (in the case of GST and biotin), respectively) which have been attached to the support, or via antibodies specific for the tags which are likewise attached to the support.

Further detection methods may be developed which are preferred to those described above. Especially for use in connection with high-throughput screening, it is expected that such methods would exhibit good sensitivity and specificity, extended linear range, low background signal, minimal fluctuation, compatibility with other reagents, and compatibility with automated handling systems.

The *in vivo* efficacy of the treatment of the present invention can be studied against chemically induced tumors in various rodent models. Tumor cell lines propagated in *in vitro* cell cultures can be introduced in experimental rodents, e.g. mice by injection, for example by the subcutaneous route. Techniques for chemical inducement of tumors in experimental animals are well known in the art.

(b) *Biological detection techniques:*

The ability of the antagonist/agonist compounds of the invention to modulate the activity of *patched-2*, which itself modulates *hedgehog* signaling, may also be measured by scoring for morphological or functional changes associated with ligand binding. Any qualitative or quantitative technique known in the art may be applied for observing and measuring cellular processes which comes under the control of *patched-2*. The activity of the compounds of the invention can also be assessed in animals using experimental models of disorders caused by or related to dysfunctional *hedgehog* signaling. For example, ineffective *Dhh* *hedgehog* signaling in mice leads to viable but sterile mice. Additionally, proper *Shh* signaling is critical to murine embryonic development at the notochord and floor plate, neural tube, distal limb structures, spinal column and ribs. Improper *Shh* signaling, is also correlative with cyclopia. Any of these phenotypic properties could be evaluated and quantified in a screening assay for *patched-2* antagonists and/or agonist. Disease states associated with overexpression of *hedgehog* is associated with basal cell carcinoma while inactive *Shh* signaling leads to improper neural development.

The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosages for use in humans. The dosage of the compounds of the invention should lie within a range

of circulating concentrations with little or no toxicity. The dosage may vary within this range depending on the dosage form employed and the route of administration.

(2) *Antisense oligonucleotides*

Another preferred class of antagonists involves the use of gene therapy techniques. include the administration of antisense oligonucleotides. Applicable gene therapy techniques include single or multiple administrations of therapeutically effective DNA or mRNA. Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes *in vivo*. Reference short antisense oligonucleotides can be imported into cells where they act as inhibitors, despite their low intracellular concentrations caused by restricted uptake by the cell membrane, Zamecnik *et al.*, *Proc. Natl. Acad. Sci. USA* 83: 4143-4146 (1986). The anti-sense oligonucleotides can be modified to enhance their uptake, e.g., by substituting their negatively charged phosphodiester groups by uncharged groups.

There are a variety of techniques known for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells *in vitro*, *ex vivo*, or *in vivo* in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells *in vitro* include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred *in vivo* gene transfer techniques include transfection with viral (typically retroviral) vectors and viral coat protein-liposome mediated transfection, Dzur *et al.*, *Trends Biotech.* 11: 205-210 (1993). In some situations it is desirable to provide the nucleic acid source with an agent that targets the cells, such as an antibody specific for a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g., capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, and proteins that target intracellular localization and enhance intracellular half-life.

The technique of receptor-mediated endocytosis is described, for example, by Wu *et al.*, *J. Biol. Chem.* 262: 4429-4432 (1987); Wagner *et al.*, *Proc. Natl. Acad. Sci. USA* 87: 3410-3414 (1990). For a review of known gene targeting and gene therapy protocols, see Anderson *et al.*, *Science* 256: 808-813 (1992).

In one embodiment of the invention, *patched-2* expression may be reduced by providing *patched-2*-expressing cells with an amount of *patched-2* antisense RNA or DNA effective to reduce expression of the *patched-2* protein.

I. Diagnostic Uses

Another use of the compounds of the invention (e.g., *patched-2*, *patched-2* and anti-*patched-2* antibodies) described herein is to help diagnose whether a disorder is driven, to some extent, by *patched-2* or hedgehog signaling. For example, basal cell carcinoma cells are associated with active hedgehog signaling, spermatocyte formation is associated with *Dhh* signaling, and defective *patched* and *patched-2* suppression may be associated with testicular carcinomas.

A diagnostic assay to determine whether a particular disorder is driven by *patched-2* modulated hedgehog signaling, can be carried out using the following steps: (1) culturing test cells or tissues; (2) administering a compound which can prevent *patched-2* binding with *Smo* (SEQ ID NO:17), thereby activating the *Hh* signaling pathway; and (3) measuring the amount of *Hh* signaling. The steps can be carried

out using standard techniques in light of the present disclosure. For example, standard techniques can be used to isolate cells or tissues and culturing or *in vivo*.

Compounds of varying degree of selectivity are useful for diagnosing the role of *patched-2*. For example, compounds which inhibit *patched-2* in addition to another form of kinase can be used as an initial test compound to determine if one of several signaling ligands drive the disorder. The selective compounds can then be used to further eliminate the possible role of the other ligands in driving the disorder. Test compounds should be more potent in inhibiting ligand-*patched-2* binding activity than in exerting a cytotoxic effect (e.g., an  $IC_{50}/LD_{50}$  of greater than one). The  $IC_{50}$  and  $LD_{50}$  can be measured by standard techniques, such as an MTT assay, or by measuring the amount of LDH released. The degree of  $IC_{50}/LD_{50}$  of a compound should be taken into account in evaluating the diagnostic assay. For example, the larger the  $IC_{50}/LD_{50}$  ratio the more relative the information. Appropriate controls take into account the possible cytotoxic effect of a compound of a compound, such as treating cells not associated with a cell proliferative disorder (e.g., control cells) with a test compound, can also be used as part of the diagnostic assay. The diagnostic methods of the invention involve the screening for agents that modulate the effects of *patched-2* upon *hedgehog* signaling. Exemplary detection techniques include radioactive labeling and immunoprecipitating (U.S.P. 5,385,915).

#### J. Pharmaceutical Compositions and Dosages

Therapeutic formulations of the compositions of the invention are prepared for storage as lyophilized formulations or aqueous solutions by mixing the *patched-2* molecule, agonist and/or antagonist having the desired degree of purity with optional "pharmaceutically-acceptable" or "physiologically-acceptable" carriers, excipients or stabilizers typically employed in the art (all of which are termed "excipients"). For example, buffering agents, stabilizing agents, preservatives, isotonicifiers, non-ionic detergents, antioxidants and other miscellaneous additives. (See Remington's Pharmaceutical Sciences, 16<sup>th</sup> Ed., A. Osol, Ed. (1980)). Such additives must be nontoxic to the recipients at the dosages and concentrations employed.

Buffering agents help to maintain the pH in the range which approximates physiological conditions. They are preferably present at concentration ranging from about 2mM to about 50 mM. Suitable buffering agents for use with the present invention include both organic and inorganic acids and salts thereof such as citrate buffers (e.g., monosodium citrate-disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-monosodium citrate mixture, etc.), succinate buffers (e.g., succinic acid-monosodium succinate mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture, etc.), tartrate buffers (e.g., tartaric acid-sodium tartrate mixture, tartaric acid-potassium tartrate mixture, tartaric acid-sodium hydroxide mixture, etc.), fumarate buffers (e.g., fumaric acid-monosodium fumarate mixture, etc.), fumarate buffers (e.g., fumaric acid-monosodium fumarate mixture, fumaric acid-disodium fumarate mixture, monosodium fumarate-disodium fumarate mixture, etc.), gluconate buffers (e.g., gluconic acid-sodium glyconate mixture, gluconic acid-sodium hydroxide mixture, gluconic acid-potassium glyconate mixture, etc.), oxalate buffer (e.g., oxalic acid-sodium oxalate mixture, oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate mixture, etc.), lactate buffers (e.g., lactic acid-sodium lactate mixture, lactic acid-

sodium hydroxide mixture, lactic acid-potassium lactate mixture, etc.) and acetate buffers (e.g., acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide mixture, etc.). Additionally, there may be mentioned phosphate buffers, histidine buffers and trimethylamine salts such as Tris.

Preservatives are added to retard microbial growth, and are added in amounts ranging from 0.2% - 1% (w/v). Suitable preservatives for use with the present invention include phenol, benzyl alcohol, *meta*-cresol, methyl paraben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalconium halides (e.g., chloride, bromide, iodide), hexamethonium chloride, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, and 3-pentanol.

Isotonifiers sometimes known as "stabilizers" are present to ensure isotonicity of liquid compositions of the present invention and include polyhydric sugar alcohols, preferably trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol. Polyhydric alcohols can be present in an amount between 0.1% to 25% by weight, preferably 1% to 5% taking into account the relative amounts of the other ingredients.

Stabilizers refer to a broad category of excipients which can range in function from a bulking agent to an additive which solubilizes the therapeutic agent or helps to prevent denaturation or adherence to the container wall. Typical stabilizers can be polyhydric sugar alcohols (enumerated above); amino acids such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, threonine, etc., organic sugars or sugar alcohols, such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myoinositol, galactitol, glycerol and the like, including cyclitols such as inositol; polyethylene glycol; amino acid polymers; sulfur containing reducing agents, such as urea, glutathione, thiocitic acid, sodium thioglycolate, thioglycerol,  $\alpha$ -monothioglycerol and sodium thio sulfate; low molecular weight polypeptides (i.e. < 10 residues); proteins such as human serum albumin, bovine serum albumin, gelatin or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone monosaccharides, such as xylose, mannose, fructose, glucose; disaccharides such as lactose, maltose, sucrose and trisaccharides such as raffinose; polysaccharides such as dextran. Stabilizers can be present in the range from 0.1 to 10,000 weights per part of weight active protein.

Non-ionic surfactants or detergents (also known as "wetting agents") are present to help solubilize the therapeutic agent as well as to protect the therapeutic protein against agitation-induced aggregation, which also permits the formulation to be exposed to shear surface stressed without causing denaturation of the protein. Suitable non-ionic surfactants include polysorbates (20, 80, etc.), polyoxamers (184, 188 etc.), Pluronic® polyols, polyoxyethylene sorbitan monoethers (Tween®-20, Tween®-80, etc.). Non-ionic surfactants are present in a range of about 0.05 mg/ml to about 1.0 mg/ml, preferably about 0.07 mg/ml to about 0.2 mg/ml.

Additional miscellaneous excipients include bulking agents, (e.g. starch), chelating agents (e.g. EDTA), antioxidants (e.g., ascorbic acid, methionine, vitamin E), and cosolvents.

The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely

affect each other. For example, it may be desirable to further provide an immunosuppressive agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsule prepared, for example, by coascervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacrylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in *Remington's Pharmaceutical Sciences*, 16th edition, A. Osal, Ed. (1980).

The formulations to be used for in vivo administration must be sterile. This is readily accomplished, for example, by filtration through sterile filtration membranes.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the compounds of the invention, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No.3,773,919), copolymers of L-glutamic acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated compounds of the invention remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

The amount of therapeutic polypeptide, antibody or fragment thereof which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. Where possible, it is desirable to determine the dose-response curve and the pharmaceutical compositions of the invention first *in vitro*, and then in useful animal model systems prior to testing in humans. However, based on common knowledge of the art, a pharmaceutical composition effective in modulating *Dhh* and *Hh* signaling may provide a local *patched-2* protein concentration of between about 10 and 1000 ng/ml, preferably between 100 and 800 ng/ml and most preferably between about 200 ng/ml and 600 ng/ml of *Pich-2* (SEQ ID NO:2).

In a preferred embodiment, an aqueous solution of therapeutic polypeptide, antibody or fragment thereof is administered by subcutaneous injection. Each dose may range from about 0.5 µg to about 50 µg per kilogram of body weight, or more preferably, from about 3 µg to about 30 µg per kilogram body weight.

The dosing schedule for subcutaneous administration may vary from once a week to daily depending on a number of clinical factors, including the type of disease, severity of disease, and the subject's sensitivity to the therapeutic agent.

*Patched-2* polypeptide may comprise an amino acid sequence or subsequence thereof as indicated in Fig. 1, active amino acid sequence derived therefrom, or functionally equivalent sequence as this subsequence is believed to comprise the functional portion of the *patched-2* polypeptide.

If the subject manifests undesired side effects such as temperature elevation, cold or flu-like symptoms, fatigue, etc., it may be desirable to administer a lower dose at more frequent intervals. One or more additional drugs may be administered in combination with *patched-2* to alleviate such undesired side effects, for example, an anti-pyretic, anti-inflammatory or analgesic agent.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

## EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Rockville, Maryland.

### EXAMPLE 1

#### Introduction

At the cell surface, *Hh* function appears to be mediated by a multicomponent receptor complex involving *Ptch* and *Smo* (SEQ ID NO:17), two multi-transmembrane proteins initially identified as segment polarity genes in *Drosophila* and later characterized in vertebrates. Nakano, Y. *et al.*, *Nature* **341**: 508-513 (1989); Goodrich *et al.*, *Gene Dev.* **10**: 301-312 (1996); Marigo *et al.*, *Develop.* **122**: 1225-1233 (1996); van den Heuvel *et al.*, *Nature* **382**: 547-551 (1996); Alcedo *et al.*, *Cell* **86**: 221-232 (1996); Stone *et al.*, *Nature* **384**: 129-134 (1996). Both genetic and biochemical evidence support the existence of a receptor complex where *Ptch* (SEQ ID NO:4) is the ligand binding subunit, and where *Smo* (SEQ ID NO:17), a G-protein coupled receptor-like molecule, is the signaling component. Stone *et al.*, *Nature* **384**: 129-134 (1996), Marigo *et al.*, *Nature* **384**: 176-79 (1996), Chen *et al.*, *Cell* **87**: 553-63 (1996). Upon binding of *Hh* to *Ptch* (SEQ ID NO:4), the normal inhibitory effect of *Ptch* (SEQ ID NO:4) on *Smo* (SEQ ID NO:17) is relieved, allowing *Smo* (SEQ ID NO:17) to transduce the *Hh* signal across the plasma membrane.

#### Results

It remains to be established if the *PTCH/SMO* receptor complex mediates the action of all 3 mammalian *Hhs* or if specific components exist. Recently, a second murine *Patched* gene, *mPatched-2* (SEQ ID NO:7) was recently isolated [Motoyama *et al.*, *Nature Genet.* **18**: 104-106 (1998)] but its function as a *Hh* receptor has not been established. In order to characterize *patched-2* (SEQ ID NO:2) and compare it to *Patched* (SEQ ID NO:4) with respect to the biological function of the various *Hh* family members, we have screened EST databases with the *Patched* (SEQ ID NO:4) protein and identified 2 EST candidates for a

novel human *patched* gene. A full length cDNA encoding human *Ptch-2* (SEQ ID NO:2) was cloned from a testis library. The initiation ATG defines a 3612 nucleotide open reading frame encoding a 1204 amino acid long protein with a predicted molecular weight of approximately 131 kDa. The overall identity between human *Ptch* (SEQ ID NO:4) and *Ptch-2* (SEQ ID NO:2) is 54% (Fig. 1), while the identity between human *PTCH-2* and the recently described mouse *Ptch-2* (SEQ ID NO:7) is 90% (Fig. 8). The most obvious structural difference between the two human *Patched* proteins is a truncated C-terminal cytoplasmic domain in *Ptch-2* (SEQ ID NO:2). In addition, only one of the two glycosylation sites present in *Ptch* (SEQ ID NO:4) is conserved in *Ptch-2* (SEQ ID NO:2).

To determine if *Patched-2* is a *Hh* receptor and if the two *Patched* molecules are capable of discriminating between the various *Hh* ligands through specific binding, Applicants transfected human 293 embryonic kidney cells with *Ptch* (SEQ ID NO:4) or *Ptch-2* (SEQ ID NO:2) expression constructs and analyzed the cells for binding of *Shh*, *Dhh* and *Ihh*. As shown on Figure 7A, binding of <sup>125</sup>I-*Shh* can be competed with an excess of *Shh*, *Dhh* or *Ihh* (SEQ ID NOS: 14, 13 and 29), respectively. Scatchard analysis of the displacement curves indicates that all *Hhs* have similar affinity for *Ptch* (SEQ ID NO:4) (*Shh*, 1.0nM (SEQ ID NO:14); *Dhh*, 2.6nM (SEQ ID NO:13); *Ihh*, 1.0nM (SEQ ID NO:29) and *Ptch-2* (SEQ ID NO:2) (*Shh*, 1.8nM (SEQ ID NO:14); *Dhh*, 0.6nM (SEQ ID NO:13); *Ihh*, 0.4nM (SEQ ID NO:29) indicating that both *PTCH* (SEQ ID NO:4) and *PTCH-2* (SEQ ID NO:2) can serve as physiological receptors for the 3 mammalian *Hh* proteins.

Applicants next determined whether, like *Patched*, *Patched-2* forms a physical complex with *Smo* (SEQ ID NO:17). Expression constructs for Flag-tagged *Ptch* (SEQ ID NO:4) or *Ptch-2* (SEQ ID NO:2) were transiently co-transfected in 293 cells with Myc-tagged *Smo* (SEQ ID NO:17). As described previously [Stone *et al.*, *Nature* 384: 129-34 (1996)], in cells expressing *Ptch* (SEQ ID NO:4) and *Smo* (SEQ ID NO:15), *Ptch* (SEQ ID NO:4) can be immunoprecipitated with antibodies against the epitope-tagged *Smo* (SEQ ID NO:15) (Fig. 7B). Similarly, *Patched-2* can be immunoprecipitated with antibodies against the epitope-tagged *Smo* (SEQ ID NO:15) when the two proteins are co-expressed in 293 cells. Together, these results suggest a model where *Patched-2* forms a multicomponent *Hh* receptor complex with *Smo* (SEQ ID NO:17) similar to the one described for *PTCH* (Stone *et al.*, *supra*). Interestingly, these results also demonstrate that the long C-terminal tail which is missing in *Patched-2* is not required for the interaction with *Smo* (SEQ ID NO:17) as was already suggested by the analysis of truncated *Patched* (Stone *et al.*, *supra*). However, it remains possible that the absence of a C-terminal domain affects the capacity of *Patched-2* to block signaling by *Smo* (SEQ ID NO:17) or leads to difference in signaling by *Patched* compared to *Patched-2*.

To further investigate whether *Patched-2* could mediate the action of a specific *Hh* molecule based on its expression profile, Applicants have compared the expression pattern of *Ptch* (SEQ ID NO:4) and *Ptch-2* (SEQ ID NO:2). First, Northern blot analysis using a probe specific for *Ptch-2* (SEQ ID NO:1) revealed high levels of *PTCH2* mRNA in the testis (Fig. 4). By this method, *Ptch-2* (SEQ ID NO:1) expression was not detected in any other tissue analyzed including embryonic tissues (data not shown). This profile is very different from the one observed for *Ptch* (SEQ ID NO:18) which was not found in testis by Northern blot but in a large number of adult and embryonic tissues [Goodrich *et al.*, *Genes Dev.* 10: 301-312

(1996)]. More detailed analysis of the expression pattern of *Ptch* (SEQ ID NO:18) and *Ptch-2* (SEQ ID NO:1) was performed by *in situ* hybridization with particular attention to testis. As previously described (Motoyama *et al.*, *supra*), low levels of *Ptch-2* (SEQ ID NO:1) expression were detected in epithelial cells of the developing tooth and skin (data not shown). High levels of *Ptch-2* (SEQ ID NO:2) encoding mRNA are expressed inside the seminiferous tubule, on the primary and secondary spermatocytes (Fig. 6B,6E) while only low levels of *Ptch* (SEQ ID NO:4) encoding mRNA can be detected on the Leydig cells located in the interstitium of the seminiferous tubules (Fig. 6A). The primary and secondary spermatocytes are in close contact with the supporting Sertoli cells, the source of *Dhh* (SEQ ID NO:13) in the testis [Bitgood *et al.*, *Curr. Biol.* 6: 298-304 (1996)]. To determine which one of the 2 receptors is the most relevant mediator of *Dhh* (SEQ ID NO:13) activity in the testis, we have analyzed the expression profile of FuRK (SEQ ID NO:10), a Fused Related Kinase that is believed to be a component of the *Hh* signaling pathway. Consistent with the idea that *Patched-2* is the target of *Dhh* in the testis, we found that FuRK (SEQ ID NO:10) is expressed only in germ cells where it colocalizes with *Ptch-2* (SEQ ID NO:2) (Figure 4c,f). *Dhh* (SEQ ID NO:13) is required for proper differentiation of germ cells since male *Dhh*-deficient mice are sterile due to lack of mature sperm (Bitgood *et al.*, *supra*). Our data suggest that *Dhh* (SEQ ID NO:13) acts directly on germ cells through *Ptch-2* (SEQ ID NO:2) while the function of *Ptch* (SEQ ID NO:4) expressed at low levels on testosterone producing Leydig cells is unclear.

#### Discussion

Loss of heterozygosity (LOH) for *Patched* was reported to occur with high frequency in familial as well as sporadic basal cell carcinoma [Johnson *et al.*, *Science* 272: 1668-71 (1996); Hahn *et al.*, *Cell* 85: 841-51 (1996); Gailani *et al.*, *Nature Genetics* 14: 78-81; Xie *et al.*, *Cancer Res.* 57: 2369-72 (1997)], suggesting that it functions as a tumor suppressor. According to the receptor model described above, loss of *Patched* function may result in aberrant signaling by *Smo* (SEQ ID NO:17), leading to hyperproliferation of the skin basal cell layer. If, as suggested above, *Patched-2* mediates the function of *Dhh*, loss of *Patched-2* may lead to tumor formation in tissues where *Smo* (SEQ ID NO:17) activity is controlled by *Patched-2*. The gene encoding *Ptch-2* (SEQ ID NO:2) was mapped by fluorescence *in situ* hybridization and by PCR using a radiation hybrid panel to human chromosome 1p33-34 (data not shown). Interestingly, recent analysis of recurrent chromosomal abnormalities in testicular tumors, including seminomas, revealed a deletion of the region 1p32-36 [Summersgill *et al.*, *B. J. Cancer* 77: 305-313 (1998)]. Loss of this region encompassing the *Patched-2* locus was consistent in 36% of the germ cell tumor cases. These data raise the possibility that, like *Patched* in basal cell carcinoma and medulloblastoma, *Patched-2* may be a tumor suppressor in *Dhh* (SEQ ID NO: 13) target cells such as spermatocytes, further implicating *Hh* signaling in cancer.

In summary, our data demonstrate that both *Patched* and *Patched-2* are genuine *Hh* receptors and that they are both capable of forming a complex with *Smo* (SEQ ID NO:17). Although binding data indicate that *Patched* and *Patched-2* do not discriminate between the various *Hh* ligands through affinity differences, the distinct tissue distribution of these 2 receptors suggests that *in vivo*, *Patched* may be the primary receptor for *Shh* whereas *Patched-2* will mediate mainly *Dhh* signaling. The function of *Patched* expression in Leydig cells in the absence of some of the *Hh* signaling components remain to be explained. Similarly, it will be of interest to determine if *Patched-2* plays a role when expressed in *Shh* expressing cells present in the

developing tooth and skin Motoyama *et al.*, *Nature Genet.* **18**: 104-106 (1998). Finally, the existence of *Patched-2* raises the question of whether additional *patched* receptors exist, in particular one that mediates the function of *lhh* (SEQ ID NO: 29).

#### Material and Methods

##### 5 1. Isolation of human *patched-2* cDNA clones

An expressed sequence tag (EST) DNA database (LIFESEQ™, Incyte Pharmaceuticals, Palo Alto, CA) was searched for a human homologue of the *Drosophila* segment polarity gene *patched-2*. Two ESTs (Incyte #905531 and 1326258) (Fig. 2) were identified as a potential candidates. In order to identify human cDNA libraries containing human *patched-2* clones, human cDNA libraries in pRK5 were first screened by

10 PCR using the following primers:

5'-905531(A): 5'-AGGCGGGGATCACAGCA-3' (SEQ ID NO:19)

3'-905531(A): 5'-ATACCAAAGAGTTCCACT-3' (SEQ ID NO:20)

A fetal lung library was selected and enriched for *patched-2* cDNA clones by extension of single stranded DNA from plasmid libraries grown in *dut<sup>-</sup>ung<sup>-</sup>* host using the 3'-905531(A) primer in a reaction containing

15 10µl of 10x PCR Buffer (Klentaq®), 1µl dNTP (200 µM), 1 µl library DNA (200 ng), 0.5 µl primer, 86.5 µl H<sub>2</sub>O and 1 µl of Klentaq® (Clontech) added after a hot start. The reaction was denatured for 1 min. at 95°C,

annealed for 1 min. at 60°C then extended for 20 min. at 72°C. DNA was extracted with phenol/CHCl<sub>3</sub>, ethanol precipitated, then transformed by electroporation into DH10B (Cibco/BRL) host bacteria. Colonies from each transformation were replica plated on nylon membranes and screened with an overlapping oligo

20 probe derived from the EST sequence (#905531) of the following sequence:

5'-*ptch2* probe: 5'-CTGCGGCGCTGCTTCCTGCTGGCCGTCTGCATCCTGCTGGTGTGC-3  
(SEQ ID NO:21)

3'-*ptch2*probe: 5'-AGAGCACAGACGAGGAAAGTGCACACCAGCAGGATGCAGACGGCC-3'  
(SEQ ID NO:22)

25 The oligo probe was labeled with [ $\gamma$ -<sup>32</sup>P]-ATP and T4 polynucleotide kinase. Filters were hybridized overnight at 42°C in 50% formamide, 5xSSC, 10xDenhardt's, 0.05M sodium phosphate (pH 6.5), 0.1% sodium pyrophosphate, 50 µg/ml of sonicated salmon sperm DNA. The filters were then rinsed in 2x SSC and washed in 0.1x SSC, 0.1% SDS then exposed to Kodak® X Ray films. Using this procedure, a partial clone was isolated from the fetal brain library (clone 3A – Fig. 10) (SEQ ID NO:8). In order to isolate the

30 missing 5'-sequence, a testis library (see northern blot analysis, *infra*) was screened. The primer set used to amplify a 204 bp probe from clone 3A to probe the testis library was:

RACE 5: 5'-ACTCCTGACTTGTCAGATT-3' (SEQ ID NO: 23) and

RACE 6: 5'-AGGCTGCATACACCTCTCAGA-3' (SEQ ID NO:24).

The amplified probe was purified by excision from an agarose gel and labeled with a random primer labeling  
35 kit (Boehringer Mannheim). Several clones were isolated, including one (clone 16.1 – Fig. 11) (SEQ ID NO:9) containing a potential initiation methionine. A full length cDNA encoding a *Patched-2* was reconstructed by assembling several of these clones. The full length cDNA encoding human *Pich-2* (Fig. 1

(SEQ ID NO:1)) has a 3612 nucleotide long open reading frame encoding a 1204 amino acid protein with a 144 kDa predicted molecular weight. Alignment with human *Ptch* (SEQ ID NO:4) reveals a 53% identity between the 2 molecules at the amino acid level (Fig. 3). All 12 transmembrane domains are conserved. The most significant difference is a shorter C-terminal intracellular domain in *Ptch-2* (SEQ ID NO:2) compared to *Ptch* (SEQ ID NO:4).

## 2. Northern blot analysis:

In order to determine the best tissue source for isolation of the complete full length *Patched-2* cDNA as well as to determine its expression profile, we probed human multiple tissue northern blots (Clontech) with a 752 bp fragment amplified from the 3' untranslated region of *Patched-2* using the following primers:

TM2: 5'-GCTTAGGCCCCGAGGAGAT-3' (SEQ ID NO:25)

UTR2: 5'-AACTCACAACCTTCTCTCCA-3' (SEQ ID NO:26).

The resulting fragment was gel purified and labeled by random priming. The blots were hybridized in ExpressHyb<sup>®</sup> hybridization solution (Clontech) in the presence of  $1 \times 10^6$  cpm/ml <sup>32</sup>P-labeled probe at 42°C overnight. The blots were washed in 2x SSC at room temperature for 10 minutes and washed in 0.1 x SSC/0.1 % SDS at 42°C for 30 minutes then exposed to x-ray film overnight. Fig. 4 shows that *Ptch-2* message is expressed at high levels in only the testis.

## 3. Chromosomal localization:

The primers TM2 (SEQ ID NO:25) and UTR2 (SEQ ID NO:26) described above were used to screen the Genome Systems (St. Louis, MO) BAC library. Two individual BAC clones were obtained from this library and chromosomal localization of both of the clones by FISH indicated that *Ptch-2* (SEQ ID NO:2) maps to human chromosome 1p33-34 (FIG 5). Loss of heterozyosity (LOH) for *Patched* was reported to occur with high frequency in basal cell carcinoma. Loss of *Patched* function is thought to lead to constitutive signaling by Smoothened (*Smo*) (SEQ ID NO:17), resulting in hyperproliferation of the basal layer of the dermis. A similar mechanism may lead to the formation of germ cell tumors. This model proposes that the first step in the progression of a germ cell tumor is an initial loss of DNA by a germ cell precursor leading to a neoplastic germ cell which then forms a seminoma [De Jong *et al.*, *Cancer Genet. Cytogenet.* **48**: 143-167 (1990)]. From the invasive seminoma, all other forms of germ cell tumor types develop. Approximately 80% of all germ cell tumors correlate with an isochromosome 12p (i12p) and is found at a higher frequency in non-seminomas than seminomas [Rodriguez *et al.*, *Cancer Res.* **52**: 2285-2291 (1992)]. However, analysis of recurrent chromosomal abnormalities in testicular tumors including seminomas revealed a deletion of the region 1p32-36. Loss of this region was consistent in 36% of the germ cell tumor cases of in a recent study Summersgill *et al.*, *B. J. Cancer* **57**: 305-313 (1998)]. A similar deletion of chromosome 1p32-36 has been reported at a frequency of 28% in oligodendrogliomas; Bello, *et al.*, *Int. J. Cancer* **57**: 172-175 (1994). While expression of *Ptch-2* (SEQ ID NO:2) in the brain was not examined here in detail, *Ptch-2* (SEQ ID NO:2) is thought to be the *Dhh* receptor (see below) and expression of *Dhh* by murine Schwann cells was previously reported [Bitgood *et al.*, *Develop. Biol.* **172**: 126-138 (1995)]. Since *Ptch-2* (SEQ ID NO:2) localizes to chromosome 1p33-34 it is possible that *Patched-2*

regulates *Smo* (SEQ ID NO:17) signaling in *Dhh* target cells and that loss of *Patched-2* function leads to abnormal *Smo* (SEQ ID NO:17) signaling in these cells and subsequent tumor formation.

#### 4. *In situ* hybridization:

Mouse testis sections were cut at 16  $\mu$ m, and processed for *in situ* hybridization by the method described in Phillips *et al.*, *Science* 250: 290-294 (1990). <sup>33</sup>P-UTP labeled RNA probes were generated as described in Melton *et al.*, *Nucleic Acids Res.* 12: 7035-7052 (1984). Sense and antisense probes were synthesized from the 3' non-coding region of the mouse *Patched* or *Patched-2* and from a mouse *FuRK* cDNA fragment corresponding to the region encoding amino acid 317-486 of the human sequence using T3 and T7, respectively.

#### PTCH:

##### 503 (Anti-sense)

5'GGATTCTAATACGACTCACTATAGGGCCCAATGGCCTAAACCGACTGC3' (SEQ ID NO:27)

##### 503 (Sense)

5'CTATGAAATTAACCCTCACTAAAGGGACCCACGGCCTCTCCTCACA3' (SEQ ID NO:28)

#### PTCH2:

##### 504 (Anti-sense)

5'GGATTCTAATACGACTCACTATAGGGCCCCTAAACTCCGCTGCTCCAC3' (SEQ ID NO:12)

##### 504 (Sense)

5'CTATGAAATTAACCCTCACTAAAGGGAGCTCCCGTGAGTCCCTATGTG3' (SEQ ID NO:11)

*FuRK* sense and antisense were synthesized from a mouse fused DNA fragment using T3 and T7, respectively, corresponding to the region encoding amino acid residues 317-486 of the human.

Figure 6 illustrates that, although both *Ptch* (SEQ ID NO:4) and *Ptch-2* (SEQ ID NO:2) are expressed in testis, their expression pattern does not overlap. *Ptch* (SEQ ID NO:4) is expressed in the Leydig cells of the interstitium while *Ptch-2* (SEQ ID NO:2) is expressed in the primary and secondary spermatocytes.

The expression of *Patched-2* specifically in the developing spermatogonia suggest that *Patched-2* is the immediate target of *Dhh* (SEQ ID NO. 13). *Dhh* (SEQ ID NO. 13) is expressed by Sertoli cells and mice deficient in *Dhh* (SEQ ID NO. 13) are sterile because of a defect in sperm production [Bitgood *et al.*, *Curr. Biol.* 6: 298-304 (1996)]. Although this effect on germ cells was thought to be indirect and mediated by *Patched* present on Leydig cells, our data suggest that *Dhh* directly acts on germ cells through *Patched-2*. This is further demonstrated by the localization of *FuRK* (SEQ ID NO. 10): an intracellular kinase homologous to *Drosophila* Fused and involved in transducing the Hedgehog (*Hh*) signal. As shown in Figure 6, *FuRK* (SEQ ID NO:10) is colocalizes with *Ptch-2* (SEQ ID NO:2) in germ cells and not with *Ptch* (SEQ ID NO:4) in Leydig cells, suggesting that *Patched-2* and not *Patched* will be able to transduce the *Dhh* signal. These results suggest that *Patched-2* is a *Dhh* receptor.

*Ptch-2* mRNA levels in *Smo*-M2 (SEQ ID NO. 16) transgenic mice [a *Smo* mutation which results in autonomous phenotypes similar to BCC, Xie *et al.*, *Nature* 391: 90-92 (1998)] can be increased upon

abnormal activation of the *Hh* signaling pathway. As indicated in Fig. 9, *Ptch-2* (SEQ ID NO:2) levels were high in tumor cells (although lower than *Ptch* (SEQ ID NO:4) levels). This suggests that antibodies directed toward *Ptch-2* (SEQ ID NO:2) may be useful in the treatments of BCC.

#### 5. Immunoprecipitation with *Smo*:

5 The binding of *Patched-2* to *Smo* (SEQ ID NO:17) was assessed by cotransfection using a transient transfection system of a myc-epitope tagged *Smo* (SEQ ID NO:15) and a FLAG-epitope tagged *Patched* or *Patched-2* expression construct in 293 cells using standard techniques (Gorman, C., *DNA Cloning: A Practical Approach*, Clover, DM ed., Vol. 11, pp. 143-190, IRL Press, Washington, D.C.). 36 hours after transfection, the cells were lysed in 1% NP-40 and immunoprecipitated overnight with the 9E10 anti-myc antibody or with the M2 anti-FLAG antibody (IBI-Kodak) followed by protein A Sepharose, and then separated on a denatured 6% polyacrylamide gel. Proteins were detected by transfer to nitrocellulose and probing with antibodies to Flag or Myc epitopes, using the ECL detection system (Amersham). Figure 7B indicates that both *Ptch* (SEQ ID NO:4) or *Ptch-2* (SEQ ID NO:2) are expressed at the same level (IP Flag, Blot Flag) and that like *Ptch* (SEQ ID NO:4), *Ptch-2* (SEQ ID NO:2) forms a physical complex with *Smo* (SEQ ID NO:17). These results suggest that like *Patched*, *Patched-2* controls *Hh* signaling through its interaction with *Smo* (SEQ ID NO:17).

#### 6. *Hh* Binding:

To determine whether *Patched-2* is able to bind to the various hedgehog ligands, 293 cells were transfected with *Ptch* (SEQ ID NO:4) or *Ptch-2* (SEQ ID NO:2) using standard procedures. Cells were incubated with 100 pM  $^{125}$ I-*Shh* (19kD amino terminal fragment of murine *Shh* (SEQ ID NO:14)) in the presence or absence of excess unlabeled *Shh* (SEQ ID NO:14) or *Dhh* (SEQ ID NO:13) for 2h at room temperature. After equilibrium was reached, the ligand bound cells were centrifuged through a continuous sucrose gradient to separate unincorporated and then counted in a scintillation counter. Figure 7A shows that both *Dhh* (SEQ ID NO:13) and *Shh* (SEQ ID NO:14) bind to *Ptch* (SEQ ID NO:4) and *Ptch-2* (SEQ ID NO:2). Varying concentrations of cold competitor indicate that the 2 ligands have similar affinity for *Ptch* (SEQ ID NO:4) and *Ptch-2* (SEQ ID NO:2).

### Example 2

#### Expression of *patched-2* in *E. coli*

The DNA sequence encoding human *patched-2* is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites that correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from *E. coli*; see Bolivar *et al.*, *Gene*, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR amplified sequences are then ligated into the vector. The vector will preferably include sequences that encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the vertebrate *patched-2* coding region, lambda transcriptional terminator, and an argU gene.

The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook *et al.*, *supra*. Transformants are identified by their ability to grow on LB plates and antibiotic

resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.

Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized vertebrate *patched-2* protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.

### Example 3

#### Expression of patched-2 in mammalian cells

The vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector. Optionally, the vertebrate *patched-2* DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the vertebrate *patched-2* DNA using ligation methods such as described in Sambrook *et al.*, *supra*. The resulting vector is called pRK5-*patched-2*.

In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10  $\mu$ g pRK5-*patched-2* DNA is mixed with about 1  $\mu$ g DNA encoding the VA RNA gene [Thimmappaya *et al.*, *Cell*, 31:543 (1982)] and dissolved in 500  $\mu$ l of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M  $\text{CaCl}_2$ . To this mixture is added, dropwise, 500  $\mu$ l of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM  $\text{NaPO}_4$ , and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in FBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200  $\mu\text{Ci/ml}$   $^{35}\text{S}$ -cysteine and 200  $\mu\text{Ci/ml}$   $^{35}\text{S}$ -methionine. After a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of vertebrate *patched-2* polypeptide. The cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.

In an alternative technique, vertebrate *patched-2* may be introduced into 293 cells transiently using the dextran sulfate method described by Sompayrac *et al.*, *Proc. Natl. Acad. Sci.*, 12:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700  $\mu$ g pRK5-*patched-2* DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5  $\mu\text{g/ml}$  bovine insulin and 0.1  $\mu\text{g/ml}$  bovine transferrin. After about four days, the

c nditioned media is centrifuged and filtered to rem ve cells and debris. The sample containing expressed vertebrate *patched-2* can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.

In another embodiment, vertebrate *patched-2* can be expressed in CHO cells. The pSVi-*patched-2* can be transfected into CHO cells using known reagents such as  $\text{CaPO}_4$  or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as  $^{35}\text{S}$ -methionine. After determining the presence of vertebrate *patched-2* polypeptide, the culture medium may be replaced with serum free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed vertebrate *patched-2* can then be concentrated and purified by any selected method.

Epitope-tagged vertebrate *patched-2* may also be expressed in host CHO cells. The vertebrate *patched-2* may be subcloned out of the pRK5 vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-his tag into an expression vector. The poly-his tagged vertebrate *patched-2* insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones. Finally, the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His tagged vertebrate *patched-2* can then be concentrated and purified by any selected method, such as by  $\text{Ni}^{2+}$ -chelate affinity chromatography.

#### Example 4

##### Expression of vertebrate *patched-2* in Yeast

The following method describes recombinant expression of vertebrate *patched-2* in yeast.

First, yeast expression vectors are constructed for intracellular production or secretion of vertebrate *patched-2* from the ADH2/GAPDH promoter. DNA encoding vertebrate *patched-2*, a selected signal peptide and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of vertebrate *patched-2*. For secretion, DNA encoding vertebrate *patched-2* can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, the yeast alpha-factor secretory signal/leader sequence, and linker sequences (if needed) for expression of vertebrate *patched-2*.

Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant vertebrate *patched-2* can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing vertebrate *patched-2* may further be purified using selected column chromatography resins.

## Example 5

Expression of vertebrate *patched-2* in Baculovirus-Infected Insect Cells

The following method describes recombinant expression of vertebrate *patched-2* in Baculovirus-infected insect cells.

5 The vertebrate *patched-2* is *patched-2* upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-his tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the vertebrate *patched-2* or the desired portion of the vertebrate *patched-2* (such as the sequence encoding the extracellular domain of a transmembrane protein) is  
10 amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.

Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGold™ virus DNA (PharMingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin  
15 (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression is performed as described by O'Reilley et al., Baculovirus expression vectors: A laboratory Manual, Oxford: Oxford University Press (1994).

Expressed poly-his tagged vertebrate *patched-2* can then be purified, for example, by  $\text{Ni}^{2+}$ -chelate  
20 affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., *Nature*, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM  $\text{MgCl}_2$ ; 0.1 mM EDTA; 10% Glycerol; 0.1% NP-40; 0.4 M KCl), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% Glycerol, pH 7.8)  
25 and filtered through a 0.45  $\mu\text{m}$  filter. A  $\text{Ni}^{2+}$ -NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline  $A_{280}$  with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM phosphate; 300 mM NaCl, 10% Glycerol, pH 6.0), which elutes  
30 nonspecifically bound protein. After reaching  $A_{280}$  baseline again, the column is developed with a 0 to 500 mM Imidazole gradient in the secondary wash buffer. One mL fractions are collected and analyzed by SDS-PAGE and silver staining or western blot with  $\text{Ni}^{2+}$ -NTA-conjugated to alkaline phosphatase (Qiagen). Fractions containing the eluted His<sub>10</sub>-tagged vertebrate *patched-2* are pooled and dialyzed against loading buffer.

35 Alternatively, purification of the IgG tagged (or Fc tagged) vertebrate *patched-2* can be performed using known chromatography techniques, including for instance, Protein A or protein G column

chromatography

#### Example 6

##### Preparation of Antibodies that Bind Vertebrate *patched-2*

This example illustrates preparation of monoclonal antibodies, which can specifically bind vertebrate *patched-2*.

Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, supra. Immunogens that may be employed include purified vertebrate *patched-2*, fusion proteins containing vertebrate *patched-2*, and cells expressing recombinant vertebrate *patched-2* on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.

Mice, such as Balb/c, are immunized with the vertebrate *patched-2* immunogen (e.g., extracellular portions or cells expressed *ptch-2*) emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect vertebrate *patched-2* antibodies.

After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of vertebrate *patched-2*. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-*patched-2* cells, myeloma hybrids, and spleen cell hybrids.

The hybridoma cells will be screened in an ELISA for reactivity against vertebrate *patched-2*. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against vertebrate *patched-2* is within the skill in the art.

The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-vertebrate *patched-2* monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

#### Example 7

##### Gli Luciferase Assay

The following assay may be used to measure the activation of the transcription factor *GLI*, the mammalian homologue of the *Drosophila cubitus interruptus* (Ci). It has been shown that *GLI* is a transcription factor activated upon *SHh* stimulation of cells.

Nine (9) copies of a *GLI* binding site present in the HNF3 $\beta$  enhancer. (Sasaki *et al.*, *Development*

124: 1313-1322 (1997)), are introduced in front of a thymidine kinase minimal promoter driving the luciferase reporter gene in the pGL3 plasmid (Promega). The sequence of the *GLI* binding sequence is: TCGACAAGCAGGGAACACCCAAGTAGAAGCTC (p9XGliLuc) (SEQ ID NO:31), while the negative control sequence is: TCGACAAGCAGGGAAGTGGGAAGTAGAAGCTC (p9XmGliLuc) (SEQ ID NO:32). These constructs are cotransfected with the full length *Ptch-2* and *Smo* in C3H10T1/2 cells grown in F12. DMEM (50:50), 10% FCS heat inactivated. The day before transfection  $1 \times 10^5$  cells per well was inoculated in 6 well plates, in 2 ml of media. The following day, 1  $\mu$ g of each construct is cotransfected in duplicate with 0.025 mg ptkRenilla luciferase plasmid using lipofectamine (Gibco-BRL) in 100  $\mu$ l OptiMem (with GlutaMAX) as per manufacturer's instructions for 3 hours at 37°C. Serum (20%, 1 ml) is then added to each well and the cells were incubated for 3 more hours at 37°C. Cells are then washed twice with PBS, then incubated for 48 hours at 37°C in 2 ml of media. Each well is then washed with PBS, and the cells lysed in 0.5 ml Passive Lysis Buffer (Promega) for 15 min. at room temperature on a shaker. The lysate is transferred in eppendorf tubes on ice, spun in a refrigerated centrifuge for 30 seconds and the supernatant saved on ice. For each measure, 20  $\mu$ l of cell lysate is added to 100  $\mu$ l of LARII (luciferase assay reagent, Promega) in a polypropylene tube and the luciferase light activity measured. The reaction is stopped by the addition of Stop and Glow buffer (Promega), mixed by pipetting up and down 3 to 5 times and *Renilla* luciferase lights activity is measured on the luminometer.

#### Deposit of Material

The following materials have been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA (ATCC):

<u>Designation:</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
pRK7.hptc2.Flag-1405	209778	4/14/98

This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The deposit will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC § 122 and the Commissioner's rules pursuant thereto (including 37 CFR § 1.14 with particular reference to 886 OG 638).

The assignee of the present application has agreed that if a culture of the materials on deposit should die or be lost or destroyed when cultivated under suitable conditions, the materials will be promptly replaced on notification with another of the same. Availability of the deposited material is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to

practice the invention. The present invention is not to be limited in scope by the construct deposited, since the deposited embodiment is intended as a single illustration of certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable  
5 the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

What is claimed is:

1. Isolated nucleic acid comprising DNA having at least a 95% sequence identity to (a) a DNA molecule encoding a *patched-2* polypeptide comprising the sequence of amino acids 1 to about 1203 of Fig. 1 (SEQ ID NO:2), or (b) the complement of (a); and encoding a polypeptide having *patched-2* biological activity.
2. An isolated nucleic acid comprising DNA having at least a 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the cDNA in ATCC Deposit No. 209778 (designation: pRK7.hptc2.Flag-1405), or (b) the complement of the DNA molecule of (a).
3. (Amended) The isolated nucleic acid of claim 2 comprising human *patched-2* encoding sequence of the cDNA in ATCC deposit No. 209778 (designation: pRK7.hptc2.Flag-1405), or a sequence which hybridizes thereto under stringent conditions.
4. A vector comprising the nucleic acid of claim 1.
5. The vector of claim 4 operably linked to control sequences recognized by a host cell transformed with the vector.
6. A host cell transformed with the vector of claim 4.
7. The host cell of claim 6 which is mammalian.
8. The host cell of claim 7 wherein said cell is a CHO cell.
9. The host cell of claim 6 which is prokaryotic.
10. The host cell of claim 9 wherein said cell is an *E. coli*.
11. The host cell of claim 7 wherein said cell is a yeast cell.
12. The host cell of claim 11 which is *Saccharomyces cerevisiae*.
13. A process for producing *patched-2* polypeptides comprising culturing the host cell of claim 9 under conditions suitable for expression of vertebrate *patched-2* and recovering *patched-2* from the cell culture.
14. (Amended) Isolated native sequence human *patched-2* polypeptide comprising amino acid residues

1 to 1203 of Fig. 1 (SEQ ID NO:2).

15. (Amended) Isolated native sequence human *patched-2* polypeptide encoded by the nucleotide deposited under accession number ATCC 209778 (Designation: pRK7.hptc2.Flag-1405) having *patched-2* biological activity.

16. A chimeric molecule comprising vertebrate *patched-2* polypeptide *patched-2* to a heterologous amino acid sequence.

17. The chimeric molecule of claim 16 wherein said heterologous amino acid sequence is an epitope tag sequence.

18. The chimeric molecule of claim 17 wherein said heterologous amino acid sequence is a constant region of an immunoglobulin.

19. An antagonist of *patched-2* which blocks, prevents, inhibits and/or neutralizes the *Dhh* function in the *Dhh* signaling pathway.

20. The antagonist of claim 19 which is a small bioorganic molecule.

21. The antagonist of claim 19 which is an antisense nucleotide.

22. An agonist of *patched-2* which stimulates or enhances the normal functioning of *patched-2* in the *Dhh* signaling pathway.

23. (Amended) The agonist of claim 22 which prevents *Smo* (SEQ ID NO:17) inactivation of *ptch-2* (SEQ ID NO:2)

24. The agonist of claim 22 which is a small bioorganic molecule.

25. The agonist of claim 24 which is a small bioorganic molecule.

26. A method of screening for antagonists or agonists of *patched-2* biological activity comprising:

- (a) exposing *patched-2* expressing target cells in culture to a candidate compound and *Dhh*; and
- (b) analyzing cells for binding of *Dhh* to *patched-2*; or
- (c) scoring phenotypic or functional changes in the treated cells;

and comparing the results to control cells which were not exposed to the candidate compound.

27. A method of screening for antagonist or agonist molecule of *patched-2* biological activity comprising:

(a) exposing a *patched-2* ligand and a compound having *patched-2* biological activity to a candidate antagonist or agonist; and

5 (b) analyzing the substrate for binding of the ligand to the compound; and comparing the results to control reactions which were not exposed to the candidate molecule.

28. A method of diagnosing to determine whether a particular disorder is modulated by *Dhh* signaling, comprising:

10 (a) culturing test cells or tissues;

(b) administering a compound which can inhibit *patched-2* modulated *Dhh* signaling; and

(c) analyzing the level of *Dhh* binding to *patched-2* or *Dhh* mediated phenotypic effects in the test cells.

1/27

1 GTTATTTCAG GCCATGGTGT TGGCGCGGAAT TAATTCCCGA TCCAGACATG ATAAGATACA TTGATGAGTT TGGACAAACC ACAACTAGAA TGCAGTGAAA  
CAATAAAGTC CCGTACCACA ACGCGGCTTA ATTAAGGGCT AGGTCTGTAC TATTCTATGT AACTACTCAA ACCTGTTTGG TGTGATCTT ACGTCACTTT  
(SEQ ID NO: 1)

101 AAAATGCTTT ATTGTGAAA TTTGTGATGC TATTGCTTTA TTGTAAACCA TTATAAGCTG CAATAAACAA GTTGGGCCAT GCGGGCCAAG CTTCTGCAGG  
TTTTACGAAA TAAACACTTT AAACACTACG ATAACGAAAT AAACATTGGT AATATTTCAC GTTATTGTT CAACCCGATA CCGCCGGTTC GAAGACGTCC

201 TCGACTCTAG AGGATCCCG GGGAAATCCG GCATGACTCG ATCGCCGCC CACAGAGAGC TGCACCCGAG TTACACACCC CCAGCTCGAA CCGCAGCACC  
AGCTGAGATC TCCTAGGGGC CCCTTAAGGC CGTACTGAGC TAGCGGGGG GAGTCTCTCG ACGGGGGCTC AATGTGTGG GGTGAGCTT GCGTCTGTG  
M T R S P P L R E L P P S Y T P P A R T A A P  
1 ^insert starts here (SEQ ID NO: 2)

301 CCAGATCCTA GCTGGGAGCC TGAAGGCTCC ACTCTGGCTT CGTGCTTACT TCCAGGGCCT GCTCTTCTCT CTGGGATGG GGATCCAGAG ACATTGTGGC  
GGTCTAGGAT CGACCCCTCG ACTTCCGAGG TGAGACCGAA GCACGAATGA AGGTCCCGGA CGAGAAAGAGA GACCCCTACG CCTAGGTCTC TGTAACACCG  
24 Q I L A G S L K A P L W L R A Y F Q G L L F S L G C G I Q R H C G

401 AAAGTGCTCT TTCTGGGACT GTTGGCCTTT GGGCCCTGG CATTAGTCT CCGCATGGCC ATTATTGAGA CAAACTTGA ACAGCTCTGG GTAGAAAGTGG  
TTTACAGAGA AAGACCCTGA CAACCGGAAA CCCCCGGACC GTAATCCAGA GCGGTACCG TAATAACTCT GTTTGAACCT TGTCGAGACC CATCTTCACC  
57 K V L F L G L L A F G A L A L G L R M A I I E T N L E Q L W V E V G

501 GCAGCCGGGT GAGCCAGGAG CTGCATTACA CCAAGGAGAA GCTGGGGGAG GAGGCTGCAT ACACCTCTCA GATGCTGATA CAGACCGCAC GCCAGGAGGG  
CGTCGGCCCA CTCGGTCTCT GACGTAATGT GGTTCCTCTT CGACCCCTCTT TGTGGAGAGT CTACGACTAT GTCTGGCGTG CCGTCCCTCCC  
91 S R V S Q E L H Y T K E K L G E E A A Y T S Q M L I Q T A R Q E G

601 AGAGAATATC CTCACACCCG AAGCACTTGG CCTCCACCTC CAGCAGCCC TCACTGCCAG TAAAGTCCAA GTATCACTCT ATGGAAGTC CTGGGATTG  
TCTCTTGTAG GAGTGTGGC TTCGTGAAC GAGGTGGAG GTCCGTCGGG AGTGACGGTC ATTCAGGTT CATAGTGAGA TACCCCTCAG GACCCCTAAC  
124 E N I L T P E A L G L H L Q A A L T A S K V Q V S L Y G K S W D L

701 AACAAAATCT GCTACAAGTC AGGAGTTCC CTTATTGAAA ATGGRATGAT TGAGTGGATG ATTGAGAAGC TGTTCCTGGT CGTGATCCTC ACCCCCTCG  
TTGTTTGTAG CGATGTTTCTG TCCTCAAGG GAATAACTTT TACCTTACTA ACTCACCTAC TAACCTCTCG ACAAGGCGAC GCACCTAGGAG TGGGGGGAGC  
157 N K I C Y K S G V P L I E N G M I E W M I E K L F P C V I L T P L D

801 ACTGCTTCTG GGAGGAGCC AAACCTCCAAG GGGGCTCCGC CTACCTGCCC GGCCGCCCCG ATATCCAGTG GACCAACCTG GATCCAGAGC AGCTGCTGGA  
TGACGAAGAC CTTCCCTCGG TTTGAGGTTT CCCCAGGGG GATGGACGGG CCGCGGGCC TATAGTCTAC CTGGTTGGAC CTAGGTCTCG TCGACGACCT  
191 C F W E G A K L Q G G S A Y L P G R P D I Q W T N L D P E Q L L E

FIG. 1A

2/27

901 GGAGCTGGGT CCCTTTGCT CCCTTGAGG CTCTGGAG AGGCACAGT GGGCAGGCC TACGTGGGC GSCCTGTCT GCACCTGAT  
CCTCGACCA GGAACCGA GGAACCTCC GAAGGCCCTC GAGGATCTGT TCCGTGTCCA CCGGTCCGG ATGACACCCG CCGGACAGA CGTGGACTA  
224 E L G P F A S L E G F R E L L D K A Q V G Q A Y V G R P C L H P D

1001 GACCTCCACT GCCAAGCTAG TGCCCCAAC CATAACAGCA GGCAGGCTCC CAATGTGGCT CACGAGCTGA GTGGGGGCTG CCATGGCTTC TCCACAAAT  
CTGAGGTGA CCGGTGATC ACGGGGTG GTAGTGTCTG CCGTCCGAGG GTTACACCGA GTGCTGACT CACCCCCGAC GGTACCGAAG AGGTGTTTA  
257 D L H C P P S A P N H H S R Q A P N V A H E L S G G C H G F S H K F

1101 TCATGCACTG GCAGGAGAA TTGCTGCTGG GAGGATGGC CAGAGACCC CAGGAGAGC TGCTGAGGC AGAGGCCCTG CAGAGCACCT TCTTGCTGAT  
AGTACGTGAC CGTCTCCTT AACGACGACC CTCCTGACCG GTCTCTGGG GTTCTCTCTG ACGACTCCCG TCTCCGGGAC GTCTCTGGA AGAAGACTA  
291 M H W Q E E L L L G G M A R D P Q G E L L R A E A L Q S T F L L M

1201 GAGTCCCCG CAGCTGTAG AGCATTTCCG GGTGACTAT CAGACACATG ACATTGGCTG GAGTAGGAG CAGGCCAGCA CAGTGTCTA AGCCTGGCAG  
CTCAGGGCG GTGACATGC TCGTAAAGC CCCACTGATA GTCTGTGTAC TGTAAACGAC CTCACCTCTC GTCCGGTCTG GTCACGATGT TCGGACCGTC  
324 S P R Q L Y E H F R G D Y Q T H D I G W S E E Q A S T V L Q A W Q

1301 CGCGCTTTG TGCAGCTGG CCAGGAGGC CTGCTTCCA ACAGATCCAT GCCTTCTCT CCACCACCCT GGATGACATC CTGCATGCTG  
GCCGGAAC ACGTCGACG GGTCTCTCCG GACGACTCT TCGAAGGT CGTCTAGTA CGGAAGAGG GGTGTGGG CTTACTGTAG GACGTACGA  
357 R F V Q L A Q E A L P E N A S Q Q I H A F S S T T L D D I L H A F

1401 TCTCTGAAGT CAGTGTGCTG CAGTGTGCTG GAGGCTATCT GCTCATGCTG GCCTATGCTG GTGTGACCAT GCTGCGGTG GACTGCGCC AGTCCCAGG  
AGAGACTCA GTCACGACG GCACACACAC CTCGATAGA CGAGTACGAC CGGATACGGA CACACTGGTA CGACGCCACC CTGACGCGGG TCAGGGTCCC  
391 S E V S A A R V V G G Y L L M L A Y A C V T M L R W D C A Q S Q G

1501 TTCCGTGGC CTTGCGGG TACTGCTGT GGCCTGCG GTGGCCTCAG GCCTTGGCT CTGTGCCCTG CTCGGCATCA CCTTCAATGC TGCCACTACC  
AAGCACCG GAACGGCCC ATGACGACCA CCGGACCG CACCGAGTC CGGAACCCGA GACACGGGAC GAGCCGTAGT GGAAGTTACG ACGGTGATGG  
424 S V G L A G V L L V A L A V A S G L G L C A L L G I T F N A A T T

1601 CAGGTGCTG CTTTCTTGG TCTGGGAATC GCGTGGATG ACGTATTCCT GCTGGCGCAT GCCTTCAACAG AGCTCTGCC TGGCACCCCT CTCCAGGAGC  
GTCCAGCAG GAAAGAACCG AGACCTTAG CCGCACCTTAC TGCATAAGGA CGACCGCGTA CGGAAGTGT TCCGAGACGG ACCGTGGGA GAGTCTCTG  
457 Q V L P F L A L G I G V D D V F L L A H A F T E A L P G T P L Q E R

1701 GCATGGCGA GTGTCTGAC CAGTGTGCT ACTACATCC ATCAACAACA TGGCCGCTT CCTCATGGCT GCCCTGTTT CCATCCCTGC  
CGTACCGCT CACAGACGTC CCGTCCCGT GTGACAGCA TGAGTGTAG TAGTTGTGT ACCGGCGGA GGAGTACCGA CCGGAGCAAG GGTAGGACG  
491 M G E C L Q R T G T S V V L T S I N N M A A F L M A A L V P I P A

FIG. 1B

1801 GCTGGAGCC TTCTCCCTAC AGCGGCCCAT AGTGGTTGGC TGCACCTTTG TAGCCGTGAT GCTTGTTCTT CCAGCCATCC TCAGCTTGA CCTACGGCGG  
CGACGCTCGG AAGAGGGATG TCCGCCGGTA TCACCAACCG ACGTGGAAAC ATCGGCACCTA CGAACAGAAG GGTGGGTAGG AGTCGGACCT GGATGCCGCC  
524 L R A F S L Q A A I V V G C T F V A V M L V F P A I L S L D L R R

1901 CGCCACTGCC AGCGCCTTGA TGTGCTCTGC TGCTTCTCCA GTCCCTGCTC TGCTCAGGTG ATTCAGATCC TGCCCCAGGA GCTGGGGGAC GGGACAGTAC  
GCGGTGACGG TCGCGGAAC ACACGAGAGC ACGAAGAGGT CAGGAGCAGC ACGAGTCCAC TAAGTCTAGG ACGGGGTCTT CGACCCCTTG CCCTGTCTATG  
557 R H C Q R L D V L C C F S S P C S A Q V I Q I L P Q E L G D G T V P

2001 CAGTGGGCAT TGCCACCTC ACTGCCACAG TTCAAGCCTT TACCACCTGT GAAGCCAGCA GCCAGCATGT GGTACCATC CTGCTCTCCC AAGCCACCT  
GTCACCCGTA ACGGTGGAG TGACGGTGT CAGGTTCGAA ATGGGTGACA CTTCGGTCTG CCGTCTGTACA CCAGTGGTAG GACGAGGGG TTCGGGTGGA  
591 V G I A H L T A T V Q A F T H C E A S S Q H V V T I L P P Q A H L

2101 GGTGCCCCCA CCTTCTGACC CACTGGGCTC TGAGCTCTTC AGCCCTGGAG GGTCCACACG GGACCTTCTA GGCCAGGAGG AGGAGACAAG GCAGAAGGCA  
CCACGGGGGT GGAAGACTGG GTACCCCGAG ACTCGAGAAG TCGGGACCTC CCAGGTGTGC CCTGGAAGAT CCGTCTCTCC TCCTCTGTTC CGTCTTCCGT  
624 V P P P S D P L G S E L F S P G G S T R D L L G Q E E T R Q K A

2201 GCCTGCAAGT CCCTGGCCTG TGCCCGCTGG AATCTTGCCC ATTTGCCCCG CTATCAGTTT GCCCGGTGTC TGCTCCAGTC ACATGCCAAG GCATCTGTGC  
CGGACGTTCA GGGACGGGAC ACGGGCGACC TTAGAACGGG TAAAGCGGGC GATAGTCAA CCGGGCAACG ACGAGGTGAG TGTCAGGTTC CCGTAGCACG  
657 A C K S L P C A R W N L A H F A R Y Q F A P L L L Q S H A K A I V L

2301 TGGTGCTCTT TGGTGCTCTT CTGGGCTGTA GCCTCTACGG AGCCACCTTG GTGCAAGACG GCCTGGCCCT GACGGATGTG GTGCTCTGGG GCACCAAGGA  
ACCACGAGAA ACCACGAGAA GACCCGGACT CCGAGATGCC TCGGTGGAGC CAGCTTCTGC CCGACCGGGA CTGCCTACAC CACGAGACCC CGTGGTTCTT  
691 V L F G A L L G L S L Y G A T L V Q D G L A L T D V V P R G T K E

2401 GCATGCTCTC CTGAGGCCCC AGCTCAGGTA CTTCTCCCTG TACGAGGTGG CCCTGGTGAC CCAGGGTGGC TTGACTACG CCCATTCCCA ACGGCCCTC  
CGTACGGAAG GACTCGGGG TCGAGTCCAT GAAAGGGGAC ATGCTCCACC GGGACCACTG GGTCCCAACG AAACGTGATGC GGGTAAGGT TGCGCGGGAG  
724 H A F L S A Q L R Y F S L Y E V A L V T Q G G F D Y A H S Q R A L

2501 TTTGATCTGC ACCAGCGCTT CAGTTCCCTC AAGGCGGTGC TGCCCCCACC GGCCACCCAG GGACCCCGCA CCTGGCTGCA CTATTACCG AACTGGCTAC  
AAACTAGACG TGGTCGCGAA GTCNAGGGAG TTCCGCCACG ACGGGGTGG CCGGTGGGTG CCGTGGGCGT GGACCGACGT GATAATGGCG TTGACCGATG  
757 F D L H Q R F S S L K A V L P P P A T Q A P R T W L H Y Y R N W L Q

2601 AGGGAATCCA GGCTGCTCTT GACCAGGACT GGGCTTCTGG GCGCATCACC CGCCACTCGT ACCGCAATGG CTCTGAGGAT GGGGCCCTGG CCTACAAGCT  
TCCCTTAGGT CCGACCGAAA CTGGTCTCTGA CCGAAGACC CCGGTAGTGG CCGGTAGCA TGCGGTACC GAGACTCCTA CCGCGGACC GGATGTTCTGA  
791 G I Q A A F D Q D W A S G R I T R H S Y R N G S E D G A L A Y K L

FIG. 1C

2701 GCTCATCCAG ACTGGAGACG CCAAGAGCC TCTGGATTTC AGCCAGCTGA CCACAGGAA GCTGGTGGAC AGAGAGGGAC TGATTCCACC CGAGCTCTTC  
 CGAGTAGGTC TGACCTCAGC GGGTCTCGG AGACCTAAAG TCGTCTGACT GGTGTTCTT CGACCACCTG TCTCTCCCTG ACTAAGGTGG GCTCGAGAAG  
 824 L I Q T G D A Q E P L D F S Q L T T R K L V D R E G L I P P E L F  
 2801 TACATGGGC TGACCGTGTG GGTGAGCAGT GACCCCTGG GTCTGGCAGC CTCACAGGCC AACTTCTACC CCCACCTCC TGAATGGCTG CACGACAAAT  
 ATGTACCCCG ACTGGCACAC CCACTCGTCA CTGGGGGACC CAGACCTGCG GAGTGTCCG TTGAAGATGG GGGTGGAGG ACTTACCGAC GTGCTGTTTA  
 857 Y M G L T V W V S S D P L G L A A S Q A N F Y P P P P E W L H D K Y  
 2901 ACGACACCAC GGGGAGAAC CTTCGCATCC CGCCAGCTCA GCCTTGGAG TTTGCCCACT TCCCTTCTT GCTGCGTGGC CTCCAGAAGA CTGCAGACTT  
 TGCTGTGGTG CCCCTCTTG GAAGCGTAGG GCGTCTGAGT CGGAACCTC AAACGGGTCA AGGGGAAGGA CGACGCACCG GAGGTCTTCT GACGTCTGAA  
 891 D T T G E N L R I P P A Q P L E F A Q F P F L L R G L Q K T A D F  
 3001 TGTGAGGCC ATCGAGGGG CCGGGCAGC ATGCGCAGG GCGGGCAGG CTGGGTGCA CGCTACCCC AGCGGCTCC CCTTCTCTT CTGGGAACAG  
 ACACCTCCGG TAGTCCCCC GGGCCCGTCG TAGCGTCTC CGGCCGTCC GACCCACGT CGGGATGGG TCGCCGAGG GGAAGGAGAA GACCTTGTG  
 924 V E A I E G A R A A C A E A G Q A G V H A Y P S G S P F L F W E Q  
 3101 TATCTGGCC TCGCGCGCTG CTTCCTGCTG GCGTCTGCA TCCTGCTGCT GTGCACCTTCT CTGCTCTGTG CTCTGCTGCT CCTCAACCCC TGGACGGCTG  
 ATAGACCCCG ACGCCGCGAC GAAGGACGAC CGGCAGACGT AGGACGACCA CACGTGAAG GAGCAGACAC GAGACGACGA GGAGTTGGG ACCTGCCGAC  
 957 Y L G L R R C F L L A V C I L L V C T F L V C A L L L L L N P W T A G  
 3201 GCCTCATAGT GCTGGTCTG GCGATGATGA CAGTGAACCT CTTTGGTATC ATGGGTTTCC TGGGCATCAA GCTGAGTGCC ATCCCCGTGG TGATCTTGT  
 CGGAGTATCA CGACCAGGAC CGCTACTACT GTACACCTTGA GAAACCATAG TACCCAAAG ACCCGTAGTT CGACTACCG TAGGGGCACC ACTAGGAACA  
 991 L I V L V L A M M T V E L F G I M G F L G I K L S A I P V V I L V  
 3301 GGCCTCTGTA GGCATTGGCG TTGAGTTTAC AGTCCACGTG GCTCTGGGT TCCTGACCAC CCAGGGCAGC CGGAACCTGC GGGCCGCCCA TGCCCTTGAG  
 CCGGAGACAT CCGTAACCGC AACTCAAGTG TCAGGTGCAC CGAGACCCGA AGGACTGGTG GGTCCCGTCG GCCTTGGAGC CCGGCGGGT ACGGGAACTC  
 1024 A S V G I G V E F T V H V A L G F L T T Q G S R N L R A A H A L E  
 3401 CACACATTG CCCCCGTGAC CGATGGGCCC ATCTCCACAT TGCTGGGTCT GCTCATGCTT GCTGTTTCCC ACTTTGACTT CATTGTAAGG TACTTCTTTG  
 GTGTGTAAC GGGGGCACTG GCTACCCCGG TAGAGGTGTA ACCACCCAGA CGAGTACGAA CGACCAAGGG TGAACCTGAA GTAACATTCC ATGAAGAAAC  
 1057 H T F A P V T D G A I S T L L G L L M L A G S H F D F I V R Y F F A  
 3501 CGGCGCTGAC AGTGCTCAGC CTCCTGGGCC TCCTCCATGG ACTCGTGTG CTGCTGTGCT TGCTGTCCAT CCTGGGCCCC CGGCCAGAGG TGATACAGAT  
 GCCGCGACTG TCACGAGTGC GAGGACCCGG AGGAGGTACC TGAGCAGCAG GACGGACACG ACGACAGGTA GGACCCGGG GCGGTCTCC ACTATGTCTA  
 1091 A L T V L T L L G L L H G L V L L P V L L S I L G P P P E V I Q M

FIG. 1D

5/ 27

```

3601 GTACAAGGAA AGCCACAGAGA TCCTGAGTCC ACCAGCTCCA CAGGAGGGCG GGCTTAGGTG GGGGGCATCC CCCAGAGCTT TGCCAGAGTG
CATGTTCCCTT TCGGGTCTCT AGGACTCAGG TGGTCGAGGT GTCCCTCCGC CCGAATCCAC CCCCCGTAGG AGGAGGGACG GGGTCTCGAA ACGGTCTCAC
1124 Y K E S P E I L S P P A P Q G G G L R W G A S S S L P Q S F A R V
3701 ACTACCTCCA TGACCGTGGC CATCCACCCA CCCCCCTGC CTGTGCCTA CATCCATCCA GCCCCTGATG AGCCCCCTTG GTCCCTGCT GCCACTAGCT
TGATGGAGGT ACTGGCACCG GTAGGTGGGT GGGGGGACG GACCACGGAT GTAGGTAGGT CCGGGACTAC TCGGGGGAAC CAGGGGACGA CCGTGATCGA
1157 T T S M T V A I H P P P L P G A Y I H P A P D E P P W S P A A T S S
3801 CTGGCAACCT CAGTTCACAG GGACCAAGTC CAGCCACTGG GTGAAGAGC AGCTGAAGCA CAGAGACCAT GTGTGGGGCG TGTGGGGTCA CTGGGAAGCA
GACCGTTGGA GTCAAGGTCC CCTGGTCCAG GTCGGTGACC CACTTCTCG TCGACTTCGT GTCTCTGGTA CACACCCCGC ACACCCAGT GACCCCTTCGT
1191 G N L S S R G P G P A T G O 1203
3901 CTGGGTCTGG TGTAGACGC AGGACGGACC CCTGGAGGGC CTGCTGCTG CTGCATCCCC TCCTCCGACC CAGCTGTCTAT GGGCCTCCCT GATATCGAAT
GACCCAGACC ACAATCTGCG TCCTGCCTGG GGACCTCCCG GGACGACGAC GACGTAGGGG AGAGGGCTGG GTCGACAGTA CCCGGAGGGA CTATAGCTTA
^T to C (silent)
4001 TCAATCGATA GAACCGAGGT GCAGTTGGAC
AGTTAGCTAT CTTGGCTCCA CGTCAACCTG

```

pRK follows, this is the 5prime end of vector^

FIG. 1E

6/27

(SEQ ID NO: 3)

```
          30          40          50          60          70
905531    GCTGGGGTGCACGCCTACCNCAGCGGNTCCCCCTTCCTCTTCTGGGAACA
          ::: :: : ***** *****
```

(SEQ ID NO: 4)

```
hpatched  CTGGGGCTGTCCAGTTACCCCAACGGCTACCCCTTCCTCTTCTGGGAGCA
          3010          3020          3030          3040          3050
```

```
          80          90          100          110          120
905531    GTATCTGGGCCTGCGGCGCTGCTTCCTGCTGGCCGTCTGCATCCTGCTGG
          *** * ***** * * * * * * * * * * * * * * * * * * * * * * *
```

```
hpatched  GTACATCGGCCTCCGCCACTGGCTGCTGCTGTTTCATCAGCGTGGTGTGG
          3060          3070          3080          3090          3100
```

```
          130          140          150          160          170
905531    TGTGCACCTTCCTCGTCTGTGCTCTGCTGCTCCTNAACCCCTGGACGGCT
          ***** ***** * * * * * * * * * * * * * * * * * * * *
```

```
hpatched  CCTGCACATTCCTCGTGTGCGCTGTCTTCCTTCTGAACCCCTGGACGGCC
          3110          3120          3130          3140          3150
```

```
          180          190          200          210          220
905531    GGCCTNATAGTGCTGGTCTGCGGATGATGACAGTGAAGTCTTTGGTAT
          ** ***** * * * * * * * * * * * * * * * * * * * *
```

```
hpatched  GGGATCATTGTGATGGTCTGCGCTGATGACGGTCGAGCTGTTCCGGCAT
          3160          3170          3180          3190          3200
```

```
          230          240          250
905531    CATGGGTTTNTCTGGGCATCAAGCTGAGT
          ***** * * * * * * * * * * * *
```

```
hpatched  GATGGGCCTCATCGGAATCAAGCTCAGT
          3210          3220          3230
```

```
          80          90          100          110          120
905531    TCTGGGCCTGCGGCGCTGCTTCCTGCTGGCCGTCTGCATCCTGCTGGTGT
          ::: :: : * * * * * * * * * * * * * * * * * * * * * * * *
hpatched  GCTGCTGCTGTTTCATCAGCGTGGTGTGGCC---TGCACATTCCTCGTGT
          3090          3100          3110          3120
```

```
          130          140          150
905531    GCACTTTCCTCGTCTGTGCTCTGCTGCT
          ** * * * * * * * * * * * * * * * * * * * * * * * *
hpatched  GCGCTGTCTTCCTTCTGAACCCCTGGAC
          3130          3140          3150
```

FIG. 2A

7/ 27

(SEQ ID NO: 5) 1326258 30 40 50 60 70  
GCTGGGGTGCACGCCTACCCCAGCGGCTCCCCCTCCTCTTCTGGGAACA  
::: :: : \*\*\*\*\*  
hpatched 3010 3020 3030 3040 3050  
CTGGGGCTGTCCAGTTACCCCAACGGCTACCCCTCCTCTTCTGGGAGCA

1326258 80 90 100 110 120  
GTATCTGGGCCTGCGGCGCTGCTTCCTGCTGGCCGTCTGCATCCTGCTGG  
\*\*\* \* \*\*\*\*\*  
hpatched 3060 3070 3080 3090 3100  
GTACATCGGCCTCCGCCACTGGCTGCTGTTTCATCAGCGTGGTGTGG

1326258 130 140 150  
TGTGCACTTTCCTCCTCTGTGCTCT  
\*\*\*\*\*  
hpatched 3110 3120 3130  
CCTGCACATTCCTCGTGTGCGCTGT

1326258 90 100 110 120 130  
TCTGGGCCTGCGGCGCTGCTTCCTGCTGGCCGTCTGCATCCTGCTGGTGT  
::: ::: \* \* \* \* \*  
hpatched 3090 3100 3110 3120  
GCTGCTGCTGTTTCATCAGCGTGGTGTGGCC---TGCACATTCCTCGTGT

1326258 140 150  
GCACTTTCCTCCTCTGTGCTCT  
\* \* \* \* \*  
hpatched 3130 3140  
GCGCTGTCTTCCTTCTGAACCC

1326258 10 20 30 40 50  
CCGGGCAGCATGCGCAGAGGCCGCGCCAGGCTGGGGTGCACGCCTACCCCA  
\*\*\*\*\*  
(SEQ ID NO: 6) hpatched.RC 710 720 730 740 750  
CCGGGCGGCATG--GCGAAGCGGACCACGCTGGGGGGTGGCTCAGGGGAG

FIG. 2B

8/27

(SEQ ID NO:4) PTCH 1 MASAGNAEPQDRGGGGGCGIGAPRPAAGGRRRRRTGGLRRAAAPDRDYL  
(SEQ ID NO:2) PTCH2 1 .....MTRSPPLREL.

PTCH 51 HRPSYCDAAFALAQISKGKAATGRKAPLWLRKAFQRLFLKLCGYIKNCGK  
PTCH2 11 -P-PSYTPP..ARTAAPQILAGSLKAPLWLRAYFQGLLFLSLGCGIORHCGK

TM1  
PTCH 101 FLVYGLLIEGAFVGLKAAALETNVEELWVEVGGRRVSRRELNYTRQKIGEE  
PTCH2 58 VLFLGLLAFGLALGLRMAIIETNLEQLWVEVGSRRVSOELHYTKEKLGEE

PTCH 151 AMFNPOQLMIQTPKKEGANVLTTEALLQHLDSALQASRVHVYMYNRQWKLE  
PTCH2 108 AAYTSQMLIQTARQEGENILTPAELGLHLQAALTASKVQVSLYGKSWDLN

PTCH 201 HLCYKSGELITETGYMDQIIIEYLYPCLLITPLDCFWEGAKLQSGTAYLLG  
PTCH2 158 KICYKSGVPLIENGMIIEWMIEKLFPCVILTPDCFWEGAKLQGSAYLPG

PTCH 251 KPPLRWTNFDPLEFLEELKKINYQVDSWEEMLNKAEVGHGYMDRPPCLNPA  
PTCH2 208 RPDIOWTNLDPEOLLEELGPFA.SLEGFRELLDKAQVGGQAYVGRPCCLHPD

PTCH 301 DPDCPATAPNKNSTKPLDMALVLNGGCHGLSRKYMHWQEELIVGGTVKNS  
PTCH2 257 DLHCPAPSAPNHHSRQAPNVAAHELSGGCHGFSHKFMHWQEELLLGGMARDP

PTCH 351 TGKLVSAHALQTMFQLMTPKQMYEHFKGYEYVSHINWNEDKAAAILAEAW  
PTCH2 307 QGELLRAEALQSTFLMLSPRLYEHRG.DYQTHDIGWSEEAQSTVLQAW

TM2  
PTCH 400 QRTYVEVVHQSVAQNSTQKVLSFTTTTLDDILKSFSDVSVIRVASGYLLM  
PTCH2 356 QRFVQLAQEALPENASQIHAFSSTTLDDILHAFSEVSAARVVGVLML

FIG. 3A

9/ 27




FIG. 3B

10/27



FIG. 3C

11/27

PTCH 1247 AGGPAHQVIVEATENPVFAHSTVVHPESRHHPPSNPRQQPHLDSGSLPPG  
PTCH2 1182 PWSPATSSGNLSSRGPGPATG  
PTCH 1297 RQGQPRRDPPREGLWPPLYRPRRDAFEISTEGHSGPSNRARWGPRGARS  
PTCH 1347 HNPRNPASTAMGSSVPGYCQPIITVTASASVTVAVHPPVPVPGGRNPRGG  
PTCH 1397 LCPGYPETDHGLFEDPHVPFHVRCERRDSKVEVIELQDVECEERPRGSSS  
PTCH 1447 N

FIG. 3D




FIG. 4



FIG. 5

SUBSTITUTE SHEET (RULE 26)



FIG. 6C



FIG. 6B




FIG. 6A




FIG. 6F




FIG. 6E



FIG. 6D

16/27




FIG. 7A




FIG. 7B

	10	20	30	40	50
<b>hPtch-2</b>	MTRSPPLRELPPSYTPPARTAAPQILAGSLKAPLWLRAYFQGLLFSLGCG * * . * ***** . ** . ***** . *****				
<b>mPatched2</b> (SEQ ID NO:7)	MVRPLSLGELPPSYTPPARSSAPHILAGSLQAPLWLRAYFQGLLFSLGCR				
	10	20	30	40	50
	60	70	80	90	100
<b>hPtch-2</b>	IQRHCGKVLFLGLLAFGALALGLRMAIIETNLEQLWVEVGSRVSQELHYT ** . ***** . ***** . * . **** . *****				
<b>mPatched2</b>	IQKHCGKVLFLGLVAFGALALGLRVAVIETDLEQLWVEVGSRVSQELHYT				
	60	70	80	90	100
	110	120	130	140	150
<b>hPtch-2</b>	KEKLGEAAAYSQM LIQTARQEGENILTPEALGLHLQAALTASKVQVS LY ***** . *** * . ***** . *****				
<b>mPatched2</b>	KEKLGEAAAYSQM LIQTAHQEGGNVLTPEALDLHLQAALTASKVQVS LY				
	110	120	130	140	150
	160	170	180	190	200
<b>hPtch-2</b>	GKSWDLNKICYKSGVPLIENGMI EWMI EKLFPCVIL TPLDCFW EGAK LQG ***** . *****				
<b>mPatched2</b>	GKSWDLNKICYKSGVPLIENGMI ERMI EKLFPCVIL TPLDCFW EGAK LQG				
	160	170	180	190	200
	210	220	230	240	250
<b>hPtch-2</b>	GSAYLPGRPD IQWTNLDP EQLLEELGP FASLEGFR EL LDKAQVGQ AYVGR ***** . *****				
<b>mPatched2</b>	GSAYLPGRPD IQWTNLDP QQLLEELGP FASLEGFR EL LDKAQVGQ AYVGR				
	210	220	230	240	250
	260	270	280	290	300
<b>hPtch-2</b>	PCLHPDDLHC PPSAPNHHSRQ APNV AHEL SGGCHGF SHKF MHWQEELL LG *** . *** ***** . ***** . *****				
<b>mPatched2</b>	PCLDPDDPHC PPSAPNRHSRQ APNV AQEL SGGCHGF SHKF MHWQEELL LG				
	260	270	280	290	300
	310	320	330	340	350
<b>hPtch-2</b>	GMARD PQGELLRAEALQSTF LLMSPRQLYEH FRGDYQTHDIG WSEEQAST * *** ** . *****				
<b>mPatched2</b>	GTARDLQ GQLLRAEALQSTF LLMSPRQLYEH FRGDYQTHDIG WSEEQASM				
	310	320	330	340	350

FIG. 8A

18/27

	360	370	380	390	400
<i>hPtc-2</i>	VLQAWQRRFVQLAQEALPENASQQIHAFSSTTLDDILHAFSEVSAARVVG				
	*****				
<i>mPatched2</i>	VLQAWQRRFVQLAQEALPANASQQIHAFSSTTLDDILRAFSEVSTTRVVG				
	360	370	380	390	400
	410	420	430	440	450
<i>hPtc-2</i>	GYLLMLAYACVTMLRWDCAQSQSVGLAGVLLVALAVASGLGLCALLGIT				
	*****				
<i>mPatched2</i>	GYLLMLAYACVTMLRWDCAQSQGAVGLAGVLLVALAVASGLGLCALLGIT				
	410	420	430	440	450
	460	470	480	490	500
<i>hPtc-2</i>	FNAATTQVLPFLALGIGVDDVFLLAHAFTEALPGTPLQERMGECLQRTGT				
	*****				
<i>mPatched2</i>	FNAATTQVLPFLALGIGVDDIFLLAHAF TKAPDTP LPERMGECLRSTGT				
	460	470	480	490	500
	510	520	530	540	550
<i>hPtc-2</i>	SVVLTSINNMAAFLMAALVPIPALRAFSLQAAIVVGCTFVAVMLVFPAIL				
	** *** ** *****				
<i>mPatched2</i>	SVALTSVNNMVAFFMAALVPIPALRAFSLQAAIVVGCNFAAVMLVFPAIL				
	510	520	530	540	550
	560	570	580	590	600
<i>hPtc-2</i>	SLDLRRRHRCQRLDVLCCFSSPCSAQVIQILPQELGDGTVPVGIAHLTATV				
	*****				
<i>mPatched2</i>	SLDLRRRHRCQRLDVLCCFSSPCSAQVIQMLPQELGDRAVPVGIAHLTATV				
	560	570	580	590	600
	610	620	630	640	650
<i>hPtc-2</i>	QAFTHCEASSQHVVITLPPQAHLPVPPSDPLGSELFSPGGSTRDLLGQEE				
	*****				
<i>mPatched2</i>	QAFTHCEASSQHVVITLPPQAHLLSPASDPLGSELYSPGGSTRDLLSQEE				
	610	620	630	640	650
	660	670	680	690	700
<i>hPtc-2</i>	ETRQKAACKSLPCARWNLAHFARYQFAPLLLQSHAKAIVLVLFGALLGLS				
	* .***. * * * *****				
<i>mPatched2</i>	GTGPQAACRPLLCAHWTLAHFARYQFAPLLLQTRAKALVLLFFGALLGLS				
	660	670	680	690	700

FIG. 8B

19/27

	710	720	730	740	750
<i>hPtc-2</i>	LYGATLVQDGLALTDVVPRGTKEHAFLSAQLRYFSLYEVALVTQGGFDYA				
	*****				
<i>mPatched2</i>	LYGATLVQDGLALTDVVPRGTKEHAFLSAQLRYFSLYEVALVTQGGFDYA				
	710	720	730	740	750
	760	770	780	790	800
<i>hPtc-2</i>	HSQRALFDLHQRFSSLKAVLPPPATQAPRTWLHYYRNWLGQIAAFDQDW				
	*****				
<i>mPatched2</i>	HSQRALFDLHQRFSSLKAVLPPPATQAPRTWLHYYRSWLQGIQAAFDQDW				
	760	770	780	790	800
	810	820	830	840	850
<i>hPtc-2</i>	ASGRITRHSYRNGSEDGALAYKLLIQTGDAQEPLDFSQLTTRKLV DREGL				
	*****				
<i>mPatched2</i>	ASGRITCHSYRNGSEDGALAYKLLIQTGNAQEPLDFSQLTTRKLV DKEGL				
	810	820	830	840	850
	860	870	880	890	900
<i>hPtc-2</i>	IPPELFYMGLTVWVSSDPLGLAASQANFYPPPPEWLHDKYDTTGENLRIP				
	*****				
<i>mPatched2</i>	IPPELFYMGLTVWVSSDPLGLAASQANFYPPPPEWLHDKYDTTGENLRIP				
	860	870	880	890	900
	910	920	930	940	950
<i>hPtc-2</i>	PAQPLEFAQFPFLLRGLQKTADFVEAIEGARAACAEAGQAGVHAYPSGSP				
	*****				
<i>mPatched2</i>	AAQPLEFAQFPFLLHGLQKTADFVEAIEGARAACTEAGQAGVHAYPSGSP				
	910	920	930	940	950
	960	970	980	990	1000
<i>hPtc-2</i>	FLFWEQYLGLRRCFLLAVCILLVCTFLVCALLLLNPWTAGLIVLVLAMMT				
	*****				
<i>mPatched2</i>	FLFWEQYLGLRRCFLLAVCILLVCTFLVCALLLLSPWTAGLIVLVLAMMT				
	960	970	980	990	1000
	1010	1020	1030	1040	1050
<i>hPtc-2</i>	VELFGIMGFLGIKLSAIPVVILVASVIGIGVEFTVHVALGFLT TQGSRNLR				
	*****				
<i>mPatched2</i>	VELFGIMGFLGIKLSAIPVVILVASIGIGVEFTVHVALGFLT SHGSRNLR				
	1010	1020	1030	1040	1050

FIG. 8C

	1060	1070	1080	1090	1100
<i>hPtc-2</i>	AAHALEHTFAPVTDGAISTLLGLLMLAGSHFDFIVRYFFAALTVLTLGL				
	** ***.*****.*****.*****.*****.*****				
mPatched2	AASALEQTFAPVTDGAVSTLLGLLMLAGSNFDFIIRYFFVVLTVLTLGL				
	1060	1070	1080	1090	1100
	1110	1120	1130	1140	1150
<i>hPtc-2</i>	LHGLVLLPVLLSILGPPPEVIQMYKESPEILSPAPQGGGLRWGASSSLP				
	****.*****.*.*.*****. ....** *****. ...**				
mPatched2	LHGLLLLVPVLLSILGPPPQVVQVYKESPTLNAAAPQRGGLRWDRPPTLP				
	1110	1120	1130	1140	1150
	1160	1170	1180	1190	1200
<i>hPtc-2</i>	QSFA RVTTSM TVAIHP PPLPGAYIHPAPDEPPWSPAATSSGNLSSRGPGP				
	*****.*****.***. **				
mPatched2	QSFA RVTTSM TVALHP PPLPGAYVHPASEEPT				
	1160	1170	1180		
<i>hPtc-2</i>	ATG				

FIG. 8D

PTCH2



PTCH



FIG. 9

22/27

> C nsensus Sequence of human patched 2 cDNA clone  
> length: 4004 bp

(SEQ ID NO:8)

```

1  CCCACCGGTC CGGGAGAAGC TGGGGGAGGA GGCTGCATAC ACCTCTCAGA TCCTGATACA GACCGCACGC CAGGAGGAG AGAATATCCT CACACCCGAA
   GGGTGGCCAG GCGCTCTTCG ACCCCCTCCT CCGACGTATG TGGAGAGTCT race 6
101 GCACTTGGCC TCCACCTCCA GGCAGCCCTC ACTGCCAGTA AAGTCCAAAGT ATCACTCTAT GGGAACTCCT GGGATTTGAA CAAAATCTGC TACAAGTCAG
   CGTGAACCGG AGGTGGAGGT CCGTGGGAG TGACGGTCAAT TTCAGGTTCA TAGTGAGATA CCCTTLAGGA CCCTAAACTT GTTTCCTACG ATGTTTCAGTC race 5'
201 GAGTCCCTCT TATTGAAAT GGAATGATTG AGCGGATGAT TGAGAACTG TTTCCGTGG TGATCCTCAC CCCCCTCGAC TGCTTCTGG AGGGAGCCAA
   CTCAGGGGA ATAACTTTTA CCTTACTAAC TCGCCTACTA ACTCTTCGAC AAAGGCACGC ACTAGGAGTG GGGGAGCTG ACGAAGACCC TCCCTCGGTT
301 ACTCCAAGG GGTCCGCT ACCTGCGCT CCCAATGTGG CTCACGAGCT GAGTGGGGC TGCCATGGCT TCTCCCACAA ATTATGCAC TGGCAGGAGG
   TGAGTTCCC CCGAGGCGGA TGGACGGCGA GGGTTACACC GAGTGTCTGA CTCACCCCG ACGTACCGA AGAGGTGTT TAAGTACGTG ACCGTCTCTC
401 AATTGCTGCT GGGAGGCATG GCCAGAGACC CCCAAGGAGA GCTGTGTAGG GCAGAGGCCC TGCAGAGCAC CTCTTTGCTG ATGAGTCCCC GCCAGCTGTA
   TTAACGACGA CCTCCGTAC CGGTCTCTGG GGGTTCCTCT CGACGACTAC CCGTCTCGGC ACGTCTCTG GAAGAACGAC TACTCAGGG CGGTCTGACAT
501 CGAGCATTTC CGGGTGACT ATCAGACACA TGACATTGGC TGGAGTGAGG AGCAGGCCAG CACAGTGCTA CAAGCCTGGC AGCGGCGCTT TGTGCAGGTC
   GTCGTAAAG GCCCACTGA TAGTCTGTGT ACTGTAACCG ACCTCACTCC TCGTCCGGTC GTGTCAAGAT GTTCGGACCG TCGCCGCGAA ACAGTCCAG
601 GGTATGGACA AGGACAGGG GGTGCCCTGA GGCCATTCCC TCCTCCTGTC CCTCCTATC CACCTGTGTT CTCCAGCTGG CCCAGGAGGC CTTGCTGAG
   CCATACCTGT TCCTGTCCCC CCACGGGACT CCGGTAAGG AGGAGGACGG GGGAGGATAG GTGGACAAA GAGTCTGACC GGSTCCTCCG GGACGGACTC
701 AACCTTCCC AGCAGATCCA TGCTTCTCC TCCACCACCC TGGATGACAT CCTGCATGCG TTCTCTGAAG TCAGTGTGCTG CCGTGTGGTG GGAGGCTATC
   TTGGAAGGG TCCTCTAGGT ACGGAAGAG AGGTGGTGG ACCTACTGTA GGACGTACCG AAGAGACTTC AGTCACGACG GGCACACCAC CCTCCGATAG
801 TGCTCATGGT GGTCTTTGCA CTTGGCACCT TGCCCCCACC CCACCTCCAA CCAGTGCCCA CCCTGGGAG CCCCTTTTCC CCCCACAGCT
   ACGAGTACCA CCCAGAACGT GGACCGTGGA ACGGGGTGG GGTGGAGGTT GGTACCGGT GGGACCCCTC GGGGAAAGG GGGGTGTCTGA

```

FIG. 10A

SUBSTITUTE SHEET (RULE 26)

23 / 27

901 GGCCTATGCC TGTGTGACCA TGCTGGGTG GGA CTGGCC CAGTCCGAG GTTCCGTGGG CCTTGCCGGG G TACTGCTGG TGGCCCTGGC GGTGGCCTCA  
 CCGGATACGG ACACACTGGT ACGACGCCAC CCTGACGCGG GTCAGGCTCC CAAGGCACCC GGAACGGGCC CATGACGACC ACCGGGACCG CCACCGGAGT  
  
 1001 GGCCTTGGGC TCTGTGCCCT GCTCGGCATC ACCTTCAATG CTGCCACTAC CCAGGTACGC CAGGACTGCA GGCAGACTC AGTGCCAGTC ACCAGGCTTC  
 CCGGAACCGG AGACACGGGA CGAGCCGTAG TCGAAGTTAC GACGGTGATG GGTCCATGCG GTCTGACGT CCCTCTGAG TCACGGTCTAG TGGTCCGAAG  
  
 1101 ACGGTCTCT AGTGCCCGC TCCTCTGCC CTCCAGGTGC TGCCCTTCTT GACTCTGGGA ATCGCGTGG ATGACGTATT CTGCTGGCG CATGCTTCA  
 TGCCAGGAG TCGACGGCG AGGAGACGG GAGGTCCAG ACGGAAGAA CTGAGACCT TAGCCGACC TACTGCATAA GGACGACCG GTACGGGAAGT  
  
 1201 CAGAGGCTCT GCCTGGCACC CCTCTCCAGG TGGGGCCTTG TCCCCGAGG CTCACTGAG GCAGCTCAGC TTACTGGTTA AGAGCTCTT GTTCAAGTG  
 GTCTCCGAGA CGGACCGTGG GGAGAGTCC ACCCCGGAAC AGGGGTCCG GAGTAGACTC CGTCGAGTCG AATGACCAAT TCTCGGAGAA CCAAGTTTCA  
  
 1301 ACCTTGGGCT GCTAATGAAC CTCGGTGCCT CTGTGCCCA TGTGTAACA GGGGAATAA TAGTCTGTG TCCTAAGGGT TATTGTTGG ATCAGTGAAG  
 TGGAAACCGA CGATTACTTG GAGCCACGGA GAACAGGGGT ACACATTTGT CCCCCTTATT ATCAGGACAC AGGATTCCCA ATAACAACC TAGTCACCTC  
  
 1401 TAACTCAAGT TGAATGCTTA GAACAGCCCA TCATACGTAC ATGGTACCCA ATAAATGCTA GCCACTGTGT TATGACTGCC CCACCTCTGC ACCCAAGTT  
 ATTGAGTTCA ACTTACGAAT CTGTGCGGT AGTATGCATG TACCATGGGT TATTACGAT CGGTGACACA ATACTGACGG GGTGGAGACG TGGGTTCAA  
  
 1501 CCTGAGCTC CCCTTCACTC CACTTTGACA CGGCCCTTCC CTTGTGACCT GAGGCGAGT CCCACTCTG TCCTGGCAGG AGCGCATGG CGAGTGTCTG  
 GGACTCGAG GGGAGTGAG GTGAACTGT GCGGGGAGG GAACACTGGA CTCCCTCCA GGGGTGAGAC AGGACCGTCC TCGGTATCCC GCTCACAGAC  
  
 1601 CAGCGCAGG GCACCAAGT TGTACTACA TCATCAACA ACATGGCCG CTTCCTCATG GTCGCCCTCG TTCCCATCCC TGGCTGCGA GCCTTCTCCC  
 GTCGCGTCC CGTGTGACA ACATGAGTGT AGGTAGTTGT TGTACCGCGG GAAGGAGTAC CGACGGGAGC AAGGGTAGGG ACGCGACGCT CGGAAGAGGG  
  
 1701 TACAGCCTGG ACCTAGGCG GCGCCACTGC CAGCGCCTTG ATGTGCTCTG CTGCTTCTCC AGGTACTGCC TGCGCCCCAG CCCCTTCTC CCGTGACCCA  
 ATGTGCGACC TGGATGCCG CGCGGTGACG GTCCGCGAAC TACACGAGAC GACGAAGAGG TCCATGACGG ACGCGGGGTC GGGGAAGGAG GGCATGGGT  
  
 1801 CGCCAGCCTG TCCCCTCACC AGCATTTCAA GGCACAGACC TGTATCCAC TCTCTACCTC TTCCAGTCCC TGCTGTGTC AGGTGATTCA GATCCTGCCC  
 GCGGTGAGC AGGGAGTGG TCGTAAAGTT CCGTGTCTGG ACAGTAGGTG AGAGATGGAG AAGGTGAGG AAGGTGAGG ACGAGACGAG TCCACTAAGT CTAGGACGGG  
  
 1901 CAGGAGCTGG GGGACGGAC AGTACAGTG GGCATTGCC ACCTCACTGC CACAGTTCAA GCCTTTACCC ACTGTGAAGC CAGCAGCCAG CATGTGGTCA  
 GTCTCGACC CCCTGCCCTG TCATGGTCA CCGTAACGGG TGGAGTGAC GTGTCAAGTT CGGAATGGG TGACACTTCG GTCTGCGTC GTACACCACT  
  
 2001 CCATCTGCC TCCCCAAGC CACTGGTGC CCCACCTTC TGACCCACTG GGCTCTGAGC TCTTCAGCCC TGAGGGGTCC ACACGGGACC TTCTAGGCCA  
 GGTAGGACGG AGGGTTCCG GTGACCCACG GGGGTGGAAG ACTGGGTGAC CCGAGACTCG AGAAGTCCG ACCTCCCGG TGTGCCCTGG AAGATCCGGT

FIG. 10B

24/27

2101 GGAGGAGGAG ACAAGGCAGA AGGAGCCTG CAAGTCCCTG CCTGTGCCC GCTGGATCT TGCCCATTTT GCCCCTATC AGTTTGCCCC GTTGCTGCTC  
CCTCTCTCTC TGTTCCTCT TCCGTCGGAC GTTCAGGGG GGGACACGGG CGACCTTGA ACGGTAAAG CGGGCGATAG TCAAACGGGG CAACGACGAG

2201 CAGTCACATG CCAAGGCCAT CGTGCTGGTG CTCTTTGGTG CCTGAGCCTC TACGGAGCCA CTTTGTGCA AGACGSCCTG GCCCTGACGG  
GTCAGTGATC GGTTCGGTA GCACGACCAC GAGAAACCAC GAGAAGACC GAGTCCGAG ATGCCTCGGT GGAACACCGT TCTGCCGGAC CGGACTGCC

2301 ATGTGGTGCC TCGGGGCACC AAGGAGCATG CCTTCCTGAG CGCCAGCTC AGGTACTTCT CCTGTACGA GGTGGCCCTG GTGACCCAGG GTGGCTTTGA  
TACACCACGG AGCCCGTGG TTCTCTGTAC GGAAGACTC GCGGTGAG TCCATGAAGA GGGACATGCT CCACCGGGAC CACTGGGTCC CACCGAAACT

2401 CTAGCCCCAC TCCCAACGG CCTCTTTGA TCTGCACAG CGTTTCAGTT CCTCAAGGC GGTGCTGCCC CCACCGGCCA CCCAGGCACC CCGCACCTGG  
GATCGGGTG AGGTTGGC GGGAGAACT AGACGTGGT GCGAAGTCAA GGGAGTCCG CCACGACGGG GGTGGCCGGT GGTGCCGTGG GCGGTGGACC

2501 CTGCACTATT ACCGCAACTG GCTACAGGA ATCCAGGCTG CCTTTGACCA GGAAGTGGT TCTGGGCCA TCACCCGCCA CTCGTACCGC AATGCTCTG  
GACGTGATAA TGGCGTTGAC CGATGTCCT TAGGTCCGAC GGAAGTGGT CCTGACCGA AGACCCGCT AGTGGGCGT GAGCATGGCG TTACCGAGAC

2601 AGGATGGGG CCTGGCCTAC AAGCTGCTCA TCCAGACTGG AGACGCCAG GAGCCTCTGG ATTTCAGCCA GGTGGGAGA GGGCTGGAGG GTTCCACTAG  
TCCTACCCCG GGACCGGATG TTCGACGAGT AGGTCTGACC TCTGCGGTC CTGCGGAGC TAAAGTCGGT CCAACCCCTT CCCGACCTCC CCAGGTGATC

2701 TACAGGGGCT GCAGGCCTCC TGGGCCCTCC CCTTCAGCCC TCTCTGCCTC TGCAGCTGAC CACAAGGAAG CTGGTGGACA GAGAGGGAAT GATTCCACCC  
ATGTCCCCGA CGTCCGGAGG ACCCGGTCC GGAAGTCGGG AGAGACGGAG ACCTCGACTG GTGTTCTCTC GACCACCTGT CTCTCCCTGA CTAAGGTGGG

2801 GAGCTCTTCT ACATGGGGT GACCGTGTG GAGGCACTG ACCCCCTGGG TCTGGCAGCC TCACAGGCCA ACTTCTACCC CCCACCTCTT GAATGGCTGC  
CTCGAGAAGA TGTACCCCGA CTGGCACACC CACTCGTCAC TGGGGGACCC AGACCGTCGG AGTGTCCGT TGAAGATGGG GGGTGGAGA CTTACCGACG

2901 ACGACAAATA CGACACCACG GGGGAGAACC TTGCGACTGA GTCTTGGGG GAGCTCGGA AGAGCCTCAG CCTCGCCAC ACAAGCCCTG AGCCTGAGGC  
TGCTGTTTAT GCTGTGGTG CCCCTCTTG AAGCTCACT CAGAACCCCG CTCGAGCCGT TCTCGGAGTC GGAGCGGGTG TGTTCGGAC TCGGACTCCG

3001 CTTGCCCACT CTGCCCCGTG CTCACCGCCC TGTCCTCTC CTCTCTCTCC CTTCCCTCC CCTCCACAGT CCGGCCAGCT CAGCCCTTGG AGTTTGCCCC  
GGAGGGGTGA GACGGGGCAC GAGTGGCGG ACAGGGAGAG GGAGAAGAG GAAGGGAGG GGAGGTGTCA GGGCGTCTGA GTCGGGAACC TCAAACGGGT

FIG. 10C

25/27

3101 GTTCCCTTC CTGCTGCGTG GCCTCCAGAA GACTGCAGAC TTTGTGGAGG CCATCAGGG GGGCCGGGCA GCATGCGCAG AGCCGGGCA GGCTGGGGTG  
CAAGGGGAAG GACGACGCAC CGGAGGTCTT CTGACGTCTG AACACCTCC GGTAGTCCC CCGGGCCCGT CGTACGCGTC TCCGGCCCGT CCGACCCAC

3201 CACGCTTACC CCAGCGGCTC CCCTTCTCTC TTCTGGGAAC AGTATCTGGG CCTGCGCGC TGCTTCTCTG TGCCCGTCTG CATCTCTCTG GTGTGCACTT  
GTGCGGATGG GGTGCGGAG GGGGAAGGAG AAGACCTTG TCATAGACCC GGACGCGCG ACGAAGGACG ACCGGCAGAC GTAGGACGAC CACACGTGAA

3301 TCCTCTGCTG TGCTCTGCTG CTCCTCAACC CCTGGACGGC TGGCCTCATA GTGAGTCTT GCAGGAGTGG GGACAGAGAC ACCCACCTT TCCTGCCCCA  
AGGAGCAGAC ACGAGACGAC GAGGAGTTGG GGACCTGCCG ACCGGAGTAT CACTCAGAA CGTCTCACC CTGTCTCTG TGGGTGGGA AGGACGGGT

3401 GCCTGTGATC CCTCTGCCA GGAGCCCTCT GTGAGCCCTG TCTCCCTCAG GTGCTGGTCC TGGCGATGAT GACAGTGGAA CTCTTTGGTA TCATGGGTTT  
CGGACAGTAG GGAGGACGGT CCTCGGGAGA CACTCGGGAC AGAGGGAGTC CACGACGAG ACCGCTACTA CTGTACCTT GAGAAACCAT AGTACCCCAA

3501 CCTGGGCATC AAGCTGAGTG CCATCCCGT GGTGATCCTT GTGGCCTCTG TAGGCATTGG CGTTGAGTTC ACAGTCCACG TGGCTCTGGT GAGCACGGGC  
GGACCCGTAG TTCGACTCAC GTAGGAGGCA CCACTAGGAA CACCGGAGAC ATCCGTAACC GCACTCAAG TGTCAGGTGC ACCGAGACCA CTCGTGCCCG

3601 ACCCGGSGA GGGACCAATC AGCTGATTCA GTATTCAACA CATATTGTTT AAGCCCTTAC TATGTGCTAG GTACTATTTA AGAATTTGGG CTGGGTGGAC  
TGGGGCCCTT CCCTGGTTAG TCGACTAAGT CATAAGTTGT GTATAACAAG TTCGGGGATG ATACACGATC CATGATAAAT TCTTAAACCC GACCCACCTG

3701 GTGGTGGCTC ATTCCTGTAA TCCAGCACT TTGGGAGGCC GAGGCGGGTG GATCACCTGA GGTCGGGAGT TCGAAACCCAG CCTGGCCCAAC ATGGTGAAC  
CACCACCGAG TAAGGACATT AGGTGCTGA AACCTCCGG CTCGCCCCAC CTAGTGGACT CCAGCCCTCA AGCTTTGGTC GGACCGGTTG TACCACCTTG

3801 CCTGTCTTTA CTAATAATAC AAAAAATTAG CCAGGCGTGG TGGCACATGC CAGTAGTCCC AGCTACTTTG GAGGCTGAGG CAGAATTGCT TGAACCTGGG  
GGACAGAAAT GATTTTATG TTTTAAATC GGTCCGCACC ACCGTGTACG GTCATCAGGG TCGATGAAC CTCCGACTCC GTCTTAACGA ACTTGGACCC

3901 AGGCGAAGGT TGCAGTGAGC TGAGATCGTG CCATTGCACT CCAGCCTGGG CAACAAGAGT GCAACTCTCC GTCTCAAAA AAAAAAAA AAGGGCGGCC  
TCCGCTTCCA ACGTCACTCG ACTTAGCAC GGTAAACGTGA GGTGCGACCC GTTGTCTCA CGTTGAGAGG CAGAGTTTTT TTTTTTTTTT TTCCCGCCGG

4001 GCGA  
CGCT

FIG. 10D

26 / 27

Clone 16.1 human patched 2

&gt; 1 ngth: 2082 bp

&gt; (SEQ ID NO:9)

```

1  TTCCGGCATG ACTCGATCGC CGCCCTCTCAG AGAGCTGCCCC CCGAGTTACA CACCCCCCAGC GCACCCACAGA TCCTAGCTGG GAGCCTGAAG
   AAGCCCGTAC TGAGCTAGCG GCGGGAGTC TCTCGACGGG GGCTCAATGT GTGGGGGTCT AGGATCGACC CTCGGACTTC

101 GCTCCACTCT GGCTTCGTGC TTACTTCCAG GGCCTGCTCT TCTCTCTGGG ATGCGGGATC CAGAGACATT GTGGCAAGT GCTCTTTCTG GGACTGTTGG
   CGAGGTGAGA CCGAAGCAGG AATGAAGGTC CCGGACGAGA AGAGAGACCC TAGCCCTAG GTCTCTGTAA CACCGTTTCA CGAGAAAGAC CCGTACAACC

201 CCTTTGGGCG CCTGGCATTG GGTCTCCGCA TGGCCATTAT TGAGACAAAC TTGGAACAGC TCTGGGTAGA AGTGGGCAGC CGGGTGAGCC AGGAGCTGCA
   GGAACCCCGG GGACCGTAAT CCAGAGGCGT ACCGGTAATA ACTCTGTTTG AACCTTGTCG AGACCCATCT TCACCCGTCG GCCCACTCGG TCCTCGACGT

301 TTACACCAAG GAGAAGCTGG GGGAGGAGGG TGCATACACC TCTCAGATGC TGATACAGAC CGCAGGCCAG GAGGGAGAGA ACATCTCTAC ACCCGAAGCA
   AATGTGGTTC CTCTTCGACC CCTCTCTCCG ACGTATGTGG AGAGTCTACG ACTATGTCTG GCGTCCGGTC CTCCTCTCTT TGTAGGAGTG TGGGCTTCGT

401 CTTGGCCTCC ACCTCCAGGC AGCCCTCACT GCCAGTAAG TCCAAGTATC ACTCTATGGG AAGTCTTGGG ATTGAACAA AATCTGTAC AAGTCAGGAG
   GAACCGGAGG TGGAGGTCCG TCGGAGTCCG CCGTCAATTC AGGTTTATAG TGAGATACCC TTCAGGACCC TAAACTTGT TTAGACGATG TTCAGTCTCTC

501 TTCCCCTTAT TGAATATGGA ATGATTGAGT GGATGATTGA GAAGCTGTTT CCCTGCGTGA TCCTCACCCC CCTCGACTGC TTCTGGGAGG GAGCCAAACT
   AAGGGGAATA ACTTTTACCT TACTAACTCA CCTACTAACT CTTGACAAA GGCACGCACT AGGAGTGGGG GGAGCTGACG AAGACCCCTC CTCGGTTTGA

601 CCAAGGGGCG TCCGCTTACC TGCCCGGCGG CCGGATATC CAGTGACCA ACTTGATCC AGAGCAGCTG CTGGAGGAGC TGGGTCCCTT TGCCTCCCTT
   GGTTCCTCCG AGGCGGATGG ACGGCGCGG CCGGCTATAG GTCACCTGGT TGGACCTAGG TCTCGTCGAC GACCTCCTCG ACCCAGGGA ACGGAGGGAA

701 GAGGGCTTCC GGGAGCTGCT AGACAAGGCA CAGGTGGGCC AGGCTTACGT GGGCGGCCG TGTCTGCACC CTGATGACCT CCACTGCCCA CCTAGTGCCC
   CTCCCGAAGG CCTTCGACGA TCTGTTCCTG GTCCACCCGG TCCGATGCA CCGCGCCGG ACAGACGTCG GACTACTGGA GGTGACGGGT GGATCACGGG

801 CCAACCATCA CAGCAGCAG GCTCCCAATG TGGCTCACGA GCTGAGTGGG GGTGCCATG GCTTCTCCA CAAATTCATG CACTGGCAGG AGGAATTGCT
   GGTGAGTAGT GTCGTCCGTC CGAGGGTTAC ACCGAGTGCT CGACTCACCC CCGACGGTAC CGAAGAGGGT GTTTAAGTAC GTGACCCGTC TCCTTAACGA

901 GCTGGGAGGC ATGGCCAGAG ACCCCCAAGG AGAGTGCTG AGGCAGAGG CCCTGCAGAG CACCTTCTTG CTGATGAGTC CCGGCCAGCT GTACGAGCAT
   CGACCTCCG TACCGGTCTC TGGGGGTTCC TCTCGACGAC TCCGCTCTCC GGGACGTCTC GTGGAAGAAC GACTACTCAG GGGCGGTGCA CATGCTCGTA

```

FIG. 11A

27/27

1001 TTCCGGGGT ACTATCAGAC ACATGACATT GGCTGGAGTG AGGAGCAGSC CAGCACAGTG CTACAAGCCT GGCAGCGGCG CTTTGTGCAG CTGGCCCGAGG  
AAGCCCCAC TGATAGTCTG TGTAAGTCTG CCGACCTCAC TCCTCGTCCG GTCGTGTCAC GATGTTCCGA CCGTCGCCGC GAAACACGTC GACCGGGTCC

1101 AGGCCCTGCC TGAGAACGCT TCCCAGCAGA TCCATGCCCTT CTCCTCCACC ACCCTGGATA ACATCTCTCA TCGCTTCTCT GAAGTCAGTG CTGCCCGTGT  
TCCGGGACGG ACTCTTGCGA AGGTCTCTCT AGGTACGGAA GAGGAGGTGG TGGGACCTAT TGTAAGACGT ACGCAAGAGA CTTCAAGTCAC GACGGGCACA

1201 GGTGGAGGC TATCTGCTCA TGCTGGCCTA TGCTGTGTG ACCATGCTGC GGTGGAGTG CGCCAGTCC CAGGGTTCCG TGGCCCTTGC CGGGGTACTG  
CCACCTCCG ATAGACGAGT ACGACCGGAT ACGGACACAC TGGTACGAGC CCACCTGAC GCGGTCAGG GTCCCAAGGC ACCCGAAGC GCGCCATGAC

1301 CTGCTGGCCC TGCGGGTGGC CTCAGGCCCTT GGGCTCTGTG CCTGTCTGG CATCACTTC ATGCTGCCA CTACCCAGGT GCTGCCCTTC TTGGCTCTGG  
GACCACCGG ACCGCCACCG GAGTCCGGAA CCGGAGACAC GGGACGAGCC GTAGTGAAG TTACGACGGT GATGGGTCCA CGACGGGAAG AACCGAGACC

1401 GAATCGGCGT GATGACGTA TTCTGTCTG CGCATGCCCTT CACAGAGGCT CTGCTCTGCA CCCTCTCCA GGAGCGCATG GCGAGTGTG TGCAGCGCAC  
CTTAGCCGCA CCTACTGCAT AAGGACGACC GCGTACGGAA GTGTCTCCGA GACGACCGT GGGGAGAGGT CCTCGCGTAC CCGCTCACAG ACGTCGCGTG

1501 GGGACACAGT GTGCTACTCA CATCCATCAA CAACATGGCC GCCTTCTCTA TGGCTGCCCT CGTTCCTATC CCTGCGTGC GAGCCTTCTC CTTACAGCCA  
CCCGTGTCTA CAGCATGAGT GTAGTAGT GTTGATCCG CGGAAGGAGT ACCGACGGGA GCAAGGGTAG GGACGCGACG CTCGGAAGAG GAATGTCGCT

1601 TCCTCAGCCT GGACCTACGG CGCGGCCACT GCCAGGCCCT TGATGTGCTC TGCTGTCTCT CCAGTCCCTG CTCTGCTCAG GTGATTCTGA TCCTGCCCCA  
AGGAGTCGGA CTGTGATGCC GCGCGGTGA CCGTCCGCGA ACTACACGAG ACGACGAGA GGTACGGAC GAGACGAGTC CACTAAGTCT AGGACGGGCT

1701 GGAGCTGGGG GACGGGACAG TACCAGTGGG CATTGCCAC CTCACTGCCA CAGTTCAAGC CTTTACCCAC TGTGAAGCCA GCAGCCAGCA TGTGCTCACC  
CTTCGACCCC CTGCCCTGTC ATGGTCAACC GTAAAGGGTG GAGTGACGGT GTCAAGTTCTG GAAATGGGTG AACTTCTGCT CGTCGGTCTG ACACCAAGTG

1801 ATCTTGCCTC CCCAGCCCCA CCTGGTGCC CCACCTTCTG ACCCACTGGG CTCTGAGCTC TTCAGCCCTG GAGGGTCCAC ACGGGACCTT CTAGGCCAGG  
TAGGACGGAG GGGTTCGGGT GGACCACGGG GGTGGAAGAC TGGGTGACCC GAGACTCGAG AAGTCCGGAC CTCCCAGGTG TGCCCTGGAA GATCCGGTCC

1901 AGGAGGAGAC AAGGCAGAAG GCAGCCTGCA AGTCCCTGCC CTGTGCCCGC TGGAACTTTG CCCATTTCCG CCGGAATTC CTGCAGCCCG GGGGATCCAC  
TCCTCTCTCTG TTCCGCTTCT CCGTCGGACGT TCAGGGACGG GACACGGGCG ACCTTAGAAC GGGTAAGCG GGGCCTTAAG GACGTCGGGC CCCCTAGGTG

2001 TAGTTCTAGA GCGGCGGCCA CCGCGGTGGA GCTCCAGCTT TTGTTCCCTT TAGTGAGGCT TAATGCGCG CTTGGGTATC TT  
ATCAAGATCT CGCGCGCGGT GCGGCCACCT CGAGGTCGAA AACAAGGGAA ATCACTCCCA ATTAACGCGC GAACCCATAG AA

FIG. 11B

## Sequence Listing

&lt;110&gt; Genentech, Inc.

&lt;120&gt; Patched-2

&lt;130&gt; P1405PCT

5 &lt;141&gt; 1999-04-02

&lt;150&gt; US 09/060,939

&lt;151&gt; 1998-04-15

&lt;160&gt; 32

&lt;210&gt; 1

10 &lt;211&gt; 4030

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

ggtatttcag gccatggtgt tgcgccgaat taattcccgga tccagacatg 50

15 ataagataca ttgatgagtt tggacaaacc acaactagaa tgcagtgaag 100

aaaatgcttt atttgtgaaa ttttgtatgc tattgcttta tttgtaacca 150

ttataagctg caataaaca gttgggcat ggccgccaag cttctgcagg 200

tgcactctag aggatccccg gggaattccg gcactgactcg atcgccgcc 250

ctcagagagc tgcccccgag ttacacaccc ccagctcgaa ccgcagcacc 300

20 ccagatccta gctgggagcc tgaaggctcc actctggctt cgtgcttact 350

tccagggcct gctcttctct ctgggatgag ggatccagag acattgtggc 400

aaagtgtctt ttctgggact gttggccttt ggggccctgg cattaggtct 450

ccgcatggcc attattgaga caaacttgga acagctctgg gtagaagtgg 500

gcagccgggt gagccaggag ctgcattaca ccaaggagaa gctgggggag 550

25 gaggctgcat acacctctca gatgctgata cagaccgcac gccaggaggg 600

agagaacatc ctcacaccg aagcaattgg cctccacctc caggcagccc 650

tactgccag taaagtccaa gtatcactct atgggaagtc ctgggatttg 700

aacaaaatct gctacaagtc aggagttccc cttattgaaa atggaatgat 750

tgagtggatg attgagaagc tgtttccgtg cgtgatcctc accccctcg 800

30 actgcttctg ggaggagcc aaactccaag ggggctccgc ctacctgcc 850

ggccgcccgg atatccagt gaccaacctg gatccagagc agctgctgga 900

ggagctgggt ccctttgcct cccttgaggg cttccgggag ctgctagaca 950  
 aggcacaggt gggccaggcc tacgtggggc ggccctgtct gcaccctgat 1000  
 gacctccact gccacctag tgccccaac catcacagca ggcaggctcc 1050  
 caatgtggct cacgagctga gtgggggctg ccatggcttc tcccacaaat 1100  
 5 tcatgcactg gcaggaggaa ttgctgctgg gaggcattggc cagagacccc 1150  
 caaggagagc tgctgagggc agaggccctg cagagcacct tcttgctgat 1200  
 ggtccccgc cagctgtacg agcatttccg gggtgactat cagacacatg 1250  
 acattggctg gagtgaggag caggccagca cagtgtaca agcctggcag 1300  
 cggcgctttg tgcagctggc ccaggaggcc ctgcctgaga acgcttccca 1350  
 10 gcagatccat gccttctcct ccaccaccct ggatgacatc ctgcatgcgt 1400  
 tctctgaagt cagtgtgcc cgtgtgggtg gaggtatct gctcatgctg 1450  
 gcctatgcct gtgtgacct gctgcgggtg gactgcgcc agtcccaggg 1500  
 ttccgtgggc cttgccggg tactgtggt ggccctggcg gtggcctcag 1550  
 gccttgggct ctgtgccctg ctggcatca ccttcaatgc tgcactacc 1600  
 15 caggtgctgc ctttcttggc tctgggaatc ggcgtggatg acgtattcct 1650  
 gctggcgcat gccttcacag aggctctgcc tggcaccct ctccaggagc 1700  
 gcatgggcga gtgtctgcag cgcacgggca ccagtgtcgt actcacatcc 1750  
 atcaacaaca tggcgcctt cctcatggct gccctcgttc ccatecctgc 1800  
 gctgcgagcc ttctccctac aggcggccat agtgggtggc tgcaccttg 1850  
 20 tagccgtgat gcttgtcttc ccagccatcc tcagcctgga cctacggcgg 1900  
 cgccactgcc agcgccctga tgtgtctgc tgcctctcca gtccctgctc 1950  
 tgctcagggtg attcagatcc tgccccagga gctgggggac gggacagtac 2000  
 cagtgggcat tgcccacctc actgccacag ttcaagcctt taccactgt 2050  
 gaagccagca gccagcatgt ggtcaccatc ctgcctcccc aagccacct 2100  
 25 ggtgccccca ccttctgacc cactgggctc tgagctcttc agccctggag 2150  
 ggtccacacg ggaccttcta ggccaggagg aggagacaag gcagaaggca 2200  
 gcctgcaagt cctgcctg tgcccgctgg aatcttgccc atttcgccc 2250  
 ctatcagttt gcccgttgct tgctccagtc acatgccaag gccatcgtgc 2300

tggtgctctt tggtgctctt ctgggcctga gcctctacgg agccaccttg 2350  
gtgcaagacg gcctggccct gacggatgtg gtgcctcggg gcaccaagga 2400  
gcatgccttc ctgagcgccc agctcaggta cttctccctg tacgaggtgg 2450  
ccctggtgac ccagggtggc tttgactacg cccattccca acgcgccttc 2500  
5 tttgatctgc accagcgctt cagttccctc aaggcgggtg tgccccacc 2550  
ggccacccag gcaccccgca cctgggtgca ctattaccgc aactggctac 2600  
agggaatcca ggctgccttt gaccaggact gggcttctgg gcgcacacc 2650  
cgccactcgt accgcaatgg ctctgaggat ggggccttg cctacaagct 2700  
gctcatccag actggagacg cccaggagcc tctggatttc agccagctga 2750  
10 ccacaaggaa gctggtggac agagaggagc tgattccacc cgagctcttc 2800  
tacatggggc tgaccgtgtg ggtgagcagt gaccccttg gtctggcagc 2850  
ctcacaggcc aacttctacc cccacctcc tgaatggctg cacgacaaat 2900  
acgacaccac gggggagAAC ctctgcctcc cgccagctca gcccttgag 2950  
tttgccagt tccccctct gctgcgtggc ctccagaga ctgcagactt 3000  
15 tgtggaggcc atcgaggggg cccgggcagc atgcgcagag gccggccagg 3050  
ctggggtgca cgctacccc agcggtccc ccttctctt ctgggaacag 3100  
tatctgggccc tgccgcgtg ctctctgtg gccgtctgca tctgtgtgt 3150  
gtgcactttc ctgctctgtg ctctgtgtc cctcaacccc tggacggctg 3200  
gcctcatagt gctggtcctg gcgatgatga cagtggaaact ctttggtatc 3250  
20 atgggtttcc tgggcatcaa gctgagtgcc atccccgtg tgatccttgt 3300  
ggcctctgta ggcattggcg ttgagttcac agtccacgtg gctctgggct 3350  
tcctgaccac ccagggcagc cggaacctgc gggccgccca tgcccttgag 3400  
cacacatttg ccccgtgac cgatggggcc atctccacat tgctgggtct 3450  
gctcatgctt gctggttccc actttgactt cattgtaagg tacttctttg 3500  
25 cggcgctgac agtgctcacg ctctgggccc tctccatgg actcgtgtg 3550  
ctgcctgtgc tgctgtccat cctgggcccg ccgccagagg tgatacagat 3600  
gtacaaggaa agcccagaga tcttgagtcc accagctcca cagggaggcg 3650  
ggcttaggtg gggggcatcc tctccctgc cccagagctt tgccagagt 3700

actacctcca tgaccgtggc catccaccca cccccctgc ctggtgcta 3750  
 catccatcca gccctgatg agcccccttg gtccccctgct gccactagct 3800  
 ctggcaacct cagttccagg ggaccaggtc cagccactgg gtgaaagagc 3850  
 agctgaagca cagagacccat gtgtggggcg tgtgggggtca ctgggaagca 3900  
 5 ctgggtctgg tgtagacgc aggacggacc cctggagggc cctgctgctg 3950  
 ctgcaccccc tctcccgacc cagctgtcat gggcctccct gatatcgaat 4000  
 tcaatcgata gaaccgaggt gcagttggac 4030

<210> 2

<211> 1203

10 <212> PRT

<213> Homo sapiens

<400> 2

	Met	Thr	Arg	Ser	Pro	Pro	Leu	Arg	Glu	Leu	Pro	Pro	Ser	Tyr	Thr
	1				5					10					15
15	Pro	Pro	Ala	Arg	Thr	Ala	Ala	Pro	Gln	Ile	Leu	Ala	Gly	Ser	Leu
					20					25					30
	Lys	Ala	Pro	Leu	Trp	Leu	Arg	Ala	Tyr	Phe	Gln	Gly	Leu	Leu	Phe
					35					40					45
	Ser	Leu	Gly	Cys	Gly	Ile	Gln	Arg	His	Cys	Gly	Lys	Val	Leu	Phe
20					50					55					60
	Leu	Gly	Leu	Leu	Ala	Phe	Gly	Ala	Leu	Ala	Leu	Gly	Leu	Arg	Met
					65					70					75
	Ala	Ile	Ile	Glu	Thr	Asn	Leu	Glu	Gln	Leu	Trp	Val	Glu	Val	Gly
					80					85					90
25	Ser	Arg	Val	Ser	Gln	Glu	Leu	His	Tyr	Thr	Lys	Glu	Lys	Leu	Gly
					95					100					105
	Glu	Glu	Ala	Ala	Tyr	Thr	Ser	Gln	Met	Leu	Ile	Gln	Thr	Ala	Arg
					110					115					120
	Gln	Glu	Gly	Glu	Asn	Ile	Leu	Thr	Pro	Glu	Ala	Leu	Gly	Leu	His
30					125					130					135
	Leu	Gln	Ala	Ala	Leu	Thr	Ala	Ser	Lys	Val	Gln	Val	Ser	Leu	Tyr
					140					145					150
	Gly	Lys	Ser	Trp	Asp	Leu	Asn	Lys	Ile	Cys	Tyr	Lys	Ser	Gly	Val
					155					160					165
35	Pro	Leu	Ile	Glu	Asn	Gly	Met	Ile	Glu	Trp	Met	Ile	Glu	Lys	Leu
					170					175					180

	Phe Pro Cys Val Ile Leu Thr Pro Leu Asp Cys Phe Trp Glu Gly	185	190	195
	Ala Lys Leu Gln Gly Gly Ser Ala Tyr Leu Pro Gly Arg Pro Asp	200	205	210
5	Ile Gln Trp Thr Asn Leu Asp Pro Glu Gln Leu Leu Glu Glu Leu	215	220	225
	Gly Pro Phe Ala Ser Leu Glu Gly Phe Arg Glu Leu Leu Asp Lys	230	235	240
10	Ala Gln Val Gly Gln Ala Tyr Val Gly Arg Pro Cys Leu His Pro	245	250	255
	Asp Asp Leu His Cys Pro Pro Ser Ala Pro Asn His His Ser Arg	260	265	270
	Gln Ala Pro Asn Val Ala His Glu Leu Ser Gly Gly Cys His Gly	275	280	285
15	Phe Ser His Lys Phe Met His Trp Gln Glu Glu Leu Leu Leu Gly	290	295	300
	Gly Met Ala Arg Asp Pro Gln Gly Glu Leu Leu Arg Ala Glu Ala	305	310	315
20	Leu Gln Ser Thr Phe Leu Leu Met Ser Pro Arg Gln Leu Tyr Glu	320	325	330
	His Phe Arg Gly Asp Tyr Gln Thr His Asp Ile Gly Trp Ser Glu	335	340	345
	Glu Gln Ala Ser Thr Val Leu Gln Ala Trp Gln Arg Arg Phe Val	350	355	360
25	Gln Leu Ala Gln Glu Ala Leu Pro Glu Asn Ala Ser Gln Gln Ile	365	370	375
	His Ala Phe Ser Ser Thr Thr Leu Asp Asp Ile Leu His Ala Phe	380	385	390
30	Ser Glu Val Ser Ala Ala Arg Val Val Gly Gly Tyr Leu Leu Met	395	400	405
	Leu Ala Tyr Ala Cys Val Thr Met Leu Arg Trp Asp Cys Ala Gln	410	415	420
	Ser Gln Gly Ser Val Gly Leu Ala Gly Val Leu Leu Val Ala Leu	425	430	435
35	Ala Val Ala Ser Gly Leu Gly Leu Cys Ala Leu Leu Gly Ile Thr	440	445	450
	Phe Asn Ala Ala Thr Thr Gln Val Leu Pro Phe Leu Ala Leu Gly	455	460	465

	Ile Gly Val Asp Asp Val Phe Leu Leu Ala His Ala Phe Thr Glu	470	475	480
	Ala Leu Pro Gly Thr Pro Leu Gln Glu Arg Met Gly Glu Cys Leu	485	490	495
5	Gln Arg Thr Gly Thr Ser Val Val Leu Thr Ser Ile Asn Asn Met	500	505	510
	Ala Ala Phe Leu Met Ala Ala Leu Val Pro Ile Pro Ala Leu Arg	515	520	525
10	Ala Phe Ser Leu Gln Ala Ala Ile Val Val Gly Cys Thr Phe Val	530	535	540
	Ala Val Met Leu Val Phe Pro Ala Ile Leu Ser Leu Asp Leu Arg	545	550	555
	Arg Arg His Cys Gln Arg Leu Asp Val Leu Cys Cys Phe Ser Ser	560	565	570
15	Pro Cys Ser Ala Gln Val Ile Gln Ile Leu Pro Gln Glu Leu Gly	575	580	585
	Asp Gly Thr Val Pro Val Gly Ile Ala His Leu Thr Ala Thr Val	590	595	600
20	Gln Ala Phe Thr His Cys Glu Ala Ser Ser Gln His Val Val Thr	605	610	615
	Ile Leu Pro Pro Gln Ala His Leu Val Pro Pro Pro Ser Asp Pro	620	625	630
	Leu Gly Ser Glu Leu Phe Ser Pro Gly Gly Ser Thr Arg Asp Leu	635	640	645
25	Leu Gly Gln Glu Glu Glu Thr Arg Gln Lys Ala Ala Cys Lys Ser	650	655	660
	Leu Pro Cys Ala Arg Trp Asn Leu Ala His Phe Ala Arg Tyr Gln	665	670	675
30	Phe Ala Pro Leu Leu Leu Gln Ser His Ala Lys Ala Ile Val Leu	680	685	690
	Val Leu Phe Gly Ala Leu Leu Gly Leu Ser Leu Tyr Gly Ala Thr	695	700	705
	Leu Val Gln Asp Gly Leu Ala Leu Thr Asp Val Val Pro Arg Gly	710	715	720
35	Thr Lys Glu His Ala Phe Leu Ser Ala Gln Leu Arg Tyr Phe Ser	725	730	735
	Leu Tyr Glu Val Ala Leu Val Thr Gln Gly Gly Phe Asp Tyr Ala	740	745	750

	His Ser Gln Arg Ala Leu Phe Asp Leu His Gln Arg Phe Ser Ser	755	760	765
	Leu Lys Ala Val Leu Pro Pro Pro Ala Thr Gln Ala Pro Arg Thr	770	775	780
5	Trp Leu His Tyr Tyr Arg Asn Trp Leu Gln Gly Ile Gln Ala Ala	785	790	795
	Phe Asp Gln Asp Trp Ala Ser Gly Arg Ile Thr Arg His Ser Tyr	800	805	810
10	Arg Asn Gly Ser Glu Asp Gly Ala Leu Ala Tyr Lys Leu Leu Ile	815	820	825
	Gln Thr Gly Asp Ala Gln Glu Pro Leu Asp Phe Ser Gln Leu Thr	830	835	840
	Thr Arg Lys Leu Val Asp Arg Glu Gly Leu Ile Pro Pro Glu Leu	845	850	855
15	Phe Tyr Met Gly Leu Thr Val Trp Val Ser Ser Asp Pro Leu Gly	860	865	870
	Leu Ala Ala Ser Gln Ala Asn Phe Tyr Pro Pro Pro Pro Glu Trp	875	880	885
20	Leu His Asp Lys Tyr Asp Thr Thr Gly Glu Asn Leu Arg Ile Pro	890	895	900
	Pro Ala Gln Pro Leu Glu Phe Ala Gln Phe Pro Phe Leu Leu Arg	905	910	915
	Gly Leu Gln Lys Thr Ala Asp Phe Val Glu Ala Ile Glu Gly Ala	920	925	930
25	Arg Ala Ala Cys Ala Glu Ala Gly Gln Ala Gly Val His Ala Tyr	935	940	945
	Pro Ser Gly Ser Pro Phe Leu Phe Trp Glu Gln Tyr Leu Gly Leu	950	955	960
30	Arg Arg Cys Phe Leu Leu Ala Val Cys Ile Leu Leu Val Cys Thr	965	970	975
	Phe Leu Val Cys Ala Leu Leu Leu Leu Asn Pro Trp Thr Ala Gly	980	985	990
	Leu Ile Val Leu Val Leu Ala Met Met Thr Val Glu Leu Phe Gly	995	1000	1005
35	Ile Met Gly Phe Leu Gly Ile Lys Leu Ser Ala Ile Pro Val Val	1010	1015	1020
	Ile Leu Val Ala Ser Val Gly Ile Gly Val Glu Phe Thr Val His	1025	1030	1035

Val Ala Leu Gly Phe Leu Thr Thr Gln Gly Ser Arg Asn Leu Arg  
 1040 1045 1050

Ala Ala His Ala Leu Glu His Thr Phe Ala Pro Val Thr Asp Gly  
 1055 1060 1065

5 Ala Ile Ser Thr Leu Leu Gly Leu Leu Met Leu Ala Gly Ser His  
 1070 1075 1080

Phe Asp Phe Ile Val Arg Tyr Phe Phe Ala Ala Leu Thr Val Leu  
 1085 1090 1095

10 Thr Leu Leu Gly Leu Leu His Gly Leu Val Leu Leu Pro Val Leu  
 1100 1105 1110

Leu Ser Ile Leu Gly Pro Pro Pro Glu Val Ile Gln Met Tyr Lys  
 1115 1120 1125

Glu Ser Pro Glu Ile Leu Ser Pro Pro Ala Pro Gln Gly Gly Gly  
 1130 1135 1140

15 Leu Arg Trp Gly Ala Ser Ser Ser Leu Pro Gln Ser Phe Ala Arg  
 1145 1150 1155

Val Thr Thr Ser Met Thr Val Ala Ile His Pro Pro Pro Leu Pro  
 1160 1165 1170

20 Gly Ala Tyr Ile His Pro Ala Pro Asp Glu Pro Pro Trp Ser Pro  
 1175 1180 1185

Ala Ala Thr Ser Ser Gly Asn Leu Ser Ser Arg Gly Pro Gly Pro  
 1190 1195 1200

Ala Thr Gly  
 1203

25 <210> 3  
 <211> 228  
 <212> DNA  
 <213> Homo sapiens

<220>  
 30 <221> unknown  
 <222> 20, 27, 135, 156, 210  
 <223> unknown base

<400> 3  
 gctggggtgc acgcctaccn cagcggntcc cccttctct tctgggaaca 50

35 gtatctgggc ctgcggcgct gcttctctgt ggccgtctgc atcctgctgg 100

tgtgcacttt cctcgtctgt gctctgctgc tctnaaccc ctggacggct 150

ggcctnatag tgctggctct ggcatgatg acagtgaac tctttggtat 200

catgggtttn ctgggcatca agctgagt 228

&lt;210&gt; 4

&lt;211&gt; 76

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

5 &lt;400&gt; 4

Leu Gly Leu Ser Ser Tyr Pro Asn Gly Tyr Pro Phe Leu Phe Trp  
 1 5 10 15

Glu Gln Tyr Ile Gly Leu Arg His Trp Leu Leu Leu Phe Ile Ser  
 20 25 30

10 Val Val Leu Ala Cys Thr Phe Leu Val Cys Ala Val Phe Leu Leu  
 35 40 45

Asn Pro Trp Thr Ala Gly Ile Ile Val Met Val Leu Ala Leu Met  
 50 55 60

15 Thr Val Glu Leu Phe Gly Met Met Gly Leu Ile Gly Ile Lys Leu  
 65 70 75

Ser  
 76

&lt;210&gt; 5

&lt;211&gt; 125

20 &lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unknown

&lt;222&gt; 115

25 &lt;223&gt; unknown base

&lt;400&gt; 5

gctgggggtgc acgcctaccc cagcggtctc cccttcctct tctgggaaca 50

gtatctgggc ctgcggegct gcttctctgt ggcggtctgc atcctgctgg 100

tgtgcacttt cctctctctgt gctct 125

30 &lt;210&gt; 6

&lt;211&gt; 50

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

35 &lt;221&gt; unknown

&lt;222&gt; 13-14

&lt;223&gt; unknown base

&lt;400&gt; 6

ccgggaggca tgnngcgaag cggaccacgc tgggggggtgg ctcaggggag 50

40 &lt;210&gt; 7

&lt;211&gt; 1182

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 7

5	Met	Val	Arg	Pro	Leu	Ser	Leu	Gly	Glu	Leu	Pro	Pro	Ser	Tyr	Thr	
	1				5					10					15	
	Pro	Pro	Ala	Arg	Ser	Ser	Ala	Pro	His	Ile	Leu	Ala	Gly	Ser	Leu	
					20					25					30	
	Gln	Ala	Pro	Leu	Trp	Leu	Arg	Ala	Tyr	Phe	Gln	Gly	Leu	Leu	Phe	
					35					40					45	
10	Ser	Leu	Gly	Cys	Arg	Ile	Gln	Lys	His	Cys	Gly	Lys	Val	Leu	Phe	
					50					55					60	
	Leu	Gly	Leu	Val	Ala	Phe	Gly	Ala	Leu	Ala	Leu	Gly	Leu	Arg	Val	
					65					70					75	
15	Ala	Val	Ile	Glu	Thr	Asp	Leu	Glu	Gln	Leu	Trp	Val	Glu	Val	Gly	
					80					85					90	
	Ser	Arg	Val	Ser	Gln	Glu	Leu	His	Tyr	Thr	Lys	Glu	Lys	Leu	Gly	
					95					100					105	
	Glu	Glu	Ala	Ala	Tyr	Thr	Ser	Gln	Met	Leu	Ile	Gln	Thr	Ala	His	
					110					115					120	
20	Gln	Glu	Gly	Gly	Asn	Val	Leu	Thr	Pro	Glu	Ala	Leu	Asp	Leu	His	
					125					130					135	
	Leu	Gln	Ala	Ala	Leu	Thr	Ala	Ser	Lys	Val	Gln	Val	Ser	Leu	Tyr	
					140					145					150	
25	Gly	Lys	Ser	Trp	Asp	Leu	Asn	Lys	Ile	Cys	Tyr	Lys	Ser	Gly	Val	
					155					160					165	
	Pro	Leu	Ile	Glu	Asn	Gly	Met	Ile	Glu	Arg	Met	Ile	Glu	Lys	Leu	
					170					175					180	
	Phe	Pro	Cys	Val	Ile	Leu	Thr	Pro	Leu	Asp	Cys	Phe	Trp	Glu	Gly	
					185					190					195	
30	Ala	Lys	Leu	Gln	Gly	Gly	Ser	Ala	Tyr	Leu	Pro	Gly	Arg	Pro	Asp	
					200					205					210	
	Ile	Gln	Trp	Thr	Asn	Leu	Asp	Pro	Gln	Gln	Leu	Leu	Glu	Glu	Leu	
					215					220					225	
35	Gly	Pro	Phe	Ala	Ser	Leu	Glu	Gly	Phe	Arg	Glu	Leu	Leu	Asp	Lys	
					230					235					240	
	Ala	Gln	Val	Gly	Gln	Ala	Tyr	Val	Gly	Arg	Pro	Cys	Leu	Asp	Pro	
					245					250					255	
	Asp	Asp	Pro	His	Cys	Pro	Pro	Ser	Ala	Pro	Asn	Arg	His	Ser	Arg	

	260	265	270
	Gln Ala Pro Asn Val Ala Gln Glu Leu	Ser Gly Gly Cys His Gly	
	275	280	285
5	Phe Ser His Lys Phe Met His Trp Gln	Glu Glu Leu Leu Leu Gly	
	290	295	300
	Gly Thr Ala Arg Asp Leu Gln Gly Gln	Leu Leu Arg Ala Glu Ala	
	305	310	315
	Leu Gln Ser Thr Phe Leu Leu Met Ser	Pro Arg Gln Leu Tyr Glu	
	320	325	330
10	His Phe Arg Gly Asp Tyr Gln Thr His	Asp Ile Gly Trp Ser Glu	
	335	340	345
	Glu Gln Ala Ser Met Val Leu Gln Ala	Trp Gln Arg Arg Phe Val	
	350	355	360
15	Gln Leu Ala Gln Glu Ala Leu Pro Ala	Asn Ala Ser Gln Gln Ile	
	365	370	375
	His Ala Phe Ser Ser Thr Thr Leu Asp	Asp Ile Leu Arg Ala Phe	
	380	385	390
	Ser Glu Val Ser Thr Thr Arg Val Val	Gly Gly Tyr Leu Leu Met	
	395	400	405
20	Leu Ala Tyr Ala Cys Val Thr Met Leu	Arg Trp Asp Cys Ala Gln	
	410	415	420
	Ser Gln Gly Ala Val Gly Leu Ala Gly	Val Leu Leu Val Ala Leu	
	425	430	435
25	Ala Val Ala Ser Gly Leu Gly Leu Cys	Ala Leu Leu Gly Ile Thr	
	440	445	450
	Phe Asn Ala Ala Thr Thr Gln Val Leu	Pro Phe Leu Ala Leu Gly	
	455	460	465
	Ile Gly Val Asp Asp Ile Phe Leu Leu	Ala His Ala Phe Thr Lys	
	470	475	480
30	Ala Pro Pro Asp Thr Pro Leu Pro Glu	Arg Met Gly Glu Cys Leu	
	485	490	495
	Arg Ser Thr Gly Thr Ser Val Ala Leu	Thr Ser Val Asn Asn Met	
	500	505	510
35	Val Ala Phe Phe Met Ala Ala Leu Val	Pro Ile Pro Ala Leu Arg	
	515	520	525
	Ala Phe Ser Leu Gln Ala Ala Ile Val	Val Gly Cys Asn Phe Ala	
	530	535	540

	Ala Val Met Leu Val Phe Pro Ala Ile Leu Ser Leu Asp Leu Arg	545	550	555
	Arg Arg His Arg Gln Arg Leu Asp Val Leu Cys Cys Phe Ser Ser	560	565	570
5	Pro Cys Ser Ala Gln Val Ile Gln Met Leu Pro Gln Glu Leu Gly	575	580	585
	Asp Arg Ala Val Pro Val Gly Ile Ala His Leu Thr Ala Thr Val	590	595	600
10	Gln Ala Phe Thr His Cys Glu Ala Ser Ser Gln His Val Val Thr	605	610	615
	Ile Leu Pro Pro Gln Ala His Leu Leu Ser Pro Ala Ser Asp Pro	620	625	630
	Leu Gly Ser Glu Leu Tyr Ser Pro Gly Gly Ser Thr Arg Asp Leu	635	640	645
15	Leu Ser Gln Glu Glu Gly Thr Gly Pro Gln Ala Ala Cys Arg Pro	650	655	660
	Leu Leu Cys Ala His Trp Thr Leu Ala His Phe Ala Arg Tyr Gln	665	670	675
20	Phe Ala Pro Leu Leu Leu Gln Thr Arg Ala Lys Ala Leu Val Leu	680	685	690
	Leu Phe Phe Gly Ala Leu Leu Gly Leu Ser Leu Tyr Gly Ala Thr	695	700	705
	Leu Val Gln Asp Gly Leu Ala Leu Thr Asp Val Val Pro Arg Gly	710	715	720
25	Thr Lys Glu His Ala Phe Leu Ser Ala Gln Leu Arg Tyr Phe Ser	725	730	735
	Leu Tyr Glu Val Ala Leu Val Thr Gln Gly Gly Phe Asp Tyr Ala	740	745	750
30	His Ser Gln Arg Ala Leu Phe Asp Leu His Gln Arg Phe Ser Ser	755	760	765
	Leu Lys Ala Val Leu Pro Pro Pro Ala Thr Gln Ala Pro Arg Thr	770	775	780
	Trp Leu His Tyr Tyr Arg Ser Trp Leu Gln Gly Ile Gln Ala Ala	785	790	795
35	Phe Asp Gln Asp Trp Ala Ser Gly Arg Ile Thr Cys His Ser Tyr	800	805	810
	Arg Asn Gly Ser Glu Asp Gly Ala Leu Ala Tyr Lys Leu Leu Ile	815	820	825

	Gln Thr Gly Asn Ala Gln Glu Pro Leu Asp Phe Ser Gln Leu Thr	
	830	835 840
	Thr Arg Lys Leu Val Asp Lys Glu Gly Leu Ile Pro Pro Glu Leu	
	845	850 855
5	Phe Tyr Met Gly Leu Thr Val Trp Val Ser Ser Asp Pro Leu Gly	
	860	865 870
	Leu Ala Ala Ser Gln Ala Asn Phe Tyr Pro Pro Pro Pro Glu Trp	
	875	880 885
10	Leu His Asp Lys Tyr Asp Thr Thr Gly Glu Asn Leu Arg Ile Pro	
	890	895 900
	Ala Ala Gln Pro Leu Glu Phe Ala Gln Phe Pro Phe Leu Leu His	
	905	910 915
	Gly Leu Gln Lys Thr Ala Asp Phe Val Glu Ala Ile Glu Gly Ala	
	920	925 930
15	Arg Ala Ala Cys Thr Glu Ala Gly Gln Ala Gly Val His Ala Tyr	
	935	940 945
	Pro Ser Gly Ser Pro Phe Leu Phe Trp Glu Gln Tyr Leu Gly Leu	
	950	955 960
20	Arg Arg Cys Phe Leu Leu Ala Val Cys Ile Leu Leu Val Cys Thr	
	965	970 975
	Phe Leu Val Cys Ala Leu Leu Leu Leu Ser Pro Trp Thr Ala Gly	
	980	985 990
	Leu Ile Val Leu Val Leu Ala Met Met Thr Val Glu Leu Phe Gly	
	995	1000 1005
25	Ile Met Gly Phe Leu Gly Ile Lys Leu Ser Ala Ile Pro Val Val	
	1010	1015 1020
	Ile Leu Val Ala Ser Ile Gly Ile Gly Val Glu Phe Thr Val His	
	1025	1030 1035
30	Val Ala Leu Gly Phe Leu Thr Ser His Gly Ser Arg Asn Leu Arg	
	1040	1045 1050
	Ala Ala Ser Ala Leu Glu Gln Thr Phe Ala Pro Val Thr Asp Gly	
	1055	1060 1065
	Ala Val Ser Thr Leu Leu Gly Leu Leu Met Leu Ala Gly Ser Asn	
	1070	1075 1080
35	Phe Asp Phe Ile Ile Arg Tyr Phe Phe Val Val Leu Thr Val Leu	
	1085	1090 1095
	Thr Leu Leu Gly Leu Leu His Gly Leu Leu Leu Leu Pro Val Leu	
	1100	1105 1110

Leu Ser Ile Leu Gly Pro Pro Pro Gln Val Val Gln Val Tyr Lys  
                   1115                  1120                  1125  
 Glu Ser Pro Gln Thr Leu Asn Ser Ala Ala Pro Gln Arg Gly Gly  
                   1130                  1135                  1140  
 5 Leu Arg Trp Asp Arg Pro Pro Thr Leu Pro Gln Ser Phe Ala Arg  
                   1145                  1150                  1155  
 Val Thr Thr Ser Met Thr Val Ala Leu His Pro Pro Pro Leu Pro  
                   1160                  1165                  1170  
 10 Gly Ala Tyr Val His Pro Ala Ser Glu Glu Pro Thr  
                   1175                  1180                  1182

<210> 8  
 <211> 4004  
 <212> DNA  
 <213> Homo sapiens

15 <400> 8  
 cccacgcgtc cgggagaagc tgggggagga ggctgcatac acctctcaga 50  
 tgctgataca gaccgcacgc caggagggag agaacatcct cacacccgaa 100  
 gcacttggcc tccacctcca ggcagccctc actgccagta aagtccaagt 150  
 atcactctat ggggaagtcct gggatttgaa caaaatctgc tacaagtcag 200  
 20 gagttcccct tattgaaaat ggaatgattg agcggatgat tgagaagctg 250  
 tttccgtgcg tgatcctcac cccctcgac tgcttctggg agggagccaa 300  
 actccaaggg ggctccgcct acctgccgct cccaatgttg ctcacgagct 350  
 gagtgggggc tgccatggct tctcccacaa attcatgcac tggcaggagg 400  
 aattgdtgct gggaggcatg gccagagacc cccaaggaga gctgctgagg 450  
 25 gcagaggccc tgcagagcac cttcttgctg atgagtcccc gccagctgta 500  
 cgagcatttc cggggtgact atcagacaca tgacattggc tggagtgagg 550  
 agcaggccag cacagtgcta caagcctggc agcggcgctt tgtgcaggtc 600  
 ggtatggaca aggacagggg ggtgccctga ggccattccc tctcctgcc 650  
 cctcctatc caccctgttt ctccagctgg ccaggaggc cctgcctgag 700  
 30 aacgcttccc agcagatcca tgccttctcc tccaccaccc tggatgacat 750  
 cctgcatgcy ttctctgaag tcaagtctgc ccgtgtggtg ggaggctatc 800  
 tgctcatggt ggggtcttgca cctggcacct tgccccacc ccacctccaa 850  
 ccagtgccca ccctggggag cccctgagac tgccctttcc cccacagct 900

ggcctatgcc tgtgtgacca tgctgcggtg ggactgcgcc cagtcccagg 950  
 gttccgtggg ccttgccggg gtactgctgg tggccctggc ggtggcctca 1000  
 ggcccttgggc tctgtgcect gctcggcatc accttcaatg ctgccactac 1050  
 ccagggtacgc caggactgca gggcagactc agtgccagtc accaggcttc 1100  
 5 acgggtcctc agctgcccgc tcctctgccc ctccagggtc tgcccttctt 1150  
 gactctggga atcggcgtgg atgacgtatt cctgctggcg catgccttca 1200  
 cagaggctct gcctggcacc cctctccagg tggggccttg tccccaggg 1250  
 ctcatctgag gcagctcagc ttactggtta agagcctctt ggttcaagt 1300  
 accttgggct gctaataaac ctcggtgcct cttgtcccca tgtgtaaaca 1350  
 10 ggggaaataa tagtgctgtg tcctaagggt tattgtttgg atcagtgaag 1400  
 taactcaagt tgaatgctta gaaagccca tcatacgtac atggtaccca 1450  
 ataaatgcta gccactgtgt tatgactgcc ccacctctgc accccaagtt 1500  
 cctgagcctc ccttcactc cactttgaca cggcccctcc cttgtgacct 1550  
 gagggcaggt cccactctg tcctggcagg agcgcatggg cgagtgtctg 1600  
 15 cagcgcacgg gcaccagtgt tgtactcaca tccatcaaca acatggccgc 1650  
 ctctctcatg gctgcccctg ttcccatccc tgcgctgca gccttctccc 1700  
 tacagcctgg acctacggcg gcgccactgc cagcgccctg atgtgctctg 1750  
 ctgcttctcc aggtactgcc tgcgccccag ccccttctc ccgtgaccca 1800  
 cgccagcctg tcccctcacc agcatttcaa ggcacagacc tgtcatccac 1850  
 20 tctctacctc ttccagtccc tgctctgctc aggtgattca gatcctgccc 1900  
 caggagctgg gggacgggac agtaccagtg ggcattgccc acctcactgc 1950  
 cacagttcaa gcctttaccc actgtgaagc cagcagccag catgtggtca 2000  
 ccatcctgcc tccccagcc cacctgggtg cccaccttc tgaccactg 2050  
 ggctctgagc tcttcagccc tggagggtcc acacgggacc ttctaggcca 2100  
 25 ggaggaggag acaaggcaga aggcagcctg caagtccctg ccctgtgccc 2150  
 gctggaatct tgcccatttc gcccgctatc agtttgcccc gttgctgctc 2200  
 cagtcacatg ccaaggccat cgtgctgggtg ctctttgggtg ctcttctggg 2250  
 cctgagcctc tacggagcca ccttgggtgca agacggcctg gccctgacgg 2300

atgtggtgcc tcggggcacc aaggagcatg ccttctgag cgcccagctc 2350  
 aggtacttct ccctgtacga ggtggccctg gtgaccagg gtggctttga 2400  
 ctacgccac tccaacgcg ccctctttga tctgcaccag cgcttcagtt 2450  
 ccctcaaggc ggtgctgccc ccaccggcca cccaggcacc cgcacctgg 2500  
 5 ctgcactatt accgcaactg gctacaggga atccaggctg cctttgacca 2550  
 ggactgggct tctgggcgca tcaccgcca ctctaccgc aatggctctg 2600  
 aggatggggc cctggcctac aagctgctca tccagactgg agacgcccag 2650  
 gagcctctgg atttcagcca ggttgggaga gggctggagg ggtccactag 2700  
 tacaggggct gcaggcctcc tgggcccagg ccttcagccc tctctgcctc 2750  
 10 tgcagctgac cacaaggaag ctggtggaca gagagggact gattccaccc 2800  
 gagctcttct acatggggct gaccgtgtgg gtgagcagtg accccctggg 2850  
 tctggcagcc tcacaggcca acttctaccc cccacctcct gaatggctgc 2900  
 acgacaaata cgacaccacg ggggagaacc ttgcagtgat gtcttggggg 2950  
 gagctcggca agagcctcag cctcgccac acaagccctg agcctgagge 3000  
 15 cctgcccact ctgccccgtg ctacccgcc tgctcctctc cctcttctcc 3050  
 cttccccctc cctccacagt cccgccagct cagcccttgg agtttgccca 3100  
 gttccccctc ctgctgcgtg gcctccagaa gactgcagac tttgtggagg 3150  
 ccatcgaggg ggcccgggca gcatgcgcag aggcgggcca ggctgggggtg 3200  
 cagcctacc ccagcggtc ccccttctc ttctgggaac agtatctggg 3250  
 20 cctgcggcgc tgcttctgc tggcgtctg catctgctg gtgtgcactt 3300  
 tctctgctg tgctctgctg ctctcaacc cctggacggc tggcctcata 3350  
 gtgagtgtt gcaggagtgg ggacagagac accccaccct tccctgcccc 3400  
 gcctgtcatc cctcctgcca ggagccctct gtgagccctg tctcctcag 3450  
 gtgctgggtc tggcgatgat gacagtggaa ctctttggta tcatgggttt 3500  
 25 cctgggcatc aagctgagtg ccatccccgt ggtgatcctt gtggcctctg 3550  
 taggcattgg cgttgagttc acagtccacg tggctctggt gagcacgggc 3600  
 accccgggga gggaccaatc agctgattca gtattcaaca catattgttc 3650  
 aagccccctac tatgtgctag gtactattta agaatttggg ctgggtggac 3700

gtgggtggctc attcctgtaa tcccagcact ttgggaggcc gaggcgggtg 3750  
 gatcacctga ggtcgggagt tcgaaaccag cctggccaac atggtgaaac 3800  
 cctgtcttta ctaaaaatac aaaaaattag ccaggcgtgg tggcacatgc 3850  
 cagtagtccc agctactttg gaggctgagg cagaattgct tgaacctggg 3900  
 5 aggcgaaggt tgcagtgage tgagatcgtg ccattgcact ccagcctggg 3950  
 caacaagagt gcaactctcc gtctcaaaaa aaaaaaaaaa aagggcggcc 4000  
 gcga 4004  
 <210> 9  
 <211> 2082  
 10 <212> DNA  
 <213> Homo sapiens  
 <400> 9  
 ttccggcatg actcgatcgc cgccccctcag agagctgccc ccgagttaca 50  
 cccccccagc tcgaaccgca gcaccccgaga tcctagctgg gagcctgaag 100  
 15 gctccactct ggcttcgtgc ttacttccag ggctgctct tctctctggg 150  
 atgcgggatc cagagacatt gtggcaaatg gctctttctg ggactgttgg 200  
 cctttggggc cctggcatta ggtctccgca tggccattat tgagacaaac 250  
 ttggaacagc tctgggtaga agtgggcagc cgggtgagcc aggagctgca 300  
 ttacaccaag gagaagctgg gggaggaggc tgcatacacc tctcagatgc 350  
 20 tgatacagac cgcacgccag gaggagaga acatcctcac acccgaagca 400  
 cttggcctcc acctccaggc agcctcact gccagtaaag tccaagtatc 450  
 actctatggg aagtccctggg atttgaacaa aatctgctac aagtcaggag 500  
 ttcccccttat tgaaaatgga atgattgagt ggatgattga gaagctgttt 550  
 ccgtgcgtga tcctaccccc cctcgactgc ttctgggagg gagccaaact 600  
 25 ccaagggggc tccgcctacc tgcccggccg cccggatata cagtggacca 650  
 acctggatcc agagcagctg ctggaggagc tgggtccctt tgcctccctt 700  
 gagggtctcc gggagctgct agacaaggca cagggtgggc aggctacgt 750  
 ggggcggccc tgtctgcacc ctgatgacct ccaactgccc cctagtgcc 800  
 ccaaccatca cagcaggcag gctcccaatg tggctcacga gctgagtggg 850  
 30 ggctgccatg gcttctccca caaattcatg cactggcagg aggaattgct 900

gctgggagggc atggccagag acccccaagg agagctgctg agggcagagg 950  
 ccctgcagag caccttcttg ctgatgagtc cccgccagct gtacgagcat 1000  
 ttccgggggtg actatcagac acatgacatt ggctggagtg aggagcaggc 1050  
 cagcacagtg ctacaagcct ggcagcggcg ctttgtgcag ctggcccagg 1100  
 5 aggcctgcc tgagaacgct tcccagcaga tccatgcctt ctctccacc 1150  
 accctggata acatcctgca tgcgttctct gaagtcagtg ctgcccgtgt 1200  
 ggtgggagggc tatctgctca tgctggccta tgctgtgtg accatgctgc 1250  
 ggtgggactg cgcccagtcc cagggttccg tgggccttgc cggggactg 1300  
 ctggtggccc tggcgggtggc ctccaggcctt gggctctgtg cctgctcgg 1350  
 10 catcaccttc aatgctgcca ctaccaggt gctgcccttc ttggctctgg 1400  
 gaatcggcgt ggatgacgta ttctgctgg cgcctgcctt cacagaggct 1450  
 ctgcctggca cccctctcca ggagcgcagtg ggcgagtgtc tgcagcgac 1500  
 gggcaccagt gtcgtactca catccatcaa caacatggcc gccttctca 1550  
 tggctgccct cgttccatc cctgcgctgc gagccttctc cttacagcca 1600  
 15 tctcagcct ggacctagg cggcgccact gccagcgcct tgatgtgctc 1650  
 tgctgcttct ccagtcctg ctctgctcag gtgattcaga tctgccccca 1700  
 ggagctgggg gacgggacag taccagtggg cattgcccac ctactgcca 1750  
 cagttcaagc ctttaccac tgtgaagcca gcagccagca tgtggtcacc 1800  
 atctgcctc cccaagccca cctgggtgcc ccaccttctg accactggg 1850  
 20 ctctgagctc ttcagccctg gagggccac acgggacctt ctaggccagg 1900  
 aggaggagac aaggcagaag gcagcctgca agtcctgcc ctgtgcccgc 1950  
 tggaatcttg ccatttcgc ccggaattc ctgcagcccg ggggatccac 2000  
 tagttctaga gcggccgcca ccgcggtgga gctccagctt ttgttccctt 2050  
 tagtgagggt taattgcgcg cttgggtatc tt 2082  
 25 <210> 10  
 <211> 1315  
 <212> PRT  
 <213> Homo sapiens  
 <400> 10  
 30 Met Glu Lys Tyr His Val Leu Glu Met Ile Gly Glu Gly Ser Phe  
 1 5 10 15

	Gly Arg Val Tyr Lys Gly Arg Arg Lys Tyr Ser Ala Gln Val Val	20	25	30
	Ala Leu Lys Phe Ile Pro Lys Leu Gly Arg Ser Glu Lys Glu Leu	35	40	45
5	Arg Asn Leu Gln Arg Glu Ile Glu Ile Met Arg Gly Leu Arg His	50	55	60
	Pro Asn Ile Val His Met Leu Asp Ser Phe Glu Thr Asp Lys Glu	65	70	75
10	Val Val Val Val Thr Asp Tyr Ala Glu Gly Glu Leu Phe Gln Ile	80	85	90
	Leu Glu Asp Asp Gly Lys Leu Pro Glu Asp Gln Val Gln Ala Ile	95	100	105
	Ala Ala Gln Leu Val Ser Ala Leu Tyr Tyr Leu His Ser His Arg	110	115	120
15	Ile Leu His Arg Asp Met Lys Pro Gln Asn Ile Leu Leu Ala Lys	125	130	135
	Gly Gly Gly Ile Lys Leu Cys Asp Phe Gly Phe Ala Arg Ala Met	140	145	150
20	Ser Thr Asn Thr Met Val Leu Thr Ser Ile Lys Gly Thr Pro Leu	155	160	165
	Tyr Met Ser Pro Glu Leu Val Glu Glu Arg Pro Tyr Asp His Thr	170	175	180
	Ala Asp Leu Trp Ser Val Gly Cys Ile Leu Tyr Glu Leu Ala Val	185	190	195
25	Gly Thr Pro Pro Phe Tyr Ala Thr Ser Ile Phe Gln Leu Val Ser	200	205	210
	Leu Ile Leu Lys Asp Pro Val Arg Trp Pro Ser Thr Ile Ser Pro	215	220	225
30	Cys Phe Lys Asn Phe Leu Gln Gly Leu Leu Thr Lys Asp Pro Arg	230	235	240
	Gln Arg Leu Ser Trp Pro Asp Leu Leu Tyr His Pro Phe Ile Ala	245	250	255
	Gly His Val Thr Ile Ile Thr Glu Pro Ala Gly Pro Asp Leu Gly	260	265	270
35	Thr Pro Phe Thr Ser Arg Leu Pro Pro Glu Leu Gln Val Leu Lys	275	280	285
	Asp Glu Gln Ala His Arg Leu Ala Pro Lys Gly Asn Gln Ser Arg	290	295	300

	Ile Leu Thr Gln Ala Tyr Lys Arg Met Ala Glu Glu Ala Met Gln	
	305	310 315
	Lys Lys His Gln Asn Thr Gly Pro Ala Leu Glu Gln Glu Asp Lys	
	320	325 330
5	Thr Ser Lys Val Ala Pro Gly Thr Ala Pro Leu Pro Arg Leu Gly	
	335	340 345
	Ala Thr Pro Gln Glu Ser Ser Leu Leu Ala Gly Ile Leu Ala Ser	
	350	355 360
10	Glu Leu Lys Ser Ser Trp Ala Lys Ser Gly Thr Gly Glu Val Pro	
	365	370 375
	Ser Ala Pro Arg Glu Asn Arg Thr Thr Pro Asp Cys Glu Arg Ala	
	380	385 390
	Phe Pro Glu Glu Arg Pro Glu Val Leu Gly Gln Arg Ser Thr Asp	
	395	400 405
15	Val Val Asp Leu Glu Asn Glu Glu Pro Asp Ser Asp Asn Glu Trp	
	410	415 420
	Gln His Leu Leu Glu Thr Thr Glu Pro Val Pro Ile Gln Leu Lys	
	425	430 435
20	Ala Pro Leu Thr Leu Leu Cys Asn Pro Asp Phe Cys Gln Arg Ile	
	440	445 450
	Gln Ser Gln Leu His Glu Ala Gly Gly Gln Ile Leu Lys Gly Ile	
	455	460 465
	Leu Glu Gly Ala Ser His Ile Leu Pro Ala Phe Arg Val Leu Ser	
	470	475 480
25	Ser Leu Leu Ser Ser Cys Ser Asp Ser Val Ala Leu Tyr Ser Phe	
	485	490 495
	Cys Arg Glu Ala Gly Leu Pro Gly Leu Leu Leu Ser Leu Leu Arg	
	500	505 510
30	His Ser Gln Glu Ser Asn Ser Leu Gln Gln Gln Ser Trp Tyr Gly	
	515	520 525
	Thr Phe Leu Gln Asp Leu Met Ala Val Ile Gln Ala Tyr Phe Ala	
	530	535 540
	Cys Thr Phe Asn Leu Glu Arg Ser Gln Thr Ser Asp Ser Leu Gln	
	545	550 555
35	Val Phe Gln Glu Ala Ala Asn Leu Phe Leu Asp Leu Leu Gly Lys	
	560	565 570
	Leu Leu Ala Gln Pro Asp Asp Ser Glu Gln Thr Leu Arg Arg Asp	
	575	580 585

	Ser	Leu	Met	Cys	Phe	Thr	Val	Leu	Cys	Glu	Ala	Met	Asp	Gly	Asn	
					590					595					600	
	Ser	Arg	Ala	Ile	Ser	Lys	Ala	Phe	Tyr	Ser	Ser	Leu	Leu	Thr	Thr	
					605					610					615	
5	Gln	Gln	Val	Val	Leu	Asp	Gly	Leu	Leu	His	Gly	Leu	Thr	Val	Pro	
					620					625					630	
	Gln	Leu	Pro	Val	His	Thr	Pro	Gln	Gly	Ala	Pro	Gln	Val	Ser	Gln	
					635					640					645	
10	Pro	Leu	Arg	Glu	Gln	Ser	Glu	Asp	Ile	Pro	Gly	Ala	Ile	Ser	Ser	
					650					655					660	
	Ala	Leu	Ala	Ala	Ile	Cys	Thr	Ala	Pro	Val	Gly	Leu	Pro	Asp	Cys	
					665					670					675	
	Trp	Asp	Ala	Lys	Glu	Gln	Val	Cys	Trp	His	Leu	Ala	Asn	Gln	Leu	
					680					685					690	
15	Thr	Glu	Asp	Ser	Ser	Gln	Leu	Arg	Pro	Ser	Leu	Ile	Ser	Gly	Leu	
					695					700					705	
	Gln	His	Pro	Ile	Leu	Cys	Leu	His	Leu	Leu	Lys	Val	Leu	Tyr	Ser	
					710					715					720	
20	Cys	Cys	Leu	Val	Ser	Glu	Gly	Leu	Cys	Arg	Leu	Leu	Gly	Gln	Glu	
					725					730					735	
	Pro	Leu	Ala	Leu	Glu	Ser	Leu	Phe	Met	Leu	Ile	Gln	Gly	Lys	Val	
					740					745					750	
	Lys	Val	Val	Asp	Trp	Glu	Glu	Ser	Thr	Glu	Val	Thr	Leu	Tyr	Phe	
					755					760					765	
25	Leu	Ser	Leu	Leu	Val	Phe	Arg	Leu	Gln	Asn	Leu	Pro	Cys	Gly	Met	
					770					775					780	
	Glu	Lys	Leu	Gly	Ser	Asp	Val	Ala	Thr	Leu	Phe	Thr	His	Ser	His	
					785					790					795	
30	Val	Val	Ser	Leu	Val	Ser	Ala	Ala	Ala	Cys	Leu	Leu	Gly	Gln	Leu	
					800					805					810	
	Gly	Gln	Gln	Gly	Val	Thr	Phe	Asp	Leu	Gln	Pro	Met	Glu	Trp	Met	
					815					820					825	
	Ala	Ala	Ala	Thr	His	Ala	Leu	Ser	Ala	Pro	Ala	Glu	Val	Arg	Leu	
					830					835					840	
35	Thr	Pro	Pro	Gly	Ser	Cys	Gly	Phe	Tyr	Asp	Gly	Leu	Leu	Ile	Leu	
					845					850					855	
	Leu	Leu	Gln	Leu	Leu	Thr	Glu	Gln	Gly	Lys	Ala	Ser	Leu	Ile	Arg	
					860					865					870	

	Asp Met Ser Ser Ser Glu Met Trp Thr Val Leu Trp His Arg Phe	875	880	885
	Ser Met Val Leu Arg Leu Pro Glu Glu Ala Ser Ala Gln Glu Gly	890	895	900
5	Glu Leu Ser Leu Ser Ser Pro Pro Ser Pro Glu Pro Asp Trp Thr	905	910	915
	Leu Ile Ser Pro Gln Gly Met Ala Ala Leu Leu Ser Leu Ala Met	920	925	930
10	Ala Thr Phe Thr Gln Glu Pro Gln Leu Cys Leu Ser Cys Leu Ser	935	940	945
	Gln His Gly Ser Ile Leu Met Ser Ile Leu Lys His Leu Leu Cys	950	955	960
	Pro Ser Phe Leu Asn Gln Leu Arg Gln Ala Pro His Gly Ser Glu	965	970	975
15	Phe Leu Pro Val Val Val Leu Ser Val Cys Gln Leu Leu Cys Phe	980	985	990
	Pro Phe Ala Leu Asp Met Asp Ala Asp Leu Leu Ile Val Val Leu	995	1000	1005
20	Ala Asp Leu Arg Asp Ser Glu Val Ala Ala His Leu Leu Gln Val	1010	1015	1020
	Cys Cys Tyr His Leu Pro Leu Met Gln Val Glu Leu Pro Ile Ser	1025	1030	1035
	Leu Leu Thr Arg Leu Ala Leu Met Asp Pro Thr Ser Leu Asn Gln	1040	1045	1050
25	Phe Val Asn Thr Val Ser Ala Ser Pro Arg Thr Ile Val Ser Phe	1055	1060	1065
	Leu Ser Val Ala Leu Leu Ser Asp Gln Pro Leu Leu Thr Ser Asp	1070	1075	1080
30	Leu Leu Ser Leu Leu Ala His Thr Ala Arg Val Leu Ser Pro Ser	1085	1090	1095
	His Leu Ser Phe Ile Gln Glu Leu Leu Ala Gly Ser Asp Glu Ser	1100	1105	1110
	Tyr Arg Pro Leu Arg Ser Leu Leu Gly His Pro Glu Asn Ser Val	1115	1120	1125
35	Arg Ala His Thr Tyr Arg Leu Leu Gly His Leu Leu Gln His Ser	1130	1135	1140
	Met Ala Leu Arg Gly Ala Leu Gln Ser Gln Ser Gly Leu Leu Ser	1145	1150	1155

Leu Leu Leu Leu Gly Leu Gly Asp Lys Asp Pro Val Val Arg Cys  
 1160 1165 1170  
 Ser Ala Ser Phe Ala Val Gly Asn Ala Ala Tyr Gln Ala Gly Pro  
 1175 1180 1185  
 5 Leu Gly Pro Ala Leu Ala Ala Val Pro Ser Met Thr Gln Leu  
 1190 1195 1200  
 Leu Gly Asp Pro Gln Ala Gly Ile Arg Arg Asn Val Ala Ser Ala  
 1205 1210 1215  
 10 Leu Gly Asn Leu Gly Pro Glu Gly Leu Gly Glu Glu Leu Leu Gln  
 1220 1225 1230  
 Cys Glu Val Pro Gln Arg Leu Leu Glu Met Ala Cys Gly Asp Pro  
 1235 1240 1245  
 Gln Pro Asn Val Lys Glu Ala Ala Leu Ile Ala Leu Arg Ser Leu  
 1250 1255 1260  
 15 Gln Gln Glu Pro Gly Ile His Gln Val Leu Val Ser Leu Gly Ala  
 1265 1270 1275  
 Ser Glu Lys Leu Ser Leu Leu Ser Leu Gly Asn Gln Ser Leu Pro  
 1280 1285 1290  
 20 His Ser Ser Pro Arg Pro Ala Ser Ala Lys His Cys Arg Lys Leu  
 1295 1300 1305  
 Ile His Leu Leu Arg Pro Ala His Ser Met  
 1310 1315  
 <210> 11  
 <211> 48  
 25 <212> DNA  
 <213> Artificial sequence  
 <220>  
 <223> Artificial sequence 1-48  
 <400> 11  
 30 ctatgaaatt aaccctcact aaagggagct cccgtgagtc cctatgtg 48  
 <210> 12  
 <211> 48  
 <212> DNA  
 <213> Artificial sequence  
 35 <220>  
 <223> Artificial sequence 1-48  
 <400> 12  
 ggattctaatac gactcact atagggcccc taaactccgc tgctccac 48  
 <210> 13

&lt;211&gt; 396

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 13

5	Met	Ala	Leu	Pro	Ala	Ser	Leu	Leu	Pro	Leu	Cys	Cys	Leu	Ala	Leu	1	5	10	15
	Leu	Ala	Leu	Ser	Ala	Gln	Ser	Cys	Gly	Pro	Gly	Arg	Gly	Pro	Val	20	25	30	
10	Gly	Arg	Arg	Arg	Tyr	Val	Arg	Lys	Gln	Leu	Val	Pro	Leu	Leu	Tyr	35	40	45	
	Lys	Gln	Phe	Val	Pro	Ser	Met	Pro	Glu	Arg	Thr	Leu	Gly	Ala	Ser	50	55	60	
	Gly	Pro	Ala	Glu	Gly	Arg	Val	Thr	Arg	Gly	Ser	Glu	Arg	Phe	Arg	65	70	75	
15	Asp	Leu	Val	Pro	Asn	Tyr	Asn	Pro	Asp	Ile	Ile	Phe	Lys	Asp	Glu	80	85	90	
	Glu	Asn	Ser	Gly	Ala	Asp	Arg	Leu	Met	Thr	Glu	Arg	Cys	Lys	Glu	95	100	105	
20	Arg	Val	Asn	Ala	Leu	Ala	Ile	Ala	Val	Met	Asn	Met	Trp	Pro	Gly	110	115	120	
	Val	Arg	Leu	Arg	Val	Thr	Glu	Gly	Trp	Asp	Glu	Asp	Gly	His	His	125	130	135	
	Ala	Gln	Asp	Ser	Leu	His	Tyr	Glu	Gly	Arg	Ala	Leu	Asp	Ile	Thr	140	145	150	
25	Thr	Ser	Asp	Arg	Asp	Arg	Asn	Lys	Tyr	Gly	Leu	Leu	Ala	Arg	Leu	155	160	165	
	Ala	Val	Glu	Ala	Gly	Phe	Asp	Trp	Val	Tyr	Tyr	Glu	Ser	Arg	Asn	170	175	180	
30	His	Ile	His	Val	Ser	Val	Lys	Ala	Asp	Asn	Ser	Leu	Ala	Val	Arg	185	190	195	
	Ala	Gly	Gly	Cys	Phe	Pro	Gly	Asn	Ala	Thr	Val	Arg	Leu	Arg	Ser	200	205	210	
	Gly	Glu	Arg	Lys	Gly	Leu	Arg	Glu	Leu	His	Arg	Gly	Asp	Trp	Val	215	220	225	
35	Leu	Ala	Ala	Asp	Ala	Ala	Gly	Arg	Val	Val	Pro	Thr	Pro	Val	Leu	230	235	240	
	Leu	Phe	Leu	Asp	Arg	Asp	Leu	Gln	Arg	Arg	Ala	Ser	Phe	Val	Ala	245	250	255	

Val Glu Thr Glu Arg Pro Pro Arg Lys Leu Leu Leu Thr Pro Trp  
 260 265 270  
 His Leu Val Phe Ala Ala Arg Gly Pro Ala Pro Ala Pro Gly Asp  
 275 280 285  
 5 Phe Ala Pro Val Phe Ala Arg Arg Leu Arg Ala Gly Asp Ser Val  
 290 295 300  
 Leu Ala Pro Gly Gly Asp Ala Leu Gln Pro Ala Arg Val Ala Arg  
 305 310 315  
 10 Val Ala Arg Glu Glu Ala Val Gly Val Phe Ala Pro Leu Thr Ala  
 320 325 330  
 His Gly Thr Leu Leu Val Asn Asp Val Leu Ala Ser Cys Tyr Ala  
 335 340 345  
 Val Leu Glu Ser His Gln Trp Ala His Arg Ala Phe Ala Pro Leu  
 350 355 360  
 15 Arg Leu Leu His Ala Leu Gly Ala Leu Leu Pro Gly Gly Ala Val  
 365 370 375  
 Gln Pro Thr Gly Met His Trp Tyr Ser Arg Leu Leu Tyr Arg Leu  
 380 385 390  
 20 Ala Glu Glu Leu Met Gly  
 395 396  
 <210> 14  
 <211> 437  
 <212> PRT  
 <213> Mus musculus  
 25 <400> 14  
 Met Leu Leu Leu Leu Ala Arg Cys Phe Leu Val Ile Leu Ala Ser  
 1 5 10 15  
 Ser Leu Leu Val Cys Pro Gly Leu Ala Cys Gly Pro Gly Arg Gly  
 20 25 30  
 30 Phe Gly Lys Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr  
 35 40 45  
 Lys Gln Phe Ile Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser  
 50 55 60  
 35 Gly Arg Tyr Glu Gly Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys  
 65 70 75  
 Glu Leu Thr Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu  
 80 85 90  
 Glu Asn Thr Gly Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp  
 95 100 105

	Lys	Leu	Asn	Ala	Leu	Ala	Ile	Ser	Val	Met	Asn	Gln	Trp	Pro	Gly	110	115	120
	Val	Arg	Leu	Arg	Val	Thr	Glu	Gly	Trp	Asp	Glu	Asp	Gly	His	His	125	130	135
5	Ser	Glu	Glu	Ser	Leu	His	Tyr	Glu	Gly	Arg	Ala	Val	Asp	Ile	Thr	140	145	150
	Thr	Ser	Asp	Arg	Asp	Arg	Ser	Lys	Tyr	Gly	Met	Leu	Ala	Arg	Leu	155	160	165
10	Ala	Val	Glu	Ala	Gly	Phe	Asp	Trp	Val	Tyr	Tyr	Glu	Ser	Lys	Ala	170	175	180
	His	Ile	His	Cys	Ser	Val	Lys	Ala	Glu	Asn	Ser	Val	Ala	Ala	Lys	185	190	195
	Ser	Gly	Gly	Cys	Phe	Pro	Gly	Ser	Ala	Thr	Val	His	Leu	Glu	Gln	200	205	210
15	Gly	Gly	Thr	Lys	Leu	Val	Lys	Asp	Leu	Arg	Pro	Gly	Asp	Arg	Val	215	220	225
	Leu	Ala	Ala	Asp	Asp	Gln	Gly	Arg	Leu	Leu	Tyr	Ser	Asp	Phe	Leu	230	235	240
20	Thr	Phe	Leu	Asp	Arg	Asp	Glu	Gly	Ala	Lys	Lys	Val	Phe	Tyr	Val	245	250	255
	Ile	Glu	Thr	Leu	Glu	Pro	Arg	Glu	Arg	Leu	Leu	Leu	Thr	Ala	Ala	260	265	270
	His	Leu	Leu	Phe	Val	Ala	Pro	His	Asn	Asp	Ser	Gly	Pro	Thr	Pro	275	280	285
25	Gly	Pro	Ser	Ala	Leu	Phe	Ala	Ser	Arg	Val	Arg	Pro	Gly	Gln	Arg	290	295	300
	Val	Tyr	Val	Val	Ala	Glu	Arg	Gly	Gly	Asp	Arg	Arg	Leu	Leu	Pro	305	310	315
30	Ala	Ala	Val	His	Ser	Val	Thr	Leu	Arg	Glu	Glu	Glu	Ala	Gly	Ala	320	325	330
	Tyr	Ala	Pro	Leu	Thr	Ala	His	Gly	Thr	Ile	Leu	Ile	Asn	Arg	Val	335	340	345
	Leu	Ala	Ser	Cys	Tyr	Ala	Val	Ile	Glu	Glu	His	Ser	Trp	Ala	His	350	355	360
35	Arg	Ala	Phe	Ala	Pro	Phe	Arg	Leu	Ala	His	Ala	Leu	Leu	Ala	Ala	365	370	375
	Leu	Ala	Pro	Ala	Arg	Thr	Asp	Gly	Gly	Gly	Gly	Gly	Ser	Ile	Pro	380	385	390

Ala Ala Gln Ser Ala Thr Glu Ala Arg Gly Ala Glu Pro Thr Ala  
395 400 405

Gly Ile His Trp Tyr Ser Gln Leu Leu Tyr His Ile Gly Thr Trp  
410 415 420

5 Leu Leu Asp Ser Glu Thr Met His Pro Leu Gly Met Ala Val Lys  
425 430 435

Ala Ser  
437

<210> 15  
10 <211> 803  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Artificial sequence 1-803

15 <400> 15  
Met Ala Ala Gly Arg Pro Val Arg Gly Pro Glu Leu Ala Pro Arg  
1 5 10 15

Arg Leu Leu Gln Leu Leu Leu Leu Val Leu Leu Gly Gly Arg Gly  
20 25 30

20 Arg Gly Ala Ala Leu Ser Gly Asn Val Thr Gly Pro Gly Pro Arg  
35 40 45

Ser Ala Gly Gly Ser Ala Arg Arg Asn Ala Pro Val Thr Ser Pro  
50 55 60

25 Pro Pro Pro Leu Leu Ser His Cys Gly Arg Ala Ala His Cys Glu  
65 70 75

Pro Leu Arg Tyr Asn Val Cys Leu Gly Ser Ala Leu Pro Tyr Gly  
80 85 90

Ala Thr Thr Thr Leu Leu Ala Gly Asp Ser Asp Ser Gln Glu Glu  
95 100 105

30 Ala His Ser Lys Leu Val Leu Trp Ser Gly Leu Arg Asn Ala Pro  
110 115 120

Arg Cys Trp Ala Val Ile Gln Pro Leu Leu Cys Ala Val Tyr Met  
125 130 135

35 Pro Lys Cys Glu Asn Asp Arg Val Glu Leu Pro Ser Arg Thr Leu  
140 145 150

Cys Gln Ala Thr Arg Gly Pro Cys Ala Ile Val Glu Arg Glu Arg  
155 160 165

Gly Trp Pro Asp Phe Leu Arg Cys Thr Pro Asp His Phe Pro Glu  
170 175 180

	Gly Cys Pro Asn Glu Val Gln Asn Ile Lys Phe Asn Ser Ser Gly	185	190	195
	Gln Cys Glu Ala Pro Leu Val Arg Thr Asp Asn Pro Lys Ser Trp	200	205	210
5	Tyr Glu Asp Val Glu Gly Cys Gly Ile Gln Cys Gln Asn Pro Leu	215	220	225
	Phe Thr Glu Ala Glu His Gln Asp Met His Ser Tyr Ile Ala Ala	230	235	240
10	Phe Gly Ala Val Thr Gly Leu Cys Thr Leu Phe Thr Leu Ala Thr	245	250	255
	Phe Val Ala Asp Trp Arg Asn Ser Asn Arg Tyr Pro Ala Val Ile	260	265	270
	Leu Phe Tyr Val Asn Ala Cys Phe Phe Val Gly Ser Ile Gly Trp	275	280	285
15	Leu Ala Gln Phe Met Asp Gly Ala Arg Arg Glu Ile Val Cys Arg	290	295	300
	Ala Asp Gly Thr Met Arg Phe Gly Glu Pro Thr Ser Ser Glu Thr	305	310	315
20	Leu Ser Cys Val Ile Ile Phe Val Ile Val Tyr Tyr Ala Leu Met	320	325	330
	Ala Gly Val Val Trp Phe Val Val Leu Thr Tyr Ala Trp His Thr	335	340	345
	Ser Phe Lys Ala Leu Gly Thr Thr Tyr Gln Pro Leu Ser Gly Lys	350	355	360
25	Thr Ser Tyr Phe His Leu Leu Thr Trp Ser Leu Pro Phe Val Leu	365	370	375
	Thr Val Ala Ile Leu Ala Val Ala Gln Val Asp Gly Asp Ser Val	380	385	390
30	Ser Gly Ile Cys Phe Val Gly Tyr Lys Asn Tyr Arg Tyr Arg Ala	395	400	405
	Gly Phe Val Leu Ala Pro Ile Gly Leu Val Leu Ile Val Gly Gly	410	415	420
	Tyr Phe Leu Ile Arg Gly Val Met Thr Leu Phe Ser Ile Lys Ser	425	430	435
35	Asn His Pro Gly Leu Leu Ser Glu Lys Ala Ala Ser Lys Ile Asn	440	445	450
	Glu Thr Met Leu Arg Leu Gly Ile Phe Gly Phe Leu Ala Phe Gly	455	460	465

	Phe Val Leu Ile Thr Phe Ser Cys His Phe Tyr Asp Phe Phe Asn	470	475	480
	Gln Ala Glu Trp Glu Arg Ser Phe Arg Asp Tyr Val Leu Cys Gln	485	490	495
5	Ala Asn Val Thr Ile Gly Leu Pro Thr Lys Lys Pro Ile Pro Asp	500	505	510
	Cys Glu Ile Lys Asn Arg Pro Ser Leu Leu Val Glu Lys Ile Asn	515	520	525
10	Leu Phe Ala Met Phe Gly Thr Gly Ile Ala Met Ser Thr Trp Val	530	535	540
	Trp Thr Lys Ala Thr Leu Leu Ile Trp Arg Arg Thr Trp Cys Arg	545	550	555
	Leu Thr Gly His Ser Asp Asp Glu Pro Lys Arg Ile Lys Lys Ser	560	565	570
15	Lys Met Ile Ala Lys Ala Phe Ser Lys Arg Arg Glu Leu Leu Gln	575	580	585
	Asn Pro Gly Gln Glu Leu Ser Phe Ser Met His Thr Val Ser His	590	595	600
20	Asp Gly Pro Val Ala Gly Ile Ala Phe Glu Leu Asn Glu Pro Ser	605	610	615
	Ala Asp Val Ser Ser Ala Trp Ala Gln His Val Thr Lys Met Val	620	625	630
	Ala Arg Arg Gly Ala Ile Leu Pro Gln Asp Val Ser Val Thr Pro	635	640	645
25	Val Ala Thr Pro Val Pro Pro Glu Glu Gln Ala Asn Leu Trp Leu	650	655	660
	Val Glu Ala Glu Ile Ser Pro Glu Leu Glu Lys Arg Leu Gly Arg	665	670	675
30	Lys Lys Lys Arg Arg Lys Arg Lys Lys Glu Val Cys Pro Leu Gly	680	685	690
	Pro Ala Pro Glu Leu His His Ser Ala Pro Val Pro Ala Thr Ser	695	700	705
	Ala Val Pro Arg Leu Pro Gln Leu Pro Arg Gln Lys Cys Leu Val	710	715	720
35	Ala Ala Asn Ala Trp Gly Thr Gly Glu Pro Cys Arg Gln Gly Ala	725	730	735
	Trp Thr Val Val Ser Asn Pro Phe Cys Pro Glu Pro Ser Pro His	740	745	750

Gln Asp Pro Phe Leu Pro Gly Ala Ser Ala Pro Arg Val Trp Ala  
755 760 765

Gln Gly Arg Leu Gln Gly Leu Gly Ser Ile His Ser Arg Thr Asn  
770 775 780

5 Leu Met Glu Ala Glu Leu Leu Asp Ala Asp Ser Asp Phe Glu Gln  
785 790 795

Lys Leu Ile Ser Glu Glu Asp Leu  
800 803

<210> 16  
10 <211> 793  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Artificial sequence 1-793

15 <400> 16  
Met Ala Ala Gly Arg Pro Val Arg Gly Pro Glu Leu Ala Pro Arg  
1 5 10 15

Arg Leu Leu Gln Leu Leu Leu Leu Val Leu Leu Gly Gly Arg Gly  
20 25 30

20 Arg Gly Ala Ala Leu Ser Gly Asn Val Thr Gly Pro Gly Pro Arg  
35 40 45

Ser Ala Gly Gly Ser Ala Arg Arg Asn Ala Pro Val Thr Ser Pro  
50 55 60

25 Pro Pro Pro Leu Leu Ser His Cys Gly Arg Ala Ala His Cys Glu  
65 70 75

Pro Leu Arg Tyr Asn Val Cys Leu Gly Ser Ala Leu Pro Tyr Gly  
80 85 90

Ala Thr Thr Thr Leu Leu Ala Gly Asp Ser Asp Ser Gln Glu Glu  
95 100 105

30 Ala His Ser Lys Leu Val Leu Trp Ser Gly Leu Arg Asn Ala Pro  
110 115 120

Arg Cys Trp Ala Val Ile Gln Pro Leu Leu Cys Ala Val Tyr Met  
125 130 135

35 Pro Lys Cys Glu Asn Asp Arg Val Glu Leu Pro Ser Arg Thr Leu  
140 145 150

Cys Gln Ala Thr Arg Gly Pro Cys Ala Ile Val Glu Arg Glu Arg  
155 160 165

Gly Trp Pro Asp Phe Leu Arg Cys Thr Pro Asp His Phe Pro Glu  
170 175 180

	Gly Cys Pro Asn Glu Val Gln Asn Ile Lys Phe Asn Ser Ser Gly	185	190	195
	Gln Cys Glu Ala Pro Leu Val Arg Thr Asp Asn Pro Lys Ser Trp	200	205	210
5	Tyr Glu Asp Val Glu Gly Cys Gly Ile Gln Cys Gln Asn Pro Leu	215	220	225
	Phe Thr Glu Ala Glu His Gln Asp Met His Ser Tyr Ile Ala Ala	230	235	240
10	Phe Gly Ala Val Thr Gly Leu Cys Thr Leu Phe Thr Leu Ala Thr	245	250	255
	Phe Val Ala Asp Trp Arg Asn Ser Asn Arg Tyr Pro Ala Val Ile	260	265	270
	Leu Phe Tyr Val Asn Ala Cys Phe Phe Val Gly Ser Ile Gly Trp	275	280	285
15	Leu Ala Gln Phe Met Asp Gly Ala Arg Arg Glu Ile Val Cys Arg	290	295	300
	Ala Asp Gly Thr Met Arg Phe Gly Glu Pro Thr Ser Ser Glu Thr	305	310	315
20	Leu Ser Cys Val Ile Ile Phe Val Ile Val Tyr Tyr Ala Leu Met	320	325	330
	Ala Gly Val Val Trp Phe Val Val Leu Thr Tyr Ala Trp His Thr	335	340	345
	Ser Phe Lys Ala Leu Gly Thr Thr Tyr Gln Pro Leu Ser Gly Lys	350	355	360
25	Thr Ser Tyr Phe His Leu Leu Thr Trp Ser Leu Pro Phe Val Leu	365	370	375
	Thr Val Ala Ile Leu Ala Val Ala Gln Val Asp Gly Asp Ser Val	380	385	390
30	Ser Gly Ile Cys Phe Val Gly Tyr Lys Asn Tyr Arg Tyr Arg Ala	395	400	405
	Gly Phe Val Leu Ala Pro Ile Gly Leu Val Leu Ile Val Gly Gly	410	415	420
	Tyr Phe Leu Ile Arg Gly Val Met Thr Leu Phe Ser Ile Lys Ser	425	430	435
35	Asn His Pro Gly Leu Leu Ser Glu Lys Ala Ala Ser Lys Ile Asn	440	445	450
	Glu Thr Met Leu Arg Leu Gly Ile Phe Gly Phe Leu Ala Phe Gly	455	460	465

	Phe	Val	Leu	Ile	Thr	Phe	Ser	Cys	His	Phe	Tyr	Asp	Phe	Phe	Asn
					470					475					480
	Gln	Ala	Glu	Trp	Glu	Arg	Ser	Phe	Arg	Asp	Tyr	Val	Leu	Cys	Gln
					485					490					495
5	Ala	Asn	Val	Thr	Ile	Gly	Leu	Pro	Thr	Lys	Lys	Pro	Ile	Pro	Asp
					500					505					510
	Cys	Glu	Ile	Lys	Asn	Arg	Pro	Ser	Leu	Leu	Val	Glu	Lys	Ile	Asn
					515					520					525
10	Leu	Phe	Ala	Met	Phe	Gly	Thr	Gly	Ile	Ala	Met	Ser	Thr	Leu	Val
					530					535					540
	Trp	Thr	Lys	Ala	Thr	Leu	Leu	Ile	Trp	Arg	Arg	Thr	Trp	Cys	Arg
					545					550					555
	Leu	Thr	Gly	His	Ser	Asp	Asp	Glu	Pro	Lys	Arg	Ile	Lys	Lys	Ser
					560					565					570
15	Lys	Met	Ile	Ala	Lys	Ala	Phe	Ser	Lys	Arg	Arg	Glu	Leu	Leu	Gln
					575					580					585
	Asn	Pro	Gly	Gln	Glu	Leu	Ser	Phe	Ser	Met	His	Thr	Val	Ser	His
					590					595					600
20	Asp	Gly	Pro	Val	Ala	Gly	Leu	Ala	Phe	Glu	Leu	Asn	Glu	Pro	Ser
					605					610					615
	Ala	Asp	Val	Ser	Ser	Ala	Trp	Ala	Gln	His	Val	Thr	Lys	Met	Val
					620					625					630
	Ala	Arg	Arg	Gly	Ala	Ile	Leu	Pro	Gln	Asp	Val	Ser	Val	Thr	Pro
					635					640					645
25	Val	Ala	Thr	Pro	Val	Pro	Pro	Glu	Glu	Gln	Ala	Asn	Leu	Trp	Leu
					650					655					660
	Val	Glu	Ala	Glu	Ile	Ser	Pro	Glu	Leu	Glu	Lys	Arg	Leu	Gly	Arg
					665					670					675
30	Lys	Lys	Lys	Arg	Arg	Lys	Arg	Lys	Lys	Glu	Val	Cys	Pro	Leu	Gly
					680					685					690
	Pro	Ala	Pro	Glu	Leu	His	His	Ser	Ala	Pro	Val	Pro	Ala	Thr	Ser
					695					700					705
	Ala	Val	Pro	Arg	Leu	Pro	Gln	Leu	Pro	Arg	Gln	Lys	Cys	Leu	Val
					710					715					720
35	Ala	Ala	Asn	Ala	Trp	Gly	Thr	Gly	Glu	Pro	Cys	Arg	Gln	Gly	Ala
					725					730					735
	Trp	Thr	Val	Val	Ser	Asn	Pro	Phe	Cys	Pro	Glu	Pro	Ser	Pro	His
					740					745					750

Gln Asp Pro Phe Leu Pro Gly Ala Ser Ala Pro Arg Val Trp Ala  
 755 760 765  
 Gln Gly Arg Leu Gln Gly Leu Gly Ser Ile His Ser Arg Thr Asn  
 770 775 780  
 5 Leu Met Glu Ala Glu Leu Leu Asp Ala Asp Ser Asp Phe  
 785 790 793  
 <210> 17  
 <211> 793  
 <212> PRT  
 10 <213> Homo sapiens  
 <400> 17  
 Met Ala Ala Gly Arg Pro Val Arg Gly Pro Glu Leu Ala Pro Arg  
 1 5 10 15  
 Arg Leu Leu Gln Leu Leu Leu Val Leu Leu Gly Gly Arg Gly  
 15 20 25 30  
 Arg Gly Ala Ala Leu Ser Gly Asn Val Thr Gly Pro Gly Pro Arg  
 35 40 45  
 Ser Ala Gly Gly Ser Ala Arg Arg Asn Ala Pro Val Thr Ser Pro  
 50 55 60  
 20 Pro Pro Pro Leu Leu Ser His Cys Gly Arg Ala Ala His Cys Glu  
 65 70 75  
 Pro Leu Arg Tyr Asn Val Cys Leu Gly Ser Ala Leu Pro Tyr Gly  
 80 85 90  
 Ala Thr Thr Thr Leu Leu Ala Gly Asp Ser Asp Ser Gln Glu Glu  
 25 95 100 105  
 Ala His Ser Lys Leu Val Leu Trp Ser Gly Leu Arg Asn Ala Pro  
 110 115 120  
 Arg Cys Trp Ala Val Ile Gln Pro Leu Leu Cys Ala Val Tyr Met  
 125 130 135  
 30 Pro Lys Cys Glu Asn Asp Arg Val Glu Leu Pro Ser Arg Thr Leu  
 140 145 150  
 Cys Gln Ala Thr Arg Gly Pro Cys Ala Ile Val Glu Arg Glu Arg  
 155 160 165  
 Gly Trp Pro Asp Phe Leu Arg Cys Thr Pro Asp His Phe Pro Glu  
 35 170 175 180  
 Gly Cys Pro Asn Glu Val Gln Asn Ile Lys Phe Asn Ser Ser Gly  
 185 190 195  
 Gln Cys Glu Ala Pro Leu Val Arg Thr Asp Asn Pro Lys Ser Trp  
 200 205 210

	Tyr Glu Asp Val Glu Gly Cys Gly Ile Gln Cys Gln Asn Pro Leu	215	220	225
	Phe Thr Glu Ala Glu His Gln Asp Met His Ser Tyr Ile Ala Ala	230	235	240
5	Phe Gly Ala Val Thr Gly Leu Cys Thr Leu Phe Thr Leu Ala Thr	245	250	255
	Phe Val Ala Asp Trp Arg Asn Ser Asn Arg Tyr Pro Ala Val Ile	260	265	270
10	Leu Phe Tyr Val Asn Ala Cys Phe Phe Val Gly Ser Ile Gly Trp	275	280	285
	Leu Ala Gln Phe Met Asp Gly Ala Arg Arg Glu Ile Val Cys Arg	290	295	300
	Ala Asp Gly Thr Met Arg Phe Gly Glu Pro Thr Ser Ser Glu Thr	305	310	315
15	Leu Ser Cys Val Ile Ile Phe Val Ile Val Tyr Tyr Ala Leu Met	320	325	330
	Ala Gly Val Val Trp Phe Val Val Leu Thr Tyr Ala Trp His Thr	335	340	345
20	Ser Phe Lys Ala Leu Gly Thr Thr Tyr Gln Pro Leu Ser Gly Lys	350	355	360
	Thr Ser Tyr Phe His Leu Leu Thr Trp Ser Leu Pro Phe Val Leu	365	370	375
	Thr Val Ala Ile Leu Ala Val Ala Gln Val Asp Gly Asp Ser Val	380	385	390
25	Ser Gly Ile Cys Phe Val Gly Tyr Lys Asn Tyr Arg Tyr Arg Ala	395	400	405
	Gly Phe Val Leu Ala Pro Ile Gly Leu Val Leu Ile Val Gly Gly	410	415	420
30	Tyr Phe Leu Ile Arg Gly Val Met Thr Leu Phe Ser Ile Lys Ser	425	430	435
	Asn His Pro Gly Leu Leu Ser Glu Lys Ala Ala Ser Lys Ile Asn	440	445	450
	Glu Thr Met Leu Arg Leu Gly Ile Phe Gly Phe Leu Ala Phe Gly	455	460	465
35	Phe Val Leu Ile Thr Phe Ser Cys His Phe Tyr Asp Phe Phe Asn	470	475	480
	Gln Ala Glu Trp Glu Arg Ser Phe Arg Asp Tyr Val Leu Cys Gln	485	490	495

	Ala Asn Val Thr Ile Gly Leu Pro Thr Lys Lys Pro Ile Pro Asp	500	505	510
	Cys Glu Ile Lys Asn Arg Pro Ser Leu Leu Val Glu Lys Ile Asn	515	520	525
5	Leu Phe Ala Met Phe Gly Thr Gly Ile Ala Met Ser Thr Trp Val	530	535	540
	Trp Thr Lys Ala Thr Leu Leu Ile Trp Arg Arg Thr Trp Cys Arg	545	550	555
10	Leu Thr Gly His Ser Asp Asp Glu Pro Lys Arg Ile Lys Lys Ser	560	565	570
	Lys Met Ile Ala Lys Ala Phe Ser Lys Arg Arg Glu Leu Leu Gln	575	580	585
	Asn Pro Gly Gln Glu Leu Ser Phe Ser Met His Thr Val Ser His	590	595	600
15	Asp Gly Pro Val Ala Gly Leu Ala Phe Glu Leu Asn Glu Pro Ser	605	610	615
	Ala Asp Val Ser Ser Ala Trp Ala Gln His Val Thr Lys Met Val	620	625	630
20	Ala Arg Arg Gly Ala Ile Leu Pro Gln Asp Val Ser Val Thr Pro	635	640	645
	Val Ala Thr Pro Val Pro Pro Glu Glu Gln Ala Asn Leu Trp Leu	650	655	660
	Val Glu Ala Glu Ile Ser Pro Glu Leu Glu Lys Arg Leu Gly Arg	665	670	675
25	Lys Lys Lys Arg Arg Lys Arg Lys Lys Glu Val Cys Pro Leu Gly	680	685	690
	Pro Ala Pro Glu Leu His His Ser Ala Pro Val Pro Ala Thr Ser	695	700	705
30	Ala Val Pro Arg Leu Pro Gln Leu Pro Arg Gln Lys Cys Leu Val	710	715	720
	Ala Ala Asn Ala Trp Gly Thr Gly Glu Pro Cys Arg Gln Gly Ala	725	730	735
	Trp Thr Val Val Ser Asn Pro Phe Cys Pro Glu Pro Ser Pro His	740	745	750
35	Gln Asp Pro Phe Leu Pro Gly Ala Ser Ala Pro Arg Val Trp Ala	755	760	765
	Gln Gly Arg Leu Gln Gly Leu Gly Ser Ile His Ser Arg Thr Asn	770	775	780

Leu Met Glu Ala Glu Leu Leu Asp Ala Asp Ser Asp Phe  
 785 790 793

- 5 <210> 18  
 <211> 228  
 <212> DNA  
 <213> Homo sapiens
- <400> 18  
 ctggggctgt ccagttaccc caacggctac cccttctct tctgggagca 50  
 gtacatcggc ctccgccact ggctgctgct gttcatcagc gtggtgttgg 100  
 10 cctgcacatt cctcgtgtgc gctgtcttcc ttctgaaccc ctggacggcc 150  
 gggatcattg tgatggtcct ggcgctgatg acggtcgagc tgttcggcat 200  
 gatgggcctc atcggaatca agctcagt 228
- 15 <210> 19  
 <211> 18  
 <212> DNA  
 <213> Homo sapiens
- <400> 19  
 aggcggggga tcacagca 18
- 20 <210> 20  
 <211> 18  
 <212> DNA  
 <213> Homo sapiens
- <400> 20  
 ataccaaaga gttccact 18
- 25 <210> 21  
 <211> 45  
 <212> DNA  
 <213> Artificial sequence
- <220>  
 30 <223> Artificial sequence 1-45
- <400> 21  
 ctgcggcgct gcttcctgct ggccgtctgc atcctgctgg tgtgc 45
- <210> 22  
 <211> 45  
 35 <212> DNA  
 <213> Artificial sequence
- <220>  
 <223> Artificial sequence 1-45
- <400> 22  
 40 agagcacaga cgaggaaagt gcacaccagc aggatgcaga cggcc 45

- <210> 23  
<211> 21  
<212> DNA  
<213> Artificial sequence
- 5 <220>  
<223> Artificial sequence 1-21
- <400> 23  
actcctgact tgttagcagat t 21
- 10 <210> 24  
<211> 21  
<212> DNA  
<213> Artificial sequence
- <220>  
<223> Artificial sequence 1-21
- 15 <400> 24  
aggctgcata cacctctcag a 21
- <210> 25  
<211> 18  
<212> DNA  
20 <213> Artificial sequence
- <220>  
<223> Artificial sequence 1-18
- <400> 25  
gcttaggccccc gaggagat 18
- 25 <210> 26  
<211> 20  
<212> DNA  
<213> Artificial sequence
- <220>  
30 <223> Artificial sequence 1-20
- <400> 26  
aactcacaac tttctctcca 20
- <210> 27  
<211> 48  
35 <212> DNA  
<213> Artificial sequence
- <220>  
<223> Artificial sequence 1-48
- <400> 27  
40 ggatttctaata acgactcact atagggcccca atggcctaaa ccgactgc 48
- <210> 28

<211> 46  
 <212> DNA  
 <213> Artificial sequence  
  
 <220>  
 5 <223> Artificial sequence 1-46  
  
 <400> 28  
 ctatgaaatt aaccctcact aaagggaccc acggcctctc ctcaca 46  
  
 <210> 29  
 <211> 449  
 10 <212> PRT  
 <213> Mus musculus  
  
 <400> 29  
 Met Glu Ser Pro Arg Ala Thr Gln Thr Pro Glu Ser Pro Lys Leu  
 1 5 10 15  
 15 Ser Gln Pro Arg Ala His Leu Ser Ala His Gln Ala Pro Ser Pro  
 20 25 30  
 Ala Ala Leu Pro Gly Tyr Pro Ala Met Ser Pro Ala Trp Leu Arg  
 35 40 45  
 20 Pro Arg Leu Arg Phe Cys Leu Phe Leu Leu Leu Leu Leu Val  
 50 55 60  
 Pro Ala Ala Arg Gly Cys Gly Pro Gly Arg Val Val Gly Ser Arg  
 65 70 75  
 Arg Arg Pro Pro Arg Lys Leu Val Pro Leu Ala Tyr Lys Gln Phe  
 80 85 90  
 25 Ser Pro Asn Val Pro Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr  
 95 100 105  
 Glu Gly Lys Ile Ala Arg Ser Ser Glu Arg Phe Lys Glu Leu Thr  
 110 115 120  
 30 Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr  
 125 130 135  
 Gly Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp Arg Leu Asn  
 140 145 150  
 Ser Leu Ala Ile Ser Val Met Asn Gln Trp Pro Gly Val Lys Leu  
 155 160 165  
 35 Arg Val Thr Glu Gly Trp Asp Glu Asp Gly His His Ser Glu Glu  
 170 175 180  
 Ser Leu His Tyr Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp  
 185 190 195  
 Arg Asp Arg Asn Lys Tyr Gly Leu Leu Ala Arg Leu Ala Val Glu

	200	205	210
	Ala Gly Phe Asp Trp Val Tyr Tyr Glu Ser Lys Ala His Val His		
	215	220	225
5	Cys Ser Val Lys Ser Glu His Ser Ala Ala Ala Lys Thr Gly Gly		
	230	235	240
	Cys Phe Pro Ala Gly Ala Gln Val Arg Leu Glu Asn Gly Glu Arg		
	245	250	255
	Val Ala Leu Ser Ala Val Lys Pro Gly Asp Arg Val Leu Ala Met		
	260	265	270
10	Gly Glu Asp Gly Thr Pro Thr Phe Ser Asp Val Leu Ile Phe Leu		
	275	280	285
	Asp Arg Glu Pro Asn Arg Leu Arg Ala Phe Gln Val Ile Glu Thr		
	290	295	300
15	Gln Asp Pro Pro Arg Arg Leu Ala Leu Thr Pro Ala His Leu Leu		
	305	310	315
	Phe Ile Ala Asp Asn His Thr Glu Pro Ala Ala His Phe Arg Ala		
	320	325	330
	Thr Phe Ala Ser His Val Gln Pro Gly Gln Tyr Val Leu Val Ser		
	335	340	345
20	Gly Val Pro Gly Leu Gln Pro Ala Arg Val Ala Ala Val Ser Thr		
	350	355	360
	His Val Ala Leu Gly Ser Tyr Ala Pro Leu Thr Arg His Gly Thr		
	365	370	375
25	Leu Val Val Glu Asp Val Val Ala Ser Cys Phe Ala Ala Val Ala		
	380	385	390
	Asp His His Leu Ala Gln Leu Ala Phe Trp Pro Leu Arg Leu Phe		
	395	400	405
	Pro Ser Leu Ala Trp Gly Ser Trp Thr Pro Ser Glu Gly Val His		
	410	415	420
30	Trp Tyr Pro Gln Met Leu Tyr Arg Leu Gly Arg Leu Leu Leu Glu		
	425	430	435
	Glu Ser Thr Phe His Pro Leu Gly Met Ser Gly Ala Gly Ser		
	440	445	449
	<210> 30		
35	<211> 228		
	<212> DNA		
	<213> Homo sapiens		
	<400> 30		

ctggggctgt ccagttaccc caacggctac cccttcctct tctgggagca 50  
gtacatcggc ctcgccact ggctgctgct gttcatcagc gtggtgttgg 100  
cctgcacatt cctcgtgtgc gctgtcttcc ttctgaaccc ctggacggcc 150  
gggatcattg tgatggtcct ggcgtgatg acggtcgagc tgttcggcat 200

5 gatgggcctc atcggaatca agctcagt 228

<210> 31  
<211> 32  
<212> DNA  
<213> Artificial sequence

10 <220>  
<223> Artificial sequence 1-32

<400> 31  
tcgacaagca gggaacaccc aagtagaagc tc 32

15 <210> 32  
<211> 32  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Artificial sequence 1-32

20 <400> 32  
tcgacaagca gggaagtggg aagtagaagc tc 32

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/07417

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/705 C12N1/19 C12N1/21 C12N5/10  
C12N15/62 C07K19/00 C12N15/11 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TAKABATAKE T. ET AL.: "Hedgehog and patched gene expression in adult ocular tissues" FEBS LETTERS, vol. 410, 30 June 1997 (1997-06-30), pages 485-489, XP002101427 ISSN: 0014-5793 the whole document	1-15
A	MOTOYAMA J. ET AL.: "Ptch2, a second mouse Patched gene is co-expressed with Sonic hedgehog" NATURE GENETICS, vol. 18, February 1998 (1998-02), pages 104-106, XP002101696 ISSN: 1061-4036 cited in the application the whole document	1-15
-/--		

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

19 July 1999

Date of mailing of the international search report

03/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/07417

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 45541 A (LELAND S STANFORD JUNIOR UNIVE ;UNIV CALIFORNIA (US)) 4 December 1997 (1997-12-04) the whole document	1-22, 26-28
E	WO 99 29854 A (ONTOGENY INC) 17 June 1999 (1999-06-17)  the whole document	1-17, 19-21, 26-28
P,X	EP 0 879 888 A (SMITHKLINE BEECHAM PLC) 25 November 1998 (1998-11-25) the whole document	16-21,26
P,X	CARPENTER D. ET AL.: "Characterization of two patched receptors for the vertebrate hedgehog protein family" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 95, no. 23, 10 November 1998 (1998-11-10), pages 13630-13634 13634, XP002101428 ISSN: 0027-8424 the whole document	1-17
P,X	ZAPHIROPOULOS P. G. ET AL.: "PTCH2, a novel human patched gene undergoing alternative splicing and up-regulated in basal cell carcinomas." CANCER RESEACH, vol. 59, 15 February 1999 (1999-02-15), pages 787-792, XP002109560 the whole document	1-15

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/07417

## Box I Observations where certain claims were found uns archable (Continuation f item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 22-25  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees w re accompanied by the applicant's protest.
- ☐ No prot st accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 22-25

Present claims 19-25 relate to a compound defined by reference to a desirable characteristic or property, namely its antagonistic or agonistic effect on 'patched-2', respectively.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to antisense oligonucleotides which can be obtained from the specific sequence as it is presented by SEQ.ID.1 by using general methods known to the person skilled in the art. Consequently, claims 19 and 20 were searched partially and claim 21 was searched completely.

Moreover, there is an inconsistency between claim 21 referring to an 'antisense nucleotide' and page 9, line 1, referring to an 'antisense oligonucleotide'. Due to the fact that only the term 'antisense oligonucleotide' makes sense in the context of claim 21, claim 21 was read as referring to an 'antisense oligonucleotide'.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/07417

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9745541	A	04-12-1997	AU 3227497 A	05-01-1998
WO 9929854	A	17-06-1999	NONE	
EP 0879888	A	25-11-1998	CA 2232808 A	23-11-1998
			JP 11075874 A	23-03-1999